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Thesis Abstract 
Protein Kinase CK2 is an enzyme discovered in the 1950s. Since then we have gained 
knowledge in many aspects of its biological function, such as cell proliferation and anti-
apoptosis. This study, by means of gene deletion mutants and unbiased genome-wide screening 
of the model organism Saccharomyces cerevisiae, has uncovered a new dimension of CK2’s 
functionality, i.e. its role in regulating metal toxicity. This discovery is then further extended 
to mammalian cells.   
 
The findings described in Chapter 3, by using the deletion mutants of CK2 subunits (CKA1, 
CKA2, CKB1 and CKB2) in S. cerevisiae, revealed that deletion of CKA2, the yeast orthologue 
of mammalian CK2α’, leads to a pronounced resistant phenotype against Zn2+ and Al3+, whilst 
deletion of CKB1 or CKB2 results in tolerance to Cr6+ and As3+. These data demonstrate that 
CK2 is involved in regulating metal toxicity, and individual CK2 subunits have distinct roles 
in this regulation. Furthermore, the results add to the growing evidence that show monomeric 
CK2 subunits can function discretely, apart from the tetrameric holoenzyme, which contains 
both catalytic and regulatory subunits. Further investigation using double deletion mutants and 
inductively coupled plasma mass spectrometry (ICP-MS) uncovered the basis for the resistant 
phenotype of cka2Δ in response to the exposure to Al3+ or Zn2+.  
 
Double deletion of CKA2 with either CKB1 or CKB2 and the inhibition of CK2 function by 
TBB (4,5,6,7-Tetrabromo-2-azabenzimidazole) in cka2Δ revealed that the resistant phenotype 
of cka2Δ under Al3+ exposure was not affected, suggesting that CKA2 is the solely responsible 
CK2 gene for Al3+ toxicity. ICP-MS analysis demonstrated that deletion of CKA2 resulted in 
52% reduction in Al3+ content compared to the wildtype at 4 h, 85% reduction at 8 h and a 65% 
reduction at 12 and 16 h post treatment. This clearly shows that Cka2p is involved in Al3+ 
uptake in a manner independent of the other CK2 subunits present in the cell. In contrast to this 
finding, the resistant phenotype of cka2Δ under Zn2+ exposure was found to be related to the 
function of the remaining CK2 subunits (Cka1p, Ckb1p and Ckb2p). The resistant growth 
phenotype was markedly reduced when CKA2 was deleted together with either of the 
regulatory subunits (CKB1 or CKB2). Further, the resistant phenotype of cka2Δ was completely 
abolished when CK2 function was inhibited by TBB. ICP-MS quantification showed that the 
level of Zn2+ found in cka2Δ was very similar to the wildtype at all time-points tested, 
indicating that, rather than conferring resistance by excluding Zn2+ from the cell, the remaining 
xvii 
 
CK2 subunits were participating in intracellular sequestration of Zn2+, possibly by interacting 
with vacuolar Zn2+ transport proteins Zrc1p and Cot1p.       
 
The monomeric regulatory subunits of CK2 are involved in As3+ toxicity. While deletion of 
CKB1 or CKB2 conferred resistance to As3+, deletion of both these genes resulted in sensitivity. 
This decrease in viability under As3+ treatment when both regulatory subunits are deleted 
indicates that the regulatory subunits have functions outside the tetramer. The genome-wide 
deletion screen data shown in Chapter 4 reveal the molecular mechanisms related to As3+ 
toxicity, uptake and detoxification by identification of tolerant and sensitive genes. Of the 
genes identified in the screen, their deletion coupled with the deletion of CK2 genes showed 
that Ckb1p or Ckb2p likely interacts with the genes in the Hog1 (MAPK) pathway.  ICP-MS 
validated that deletion of CKB1 and CKB2 resulted in lower intracellular levels of As3+.  
 
Similarly, deletion of CKB1 or CKB2 leads to resistance against Cr6+ due to the reduced 
intracellular level of the metal ion. The genome wide screen demonstrates oxidative stress as a 
major cause for Cr6+ toxicity. The increased growth of CKB1 and CKB2 deletion mutants under 
Cr6+ exposure was found to also be correlated with reduced oxidative stress.  
 
Finally, the experimental findings in mammalian neuronal cells with the CK2 inhibitor TBB 
demonstrated that CK2 activity under the exposure of metal ions such as Al3+ and Zn2+ is 
disadvantageous to the cell’s viability. Further analysis with specific siRNA against the 
individual CK2 subunits reveals that such negative effect of CK2 to the cell’s viability under 
metal stress is largely a result of the CK2α’ subunit. The viability of both Neuro2a and SH-
SY5Y cells, when exposed to IC25 and IC50 doses of Zn
2+ or Al3+, was significantly increased 
when Ck2α’ expression was knocked down (p < 0.001). This finding demonstrates CK2 is 
involved in the regulation of metal toxicity in mammalian cells, just like what is described 
previously in S. cerevisiae.      
 
Overall, the work contained in this thesis establishes a new role for protein kinase CK2 in metal 
ion toxicity and demonstrates that individual subunits of CK2 have discrete functions. The 
findings, which have already been published in peer-reviewed journals, have enhanced our 
knowledge and understanding of CK2’s biological roles, and have provided useful data which 
have been used to update the yeast genomic functionality in Saccharomyces Genome Database 
xviii 
 
(https://www.yeastgenome.org/). Due to the links between metals, neurodegenerative diseases 
and cancers, the discovery of the linkage of CK2 with metal toxicity here opens an exciting 
vista for tackling major health problems such as cancers and neurodegenerative disorders.   
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Note on the nomenclature of yeast genes, proteins and deletion mutant strains: 
When referring to a gene in Saccharomyces cerevisiae the convention is to use all italicised 
capital letter (e.g. CKA1), when referring to the protein for which the gene codes the 
convention is to use a capital letter for the first letter and lower case for the subsequent letters 
followed by a lower case p (e.g. Cka1p). When referring to a deletion mutant strain the 
convention is to use lower case italics followed by the greek letter delta (e.g. cka2Δ).    
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1 Literature review 
1.1 General introduction 
This thesis has its foundations in the previous work of our laboratory group. The novel and 
interesting finding that the pleiotropic protein kinase CK2 may be related to metal biology was 
the seed from which this research grew. 
 
As detailed in Chapter 1.1.4, protein kinase has a wide range of substrates and interacts with 
many pathways, however there has been little investigation into its role in metal ion toxicity 
and homeostasis. The toxic effects of metal ions have been a focus of our laboratory group for 
some time. As detailed in 1.2, metal ions, both essential and non-essential, can interact with 
biological systems in negative ways and have been linked with cancers and neurodegenerative 
diseases.  
 
Chapter 1.1.6 “CK2 and neurodegenerative disorders” and 1.1.7 “CK2 and cancer” explain that 
aberrant activity or dysregulation of CK2 are also related to neurodegenerative disorders and 
cancer. The finding that metal ions and CK2, both related to cancer and neurodegenerative 
pathologies, are linked to each other prompted the research contained herein. The initial stages 
of this research were aimed at exploring the link between CK2 and metal ion homeostasis and 
toxicity. This link was explored through various genetic and biochemical means in the model 
organism S. cerevisiae and in mammalian cell lines.  
 
This research focused on a small panel of metals spanning the spectrum of biological relevance. 
From the essential zinc, the micronutrient chromium, the functionless and enigmatic 
aluminium to the toxic arsenic, this disparate array of metals shares a common feature… their 
biological action is impacted by protein kinase CK2.  
 
1.2 Metals and biology  
The ability to transport substances into and out of the cell is essential for life (Ussing, 1949). 
Erroneous uptake of toxicants can result in cell stress or death, while failure to maintain the 
homeostasis of biologically-relevant substances can lead to adverse consequences. Metal ions 
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are a group of substances which straddle both aspects i.e. some metal ions are toxic, such as 
arsenic and chromium, while some are essential and required for a range of cellular functions. 
For example, iron is a cofactor for several redox-active metalloenzymes and zinc is required 
for the catalytic activity of numerous enzymes such as protein kinase CK2 (Eide, 1998; Filhol, 
Benitez, & Cochet, 2005), the protein of interest for this project. However, overload of such 
essential metal ions is inimical, therefore, their uptake, storage and secretion is tightly 
controlled or regulated (Nelson, 1999). Cells contain various metal ion transporters in plasma 
and subcellular membranes that are the effectors in maintaining metal ion homeostasis (Nelson, 
1999). As shown in Figure 1.1., the ways metal distribution are maintained are based on influx 
(1) and efflux (5) protein channels, which govern the exchange of metal ions with the 
environment; subcellular metal ion channels (2) which exert control over the cytosolic levels 
of metal ions; and metalloenzymes (3) or thiol containing peptides/proteins (4), which exert 
control over the free, cytosolic metal ions.  
 
 
Figure 1.1 Schematic of general mechanisms of metal ion homeostasis.  
Metals enter the cell through metal ion transporters (1), their sub-cellular location is controlled 
by transporters embedded in organelles (2). They may form structural components of enzymes 
or participate as co-factors in metabolic processes (3). Certain proteins, such as 
metallothioneins may sequester metals if metal concentrations are too high (4). Efflux of metals 
is facilitated by other membrane bound transporters (5). 
 
Metal toxicity has been linked to certain cancers and neurodegenerative diseases. In the case 
of cancer, although genetic abnormality such as gene mutation is the main focus of cancer 
research, a recent study has determined that intrinsic risk factors contribute between 
approximately 10-30% to cancer development (Wu, Powers, Zhu, & Hannun, 2016). This 
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estimate leaves the majority of cancers to be accounted for by interactions of genes and 
environmental factors such as metal ions. Similarly, for many neurodegenerative diseases,  
gene/environment interactions also seem to be in play (Cannon & Greenamyre, 2011; Migliore 
& Coppede, 2002). For example, familial amyotrophic lateral sclerosis (fALS) only accounts 
for 5-10% of cases, while sporadic ALS (sALS) accounts for 90-95% (Banack, Murch, & Cox, 
2006; Bradley & Mash, 2009) which may be associated with environmental factors. Much 
research has been devoted to uncovering carcinogenic and neurodegenerative causative agents 
and metal ions have emerged as major players in the development of these diseases.  
 
Metals such as chromium and arsenic have been shown to be potent mutagens and carcinogens 
(NRC, 2001; WHO, 1990), while cellular zinc content has been linked with certain cancers 
(Franklin & Costello, 2009). The progression of cancer development can be summed up by the 
four stages; initiation, promotion, progression and metastasis. The role of metal ions is believed 
to be associated with each stage (Wang & Shi, 2001). The carcinogenicity of metal ions has 
been linked to the direct, but transient binding of the metal to DNA and nuclear proteins causing 
DNA damage and conformation changes (Berg, 1986; Gebhart, 1984). Alternatively, the role 
of metal-induced reactive oxygen species (ROS) in carcinogenesis is well attested (Breimer, 
1990; Dizdaroglu, 1991; Kasprzak, 1995; Matés, Segura, Alonso, & Márquez, 2010; Valko, H. 
Morris, & M. Cronin, 2005; Valko, Rhodes, Moncol, Izakovic, & Mazur, 2006; Vallyathan, 
Shi, & Castranova, 1998). The role of metal ions in neurodegenerative disease is equally well 
attested. Table 1 shows a list of neurodegenerative diseases and their link to metal ions.
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Table 1.1 Protein aggregates, genetic risk factors and metals in neurodegenerative diseases 
Disease  Aggregate  Genes linked to the disorder   Metals linked to the 
disorder 
Region of the brain/nervous 
system affected  
Huntington’s disease  Mutant huntingtin protein (polyglutamine 
tract at N-terminal) 
Excessive (>35) CAG repeats in huntingtin 
protein gene 
N/A Basal ganglia (particularly 
striatum), cortex  
Alzheimer’s disease  Neurofibrillary tangles of 
hyperphosphorylated tau,  
Extracellular neuritic plaques of Amyloid 
beta from amyloid precursor protein (APP) 
Apolipoprotein E type 4 allele (expressing the 
protein isoform apoE4) is a risk factor for 
developing the disorder 
Mutations to the gene coding APP and to the 
genes encoding proteins that cleave APP 
(presenilin 1 and 2) 
Al, Cu, Fe and Zn Basal forebrain, hippocampus, 
cortex, brain stem  
Parkinson’s disease  Lewy bodies containing alpha synuclein  
Lewy neurites  
PARK 2 (mutated gene coding for Parkin), 
PARK7 (mutated gene encoding DJ-1), PINK1 
Double or triple copies of the gene that codes 
for alpha-synuclein (SNCA), PARK1 (mutated 
form of gene coding for alpha synuclein) 
Al, Mn, Cu, Pb, Fe, Hg, 
Zn 
Substantia nigra, cortex, locus 
ceruleus  
Amyotrophic lateral 
sclerosis   
Several Proteins including: FUS, TDP-43, 
OPTN, UBQLN2 also aggregates of the 
translated products of repeated introns of the 
gene C9ORF72 
Mutations to the gene encoding superoxide 
dismutase (SOD1) 
Zn, Hg Motor neurons of the lateral horn 
of the spinal cord, motor neurons 
of the cerebral cortex  
Note: the table is compiled according to the following publications (Blokhuis, Groen, Koppers, van den Berg, & Pasterkamp, 2013; Chartier-
Harlin et al., 2004; Dawson & Dawson, 2003; Finder & Glockshuber, 2007; Ibanez et al., 2004; Praline et al., 2007; Ross & Poirier, 2004; Sanan 
et al., 1994; Uversky, Li, & Fink, 2001). 
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1.2.1 Zinc (Zn2+) 
Zn2+ is the most essential trace metal ion after iron (Fe2+/3+) to all living organisms. The 
biological roles of Zn2+ have long been known, such as its involvement in gene expression 
(Vallee, 1983), the stabilisation of structure of proteins and nucleic acids (Vallee & Auld, 
1990), subcellular organelle integrity (Vallee & Auld, 1990), activity of numerous enzymes 
(Eide, 1998) and signal transduction as a second messenger (Grummt, Weinmann-Dorsch, 
Schneider-Schaulies, & Lux, 1986). It has been estimated that approximately 10% of all 
proteins in eukaryotic cells bind zinc, which means there are about 3000 zinc proteins in 
humans (Andreini, Banci, Bertini, & Rosato, 2006; Maret, 2012). 
 
Zn2+ is reported to have proliferative and anti-apoptotic properties (Chai, Truong-Tran, Ho, & 
Zalewski, 1999), while other reports show that zinc can induce apoptosis (Chang et al., 2006). 
Such diametric reports are likely due to the experimental conditions of those studies, such as 
Zn2+ concentration and tissue type. The level of zinc in malignant ovarian tumours has been 
found to be lower than that of benign tissue (Lightman, Brandes, Binur, Drugan, & Zinder, 
1986). It has been found that upon zinc treatment, zinc accumulation is higher in ovarian cancer 
cells than in normal human ovarian epithelial cells and this accumulation leads to the induction 
of apoptosis (Bae, Lee, Kim, Kim, & Park, 2006). These studies suggest that the introduction 
of zinc may lead to selective cancer cell death. Similar to ovarian cancer, prostate cancer cells 
have lower levels of zinc than normal prostate epithelial cells (Costello & Franklin, 2006). 
When exposed to zinc the growth of prostate cancer cells are inhibited and apoptosis is induced 
(Franklin & Costello, 2007; Liang et al., 1999). Hepatocellular cancer cells have lower 
intracellular zinc (Ebara et al., 2000) and the zinc import channel ZIP14 has been found to be 
down-regulated in malignant liver tissue (Liu et al.). In contrast to the above mentioned 
malignancies, the zinc level of breast cancer has been shown to be markedly increased 
(Margalioth, Schenker, & Chevion, 1983; Rizk & Sky-Peck, 1984). Overexpression of ZIP10 
was shown to correlate with increased aggressiveness of the cancer (Kagara, Tanaka, Noguchi, 
& Hirano, 2007). Other studies have shown that upregulation of the zinc transporter ZIP6 is 
associated with progression of breast cancer (Manning et al., 1994; Taylor et al., 2007).  
Apoptosis can be induced in normal breast epithelial cells by zinc while cancerous cells avoid 
the zinc-induced apoptosis via suppression of p53 (Ostrakhovitch & Cherian, 2005). Li et al 
(2007) found that an increase in the expression of ZIP4 was associated with pancreatic cancer 
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development. The increase in ZIP4 leads to accumulation of zinc, which in turn stimulates cell 
proliferation (Li et al., 2007). While the previous studies demonstrate contrasting roles for zinc 
in cancerous tissues they all point to the fact that Zn2+ transporters or the mechanisms that 
regulate them play an integral role in cancer. 
 
In Alzheimer’s disease Zn2+ has been shown to be a major factor responsible for precipitation 
of Aβ followed by a build-up of protease resistant aggregates (Bush, 2003). Mutations in 
superoxide dismutase (SOD-1), which is linked to ALS, alter the ability of SOD1 to bind zinc, 
leading to the accumulation of  reactive oxygen species  such as superoxide (Bush, 2000). 
Epidemiological studies suggest that environmental exposure to zinc is a risk factor for 
Parkinson’s disease (PD) and elevated zinc levels have been found in the substantia nigra of 
PD brains (Uversky et al., 2001). 
 
My PhD project, here reported, will enhance the understanding of zinc toxicity at a molecular 
level, which will in turn contribute to our knowledge of cancer and neurodegeneration. 
 
1.2.2 Aluminium (Al3+) 
Aluminium comprises about 7% of the earth’s crust, making it the most abundant metal in the 
crust (Delhaize & Ryan, 1995). It has no known biological function, yet we are constantly 
exposed to it, such as the trace quantities of aluminium present in drinking water, food and 
medicines (e.g. vaccine adjuvants). Solubility is a critical parameter for aluminium toxicity. At 
acidic pH, aluminium exists as an octahedral hexahydrate, [Al(H2O)6]
3+, commonly 
abbreviated as Al3+, which is the key toxic species of aluminium ions. The concentrations of 
Al3+ in drinking water, plants and foods increases with soil acidity due to pollution (Becaria, 
Campbell, & Bondy, 2002; Becaria et al., 2006). Beyond water, food and medicine, we are 
exposed every day to aluminium due to its usage in cooking utensils and anti-perspirants.  The 
chronic accumulation of aluminium in humans is insidious and may lead to health 
complications later in life. 
 
The dangers of aluminium have been suspected for over 100 years (Gies, 1911). More recently 
aluminium has been linked to the presence of certain hallmarks of Alzheimer’s disease. 
Neurofibrillary tangles (NFTs) are aggregates of hyperphosphorylated tau protein and are the 
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primary marker of Alzheimer’s disease. Evidence shows that aluminium is linked with the 
formation and growth of NFTs (Bharathi, Govindaraju, Palanisamy, Sambamurti, & Rao, 2008; 
Perl, Gajdusek, Garruto, Yanagihara, & Gibbs, 1982; Walton, 2010). The aggregation of 
hyperphosphorylated tau may be due to cross linking of the tau proteins facilitated by 
aluminium, simply due to the interaction between negatively charged phosphate groups and 
positively charged Al3+ (Zatta, Drago, Bolognin, & Sensi, 2009). Another feature of 
Alzheimer’s disease is the presence of plaques of amyloid β. The misfolding and aggregation 
of amyloid β have also been shown to be influenced by Al3+ (VanDuyn et al., 2013; Zatta et 
al., 2009). Recent evidence suggests that amyloid β conjugated with Al3+ causes a build-up of 
the oligomeric form of amyloid β (Zatta et al., 2009). In laboratory studies using Wistar rats, 
Alzheimer’s-type senile dementia was induced through the administration of aluminium 
chloride (Chakrabarty et al., 2012), demonstrating that Al3+ exposure is linked with the 
cognitive defects as well as the protein aggregate markers. 
 
Aluminium has also been linked with Parkinson’s disease. Aluminium accumulation has been 
found in the substantia nigra of Parkinson’s disease patients (Good, Olanow, & Perl, 1992). 
The potential for aluminium as a causative agent of Parkinson’s disease, through the generation 
of oxidative stress in certain brain regions, has been investigated and it has been revealed that 
aluminium is a risk factor for Parkinson’s disease development (Sanchez-Iglesias et al., 2009). 
Lewy bodies are protein aggregates largely composed of misfolded α synuclein. They are a 
characteristic feature in nerve cells in Parkinson’s disease. Studies have revealed that exposure 
to aluminium results in an acceleration in the rate of α synuclein fibril formation (Uversky et 
al., 2001).  
 
As aluminium has no cellular function, its presence in brain tissue is still a puzzle. Cellular 
uptake of Al3+ can be regarded as a mistake and diseases associated with this metal are not only 
due to its erroneous uptake (possibly due to mistaken identity), but also due to an inability of 
the cell to deal with this unknown invader. Due to the ubiquitous nature, our constant exposure 
to aluminium and its links with neurodegenerative disease, understanding the molecular basis 
for Al3+ toxicity and its detoxification is vital. This is indeed one of the goals of this project. 
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1.2.3 Chromium (Cr6+) 
Since its discovery in 1797 by Louis Nicholas Vauquelin (Lennartson, 2014), the benefits of 
chromium have been exploited in many areas such as leather tanning, electroplating, stainless 
steel production and clinical orthopaedics. The flip side of chromium is its adverse effects on 
living organisms such as the development of lung cancer amongst chromate-exposed workers 
(Beveridge, Pintos, Parent, Asselin, & Siemiatycki, 2010; Coyle, Minahjuddin, Hynan, & 
Minna, 2006). In fact, chromium’s relationship with life is still enigmatic and divergent, due 
to the biological properties of its two prominent oxidation variants, the hexavalent Cr6+ and the 
trivalent Cr3+. Cr6+ is found to be highly toxic whilst Cr3+ is regarded as a micronutrient and 
widely used in health supplements (Liu et al., 2015; Urbano, Ferreira, & Alpoim, 2012; Wu et 
al., 2016). Recent studies demonstrated that its trivalent form is beneficial to human health 
because Cr3+ can potentiate the effect of insulin in regulating carbohydrate and lipid 
metabolism (Vincent, 2004), although there is a risk that excessive Cr3+ could be oxidized to 
Cr6+ in the cell under oxidative conditions (Wu et al., 2016).  
 
Chromium toxicity has recently been brought to the public’s attention by patients suffering 
from faulty hip implants (Scharf et al., 2014). Stainless steel, which typically contains 8% 
hexavalent chromium, has been used in metal-on-metal hip prostheses. Thousands of patients 
worldwide have experienced pain, discomfort and memory loss after receiving the defective 
hip implants, due at least partly to the toxic Cr6+ released by metal-on-metal erosion (Schaffer, 
Pilger, Engelhardt, Zweymueller, & Ruediger, 1999).  
 
The structural characteristics and reduction potential of Cr6+ underpin its toxicity. Cr6+ in 
aqueous solution exists as oxyanions such as chromate (CrO4
2-) or dichromate anions      
(Cr2O7
2-); they are powerful oxidants, highly soluble and mobile. It is the structural similarity 
between the chromate ion and sulfate (SO4
2-) that enables the entry of Cr6+ into the cell, causing 
cytotoxicity (Pereira et al., 2008). In contrast, Cr3+ is easily precipitated out in aqueous solution 
by forming Cr(OH)3, and is impermeable to the cell. Under physiological conditions the 
reduction of Cr6+ to Cr3+ is dominant because of the high reduction potential of the hexavalent 
chromium and the presence of abundant reductants in the cell such as vitamin C, glutathione 
and cysteine. Therefore, under physiological circumstances Cr3+ is the end-form of Cr6+ taken 
up by the cell. According to the study by Armienta-Hernández and Rodríguez-Castillo (1995), 
free radicals generated from the reduction of Cr6+ to Cr3+ are responsible for oxidative stress 
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and cellular toxicity (Valko, Morris, & Cronin, 2005). The unstable intermediates generated by 
the reduction process, Cr5+ and Cr4+, as well as  Cr3+ could also directly attack biomolecules 
such as nucleic acids, lipids and carbohydrates (Slade, Hailer, Martin, & Sugden, 2005). 
Surprisingly, a previous study in S. cerevisiae related Cr6+ toxicity solely to mRNA 
mistranslation and protein aggregation (Holland et al., 2007), whilst another revealed diverse 
mechanisms involving intracellular trafficking, cell wall integrity, molecular regulatory 
pathways, sulfur metabolism and ubiquitin-dependent protein sorting (Jin et al., 2008).  
Despite the significant progress made thus far, knowledge of many molecular aspects of 
chromium toxicity and the cell’s detoxification responses is lacking. Moreover, there is a 
vacuity in our understanding of the cell’s regulation of chromium toxicity. With the advent of 
genomic tools such as genome-wide deletion mutant collections of model organisms, avenues 
into the study of these aspects of Cr6+ have been opened and this project aimed to obtain a 
holistic view on chromium toxicity and its detoxification at the gene level. 
 
1.2.4 Arsenic (As3+) 
Arsenic is naturally present in ground and drinking water, air and foods. Its mining and 
industrial usage leads to the increased contamination of water and crops. Rice, the staple food 
of Asia, often contains an elevated level of arsenic, due to pollution and its natural prevalence 
in ground waters originating from the river systems of the Himalayas (McCarty, Hanh, & Kim, 
2011; Sohn, 2014). The metalloid ion exists in multiple oxidation states, but mainly trivalent 
As3+ or pentavalent As5+. Both As3+ and As5+ are toxic. As3+ is predominantly present as 
As(OH)3 in aqueous environments, mimicking the structure of glycerol, a common metabolite 
in microorganisms and mammalian cells. Therefore, it can enter the cell via aquaglycerin 
transporter (Fps1p) (Tun et al., 2015), which explains the higher toxicity of As3+ over As5+ and 
the other organic arsenic derivatives such as mono-, di- and trimethylated arsenicals.  
Although it is historically and publically known that a high dose of arsenic is lethal, it is the 
chronic exposure to arsenic through drinking water and food, dubbed as “a silent assassin”, 
that is insidious to the health of millions of people around the world. Chronic arsenic 
exposure is associated with cancer of the bladder, lungs, skin and prostate, as well as 
neurodegenerative and cardiovascular diseases (Naujokas et al., 2013; O'Brien, Remm, & 
Sonnhammer, 2005). As a consequence, the application of arsenic in certain medicines, 
which are used in treating acute promyelocytic leukaemia (Shen et al., 2004) and infectious 
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diseases such as syphilis and trypanosomiasis (Ravandi, 2004), unavoidably has adverse side-
effects on the health of patients. The underlying molecular mechanism of arsenic toxicity in 
living organisms is still a subject of active research and is here addressed.   
 
1.3 Utility of the model organism-Saccharomyces cerevisiae 
To investigate the biological effects of metals one would often turn to a biological system. The 
yeast S. cerevisiae has long been used as a model organism due to its applications in basic 
science and toxicology and the fact that it has been at the forefront of functional genomics and 
systems biology (Botstein & Fink, 2011). S. cerevisiae is extensively used due to its eukaryotic, 
single celled nature, relatively short generation time and simple genome which is comprised of 
approximately 6000 genes (Gershon & Gershon, 2000; Goffeau et al., 1996; Sherman, 2002). 
It was the first eukaryote to have had its genome fully sequenced (Goffeau et al., 1996), and 
the genetic manipulation techniques for S. cerevisiae are well established (Sherman, 2002). 
The contributions of S. cerevisiae to our understanding of basic cellular function is inarguable 
and include cell cycle progression (Li et al., 2009; Nasmyth, 1996), signal transduction 
(Pokholok, Zeitlinger, Hannett, Reynolds, & Young, 2006; Whitmarsh & Davis, 1998), 
transcriptional regulation (Biddick & Young, 2009), apoptosis (Silva, Saraiva, Coutinho, 
Gonçalves, & Côrte-Real, 2012), intracellular protein trafficking as well as many other areas 
of study  (Kim, Schilke, Craig, & Horwich, 1998; Steinkraus, Kaeberlein, & Kennedy, 2008).  
The findings from S. cerevisiae are highly applicable to humans due to the genomic homology 
of the two organisms. S. cerevisiae and humans share thousands of orthologous genes, 
accounting for about one-third of the yeast genome (Kachroo et al., 2015; O'Brien et al., 2005). 
Additionally, there exists a high level of conservation between the cellular processes of yeast 
and those of mammalian cells (Mager & Winderickx, 2005; Simon & Bedalov, 2004). The 
publication of the yeast genome sequence led to the advent of numerous resources including 
complete collections of yeast gene deletion mutants such as the collection from EUROSCARF 
employed in this study.  
 
The yeast S. cerevisiae has widely been used as a model organism to delineate molecular 
mechanisms for metal toxicity. Two commonly employed experimental approaches are gene 
expression profiling by transcriptomics and genome-wide deletion mutant screening. By utilising 
the genome wide deletion screen, the function of a gene can be revealed by observing the 
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phenotype of the deletion mutant under a given condition. The beauty of such an approach is that 
it is totally unbiased and untargeted. By using such a method, previously undiscovered 
connections can be made apparent. In years past, our laboratory group has employed such a 
method and in doing so revealed a novel role for a long-studied tetrameric kinase, protein kinase 
CK2, in aluminium toxicity (Tun et al., 2014). This finding not only implicated the renowned 
kinase in aluminium toxicity, but also suggested an individual function for one of the subunits, 
cka2p. The discovery of the protein kinase CK2 in the context of Al3+ toxicity sets the basis of 
this project.   
 
1.4 Protein kinase CK2 – a pleiotropic kinase 
Protein kinase CK2 was first discovered in 1954 (Burnett & Kennedy, 1954). It is one of the 
earliest discovered kinases in the kinome, which currently has about 500 members (Burnett & 
Kennedy, 1954; Fabbro, Cowan-Jacob, & Moebitz, 2015). Over the ensuing decades its 
structure, function and substrates have been progressively characterized (Litchfield, 2003; 
Meggio & Pinna, 2003; Pinna, 1993). Despite the enormous progress in characterisation of its 
roles in cell proliferation, differentiation and anti-apoptosis, several aspects of CK2 are yet to 
be fully understood such as its regulatory mechanisms in response to extracellular signals. Also, 
scarcely known is its role in metal ion uptake and toxicity. 
 
CK2 is a ubiquitous, pleiotropic, serine/threonine protein kinase with a wide range of substrates 
and has been referred to as the most pleiotropic protein kinase existing in eukaryotic organisms 
(Meggio & Pinna, 2003; Litchfield, 2003). Originally the enzyme was termed casein kinase 2 
due to its phosphorylation of casein as the first substrate used to assay enzyme activity, and the 
numerical designation 2 to denotes its elution from DEAE-cellulose after the enzyme CK1 
(Allende & Allende, 1995; Burnett & Kennedy, 1954; Litchfield, 2003; Venerando, Ruzzene, 
& Pinna, 2014). However, casein does not appear to be a physiological substrate for CK2 and 
therefore in 1994 it was suggested that the name be changed to protein kinase CK2 to avoid 
the misnomer confusion (Allende & Allende, 1995; Venerando et al., 2014). CK2 is an unusual 
protein kinase in several respects. For examples, it is constitutively active and can use both 
ATP and GTP as the phosphate donor, thus different from the other eukaryotic protein kinases 
(Allende & Allende, 1995; Antonelli, Daniotti, Rojo, Allende, & Allende, 1996; Meggio & 
Pinna, 2003; Niefind, Putter, Guerra, Issinger, & Schomburg, 1999; Pinna, 2003). The known 
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substrates of this enzyme are still expanding (Meggio & Pinna, 2003). It has been suggested 
that the proteins phosphorylated by CK2 may make up one quarter of the eukaryotic 
phosphoproteome (Meggio & Pinna, 2003). Its renowned role is regulation of cell proliferation, 
including the processes of DNA replication, transcription, tRNA and rRNA synthesis, 
chromatin remodelling and anti-apoptosis (Guerra & Issinger, 1999; Kappes et al., 2004). 
Because of this, CK2 has been a major target of cancer research. CK2 inhibitors have been 
shown to induce apoptosis in cells resistant to TNFα-mediated cell death (Dixit, Sharma, 
Ghosh, Mehta, & Sen, 2012).  
 
With its high pleiotropism, it is not surprising that new aspects of CK2 functionality are 
continually unravelled, such as its involvement in metal ion transport and toxicity (Taylor, 
Hiscox, Nicholson, Hogstrand, & Kille, 2012; Tun et al., 2014). 
 
1.4.1 Structure and function of CK2 
The mammalian CK2 heterotetramer is a protein kinase composed of two catalytic subunits (α 
and α’), bound to a central homodimer of regulatory β subunits. The fact that the holoenzymes 
are formed spontaneously in vitro from the mixture of individual subunits tells us there is 
probably a built-in code for such action amongst their primary structures. Notably, the affinity 
of CK2 α′ for CK2 β is about 12 times lower than that of CK2 α (Bischoff et al., 2011), 
suggesting that the tetramer ααββ of CK2 could be the dominant species. The amino acid 
sequences of human α and α’ catalytic subunits are 391 and 350 residues long, respectively. 
The apparent sizes after purification in vitro are smaller than their theoretical molecular masses 
(45.144 and 41.213 kDa), due to proteolytic cleavage modifications at the C-terminus (Guerra, 
Niefind, Ermakowa, & Issinger, 2001; Niefind, Guerra, Ermakowa, & Issinger, 2001). The β 
subunit is much smaller (around 25 kDa) (Schnitzler, Olsen, Issinger, & Niefind, 2014; Shi, 
Brown, & Walsh, 1994). The crystallographic structures of the subunits of CK2 and the 
holoenzyme demonstrate that the catalytic subunits of CK2 contain the typical architecture 
found in eukaryotic protein kinases (Bischoff et al., 2011). Such architecture consists of two 
domains: a β-sheet based N-terminal domain and an α-helical C-terminal domain. The active 
site is located in a cleft between the two domains (Bischoff et al., 2011; Niefind et al., 2001; 
Pechkova, Zanotti, & Nicolini, 2003). The main difference between the two catalytic subunits 
in terms of the three-dimensional structure is found in the CK2 β interface region (β4/β5 loop). 
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Unbound CK2 α typically has a closed β4/β5 loop while CK2 α’ has an open one (Bischoff et 
al., 2011). 
 
A worthwhile notion in the context of this study is that two zinc ions are involved in the 
holoenzyme. The CK2 β subunit contains a zinc finger that has been shown to be essential for 
the homodimerisation of the β subunits (Chantalat et al., 1999). The four cysteines (cys109, 
cys114, cys137 and cys140) of CK2 β are in a zinc finger-like arrangement reminiscent of DNA 
binding proteins (Allende & Allende, 1995). Mutations to cys109 and cys114 result in disruption 
of subunit interactions. Each CK2 β monomer consists of an α-helical N-terminal domain and 
the zinc stabilising area and a C-terminal “tail” (Niefind et al., 2001; Raaf, Brunstein, Issinger, 
& Niefind, 2008). The tail crosses the dimer interface and attaches to the other β monomer. 
This tail segment has been shown to be essential for holoenzyme formation (Raaf et al., 2008). 
The holoenzyme complex is shaped like a butterfly with the catalytic subunits attached to a 
central dimer of regulatory β subunits (Niefind et al., 2001). The arrangement is such that both 
regulatory subunits make contact with each of the catalytic subunits while neither catalytic 
subunit contacts the other (Niefind et al., 2001). The conservation of the active site of unbound 
CK2 α and the holoenzyme-bound CK2 α supports the idea that CK2 α is catalytically active 
in isolation and that CK2 β is not an on/off switch as is found in similar kinases such as cyclin 
dependent kinase 2 (Niefind et al., 2001; Raaf et al., 2008).  
 
Its extensive list of protein substrates reflects the pleiotropic nature of CK2 functionality, and 
is structurally due to the acidic consensus sequences (e.g. -SXXE/D-, S for serine which is the 
most common phosphoacceptor) recognised by the kinase (Litchfield, 2003; Mazzorana, Pinna, 
& Battistutta, 2008; Pinna & Meggio, 1997). The multiple tetrameric forms (ααββ, α’α’ββ, 
αα’ββ) are present in all animals including mammals, amphibians and insects (Niefind et al., 
2001; Pinna, 1990; Schnitzler et al., 2014). Evidence shows that the formation of human CK2 
tetramers occurs via the catalytic subunits attaching independently to a stable dimer of the β 
subunits (Niefind et al., 2001; Raaf et al., 2008). The free monomeric α and α’ subunits of CK2 
are catalytically active as well in the absence of the β subunit and there is evidence that the 
discrete subunits possess individual functions different to the functions of the tetramer (Bibby 
& Litchfield, 2005; Blanquet, 2000; Boldyreff & Issinger, 1997; M. Faust & Montenarh, 2000; 
Perez, Gil, & Martinez, 2010). The α and α’ subunits are structurally analogous but are encoded 
by different genes (Allende & Allende, 1995). The β subunits in tetramers may provide 
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stability, protect α-subunits against denaturing agents or conditions, modulate activity of the 
enzyme or alter substrate specificity and interactions with inhibitors  (Allende & Allende, 1995; 
Guerra, Boldyreff, et al., 1999). It has been noted that catalytic activity is increased 5 to 10 fold 
for certain substrates by the presence of the β subunit (Allende & Allende, 1995; Cochet & 
Chambaz, 1983).   
 
Unlike mammalian CK2, yeast cells possess two genes (CKB1 and CKB2) encoding two 
distinct regulatory subunits, while the two catalytic subunits are encoded by CKA1 and CKA2 
genes. Yeast CK2 tetrameric holoenzymes have been found to require both CKB1 and CKB2 
subunits (Kubiński et al., 2007). See Figure 1.2 for a schematic of the different holoenzymes 
found in yeast and mammalian cells. 
 
 
Figure 1.2. The tetrameric isoforms of CK2 in S. cerevisiae and mammals.   
In S. cerevisiae there are two regulatory subunits, both of which are required for 
tetramerisation, forming a heterodimer to which two catalytic subunits attach. Different 
combinations of the catalytic subunits account for the different tetramers possible. In mammals 
a key difference is there is only one regulatory subunit (β) and therefore the initial step in 
tetramer formation is the formation of a β homodimer to which the catalytic subunits attach. 
Again, different combinations of catalytic subunits accounts for the different isoforms.   
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1.4.2 Distinctive functions for individual CK2 subunits 
As the yeast S. cerevisiae  contributes to our understanding of mammalian cell biology such as 
cell cycle control (Hartwell, Mortimer, Culotti, & Culotti, 1973; Lee & Nurse, 1987),  and the 
signaling serine/threonine kinase TOR (target of rapamycin) (Heitman, Movva, & Hall, 1991; 
Loewith, 2011), it proves to be a useful tool again towards understanding CK2. The genes of 
CK2 were first deleted in S. cerevisiae by homologous recombination. The yeast cells with 
disruption of either CKA1 or CKA2 genes are still viable; however disruption of both CKA1 
and CKA2 genes at the same time is lethal (Padmanabha, Chen-Wu, Hanna, & Glover, 1990). 
It is therefore clear that under normal growth conditions the catalytic subunits are 
compensatory. There are exceptions from this general statement. Several studies imply that, 
under certain environmental conditions, individual subunits confer different phenotypes 
(Johnson et al., 2016a, 2016b; Johnson et al., 2017; Rethinaswamy, Birnbaum, & Glover, 1998; 
Tun et al., 2014) , therefore  cannot be compensated by one another. In terms of the regulatory 
subunits, deletion of CKB1 or CKB2 or both does not lead to lethality while this does lead to 
high salt sensitivity (Bidwai, Reed, & Glover, 1995). Again, exceptions apply, as reflected by 
the fact that in mammals such as mice, homozygous knockout of CK2 β is fatal at the 
embryonic development stage (Blond et al., 2005).  While the CK2 α′ subunit appears to be 
essential only for normal spermatogenesis (Xu, Toselli, Russell, & Seldin, 1999), the disruption 
of  the CK2 α gene in mice leads to death in mid-gestation (Lou et al., 2008). Taken together, 
these structural and functional data tell us three basic points: (1) between the two catalytic 
subunits, CK2 α is more critical than CK2 α’; (2) Both CK2 α and CK2 α’ have distinct 
functions; (3) the tetrameric holoenzymes are essential in mammals since disruption of CK2 β 
would abolish formation of the CK2 holoenzyme and leads to lethality. It is possible that each 
entity not only functions in concert, as in the different forms of the tetramer, but also as 
individual monomers. While further research is required, there is a body of research that is 
suggestive of distinct functions for different iterations of CK2. 
 
The conservation of the active site of free and tetrameric CK2α supports the idea that CK2 
alpha is catalytically active in isolation and that CK2β is not an on/off switch  (Litchfield & 
Luscher, 1993; Niefind et al., 2001; Raaf et al., 2008). While some substrates are dependent on 
the presence of the β subunit (Salvi et al., 2006), biochemical analyses have shown that the 
regulatory subunit increases the activity of CK2α for most, but not all substrates. For example 
CK2α has greater catalytic activity towards calmodulin than does the holoenzyme (Arrigoni et 
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al., 2004). A recent astounding study that managed to produce cells that lack catalytic subunits 
indicates that, when CK2α and CK2α’ are deleted, the β subunit is rapidly degraded (Borgo et 
al., 2017). This tacitly supports the notion that the β subunit’s main purpose is CK2 tetramer 
formation. However, previous findings demonstrate the presence of monomeric β in a tissue 
dependent manner, suggesting CK2β monomeric function in specific tissues (Guerra, Siemer, 
Boldyreff, & Issinger, 1999). Interestingly the astounding study mentioned above found that 
when the regulatory β subunit is deleted, CK2α is upregulated while CK2α’ is downregulated 
(Borgo et al., 2017). This is suggestive of CK2α monomers substituting for tetramer activity. 
Other evidence has been published that demonstrates that CK2α subunits participate in tetramer 
formation in a manner dependent on subcellular localization and that a large portion of nuclear 
CK2α does not form tetramers but binds to other nuclear components (Stigare, Buddelmeijer, 
Pigon, & Egyhazi, 1993). Based on the findings collected above, one underlying hypothesis of 
this thesis is that the CK2 subunits have different functions. The previous finding in our lab, 
mentioned earlier, supports this hypothesis. It is that deletion of CKA2 in yeast results in 
aluminium toxicity resistance while deletion of the other subunits does not confer such 
resistance. This project garners additional evidence for individual CK2 subunit function. 
 
1.4.3 Factors related to CK2 activity 
Since CK2 is constitutively active, its activity does not rely upon the activity of other kinases. 
The alternative ways to regulate its activity are by level of expression, subcellular location of 
the enzyme, and extracellular signals. This is evident in cancers where CK2 is highly over-
expressed (Litchfield, 2003; Trembley, Wang, Unger, Slaton, & Ahmed, 2009). 
Spatiotemporal dynamics of CK2 in the nucleus and cytoplasm are shown in live cell 
fluorescence imaging (Filhol et al., 2003). The remaining question is what triggers up-
regulation of CK2 expression or changes its nucleocytoplasmic distribution. Heretofore, there 
are scant details in terms of what regulates dynamic distribution of CK2. A recent study by 
Kalathur et al. (2015) strongly demonstrates that the transcription factor, STAT3 (Signal 
Transducer and Activator of Transcription 3), regulates CK2 transcription and the protein level 
in mammalian cells. STAT3 itself is phosphorylated in response to growth factors or cytokines. 
The up-regulation of CK2 results in phosphorylation of the tumor suppressor, PML 
(Promyelocytic Leukemia protein), which in turn leads to PML ubiquitination and degradation. 
As a result, oncogenesis ensues (Kalathur et al., 2015).  
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In vitro assays have demonstrated that divalent metal ions such as Mg2+, Mn2+ and Co2+ are 
required for CK2 activity but beyond their optimal concentration these metals are actually 
inhibitory to CK2 (Gatica, Hinrichs, Jedlicki, Allende, & Allende, 1993; Hathaway & Traugh, 
1984a). These studies were performed using a substrate that precipitates, such as casein, in the 
presence of certain metals (e.g. Mg2+). The inhibition of CK2 in the presence of Mg2+ 
concentrations greater than its optimum is due to casein precipitation (Jiménez et al., 1995). 
The optimal concentration of Mg2+  may represent the point at which Mg2+-ATP (required for 
activity) is highest before precipitation occurs (Jiménez et al., 1995). While this is the case for 
Mg2+, substrate precipitation in the presence of Co2+ and Mn2+ does not occur and therefore the 
inhibition of enzyme activity at levels above the optimum of these ions may be a regulatory 
mechanism (Jiménez et al., 1995). Interestingly, when activity is assayed using Mn2+ and Co2+ 
instead of Mg2+ the preferred phosphoryl donor is GTP rather than ATP (Gatica et al., 1993). 
Zn2+ is inhibitory to CK2 at concentrations above 150 µM (Gatica et al., 1993). The inhibition 
of CK2 by zinc as well as the reported inhibition of activity found when Ni2+ is present is 
thought to be via direct interaction with the enzyme, perhaps in a manner similar to Mn2+ and 
Co2+ (Gatica et al., 1993; Jiménez et al., 1995). Given that the ionic strength of solution greatly 
impacts enzyme activity (Jiménez et al., 1995) and the requirements of CK2 for zinc in order 
for functional tetramers to form, there might be certain inextricable relationships between CK2 
and metal ions. 
 
Under certain conditions, polyamines are known to increase the activity of CK2 while 
polyanionic compounds are inhibitory to CK2 (Allende & Allende, 1995; Hathaway, Lubben, 
& Traugh, 1980). The stimulatory and inhibitory effects of CK2β on CK2α strongly depend on 
the salt concentration and on the presence of effector molecules such as polyamines or 
polybasic peptides (Hathaway & Traugh, 1984b; Niefind et al., 2001; Pinna & Meggio, 1997). 
This suggests that CK2 activity is regulated in specific cells and tissues by activating and 
inhibitory compounds. For example, CK2 activity may be tissue and location specific such as 
being subject to heparin concentration in the liver. The finding that CK2β’s effects on catalytic 
activity are substrate dependent, further emphasizes the notion that CK2β is a subtle modulator 
of catalytic activity rather than an on/off switch and that the activity of CK2 and its various 
iterations are regulated by varying factors. 
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1.4.4 CK2 and neurodegenerative disorders 
There is evidence that CK2 plays an important role in neurons. CK2 is more abundant in brain 
tissue than in any other part of the body and CK2 activity in adult rat tissues has been shown 
to be highest in brain and testis (Blanquet, 2000). Many CK2 substrates exist in synaptic and 
nuclear compartments and CK2 is involved in long-term potentiation in the hippocampus, and 
neurotrophins stimulate activity of CK2 in the hippocampus (Blanquet, 2000; Perez et al., 
2010). It is suggested that CK2 may play a role in neuronal adaptations to a changing 
environment through modulating synaptic connections, and may also regulate specific neuronal 
activities and participate in survival and death decision-making events (Blanquet, 2000). 
 
CK2 has also been linked to various neurodegenerative diseases, particularly Alzheimer’s 
disease (Aksenova, Burbaeva, Kandror, Kapkov, & Stepanov, 1991). Neurodegeneration is the 
deterioration of neurons of the central nervous system. A common feature of neurodegenerative 
diseases is that they result in severe mental and physical effects caused by the loss of structure 
and function of neurons (Cannon & Greenamyre, 2011). Such damage and dysfunction of 
neurons is commonly accompanied by protein aggregation, a feature of more than 20 
degenerative conditions (see Table 1.1) (Stefani & Dobson, 2003). 
 
Alzheimer’s disease is a major cause of dementia in people over the age of 65 years. 
Approximately 10-15% of people in this age group are affected. It is characterised by a loss of 
neurons from cortical and subcortical regions in the brain. Another feature of the disease is that 
a portion of the remaining neurons contain neurofibrillary tangles (NFT) and neuritic plaques 
(NPs) at neuroterminals. Phosphorylation and dephosphorylation are important in regulating 
the activity of enzymes and gene expression. Errors in phosphorylation and dephosphorylation 
may lead to a cellular loss of function or even cell death characteristic of Alzheimer’s disease 
(Iimoto, Masliah, DeTeresa, Terry, & Saitoh, 1990). Previous studies have indicated that the 
activity of certain kinase enzymes including CK2 is altered in Alzheimer’s disease, and that 
tau, a protein involved in tubulin polymerization is overphosphorylated in the disease (Iimoto 
et al., 1990; Perez et al., 2010). The overphosphorylation of tau is significant as it is found in 
NFTs and NPs present in Alzheimer’s disease (Ihara, Nukina, Miura, & Ogawara, 1986; Iimoto 
et al., 1990). The overphosphorylation of tau in the disease has been investigated and it has 
been suggested that due to the fact that CK2 activity is altered in Alzheimer’s disease and that 
tau contains sites that satisfy the target criteria of CK2, aberrant CK2 phosphorylation of tau 
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may be linked to Alzheimer’s disease pathology (Iimoto et al., 1990). In a study conducted in 
1991, when compared to normal samples, the level of soluble CK2 was found to be decreased 
in Alzheimer’s disease and schizophrenic frontal cortex post mortem brain samples as was the 
level of CK2 activity (Aksenova et al., 1991). ApoE, involved in lipid transport in neuronal 
cells, is thought to prevent tau hyperphosphorylation. CK2 has been shown to phosphorylate 
human apoE, and apoE has been shown to activate CK2 (Perez et al., 2010). Transport of 
proteins along the axon is essential for survival of the cell. Disruption of axonal transport 
mechanisms has been suggested as a means by which amyloids cause neuronal death in 
diseases such as Alzheimer’s disease. Recent evidence shows that oligomeric amyloid β (OAβ) 
might be activating CK2 and causing it to interact with both anterograde and retrograde fast 
axonal transport systems causing kinesin and dynein to drop their cargo (Pigino et al., 2009).  
OAβ was not found to interfere with the transport system when CK2 was inhibited (Perez et 
al., 2010; Pigino et al., 2009). GSK-3, a protein kinase, has been shown to cause disruption of 
fast axonal transport by causing kinesin to release the microtubule track. OAβ activates CK2 
causing it to prime the above mentioned GSK-3 aberrant function (Morfini, Szebenyi, Elluru, 
Ratner, & Brady, 2002; Perez et al., 2010; Pigino et al., 2009).  
 
The pathogenesis of Parkinson’s disease has also been linked with CK2. Both the catalytic and 
regulatory subunits of CK2 have been found in α-synuclein cytoplasmic inclusions. In vitro 
and immunohistochemical studies on Parkinson’s disease brains have shown CK2β subunits 
co-localised with α-synuclein in the majority of Lewy bodies (Ryu et al., 2008). Furthermore, 
CK2 is responsible for the phosphorylation of synphilin-1 which is present in Lewy bodies and 
binds α-synuclein. This interaction is dependent on phosphorylation and does not occur when 
CK2 is inhibited (Perez et al., 2010).  
 
Albeit both CK2 and metal ions are associated with neurodegenerative disorders, there is scant 
information on the interactions between CK2 and metal ions. This project aims to shed light 
on this area. 
 
1.4.5 CK2 and cancer  
Since 1984 it has been known that CK2 function is enhanced in rapidly proliferating tissue 
(Guerra, Boldyreff, et al., 1999). CK2 expression is dysregulated in all cancers examined and 
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this has led to CK2 being investigated for a role in oncogenesis (Trembley et al., 2009). It has 
been shown that the increased presence of CK2 in cancer tissue is a marker of dysplasia rather 
than simply an indicator of increased proliferation (Faust et al., 1999). While CK2 is not 
classified as an oncogene, dysregulation of CK2 imparts inordinate oncogenic potential on cells 
(Trembley et al., 2009). For example, tal-1 is a basic helix-loop-helix transcription factor. The 
dysregulation of tal-1 expression has been shown to lead to the development of T cell 
lymphoblastic leukemia/lymphoma in mice (Kelliher, Seldin, & Leder, 1996). In that same 
study it was shown that over-expression of CK2α with tal-1 resulted in dramatically accelerated 
leukemogenesis (Kelliher et al., 1996). The development of lymphoma has been linked to CK2 
over-expression and this was found to be synergistic with co-expression of the c-myc oncogene 
(Seldin & Leder, 1995). Additionally synergism was observed between over-expression of 
CK2α and loss of p53 – tumor suppressor gene, resulting in acceleration of lymphoma in mice 
(Landesman-Bollag, Channavajhala, Cardiff, & Seldin, 1998). CK2 can phosphorylate the key 
signalling molecule in the Wnt pathway, β-catenin and is a positive regulator of the Wnt 
signalling pathway (Seldin et al., 2005). CK2 regulates the basal NFκB through 
phosphorylation of IKB (Landesman-Bollag et al., 2001). For extensive reviews of CK2 and 
cancer see Trembley et al. (2009), Trembley et al. (2010) and Dominguez, Sonenshein, & 
Seldin (2009).  
 
While there has been extensive research on CK2’s role in cancer, there is very little on this 
topic in the context of metal ions. As CK2 and metal ions are both linked to cancer I believe 
understanding the role of CK2 in metal ion toxicity and regulation can help illuminate cancer 
research. 
  
1.4.6 CK2 and metal ions  
Jin et al. (2008) revealed, via transcriptomics of S. cerevisiae, that the expression of genes 
encoding subunits of protein kinase CK2 (e.g. CKA2) was repressed by transitional metal ions, 
suggesting that CK2 gene expression is undesirable for the cells under metal ion exposure. On 
the other hand, analysis of the ionomic data generated in a genome-wide yeast screen using 
overexpression strains indicates that the overexpression of CK2 subunits resulted in an increase 
of certain metals inside the cell including copper, iron and zinc (Yu et al., 2012). Apart from 
the yeast model organism, a similar finding was demonstrated in mammalian cells (Ye & Shi, 
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2001), in which CK2 transcripts were markedly reduced upon chromium exposure. In a study 
using mouse epidermal JB6 cells the phosphorylation of p53 (resulting in p53 DNA binding) 
by CK2 was found to be reduced in the presence of arsenic (Tang et al., 2006). 
 
How does CK2 regulate metal ion transport, biochemically? Two studies so far can provide us 
some insights. In response to the extracellular stimuli, CK2 was found to phosphorylate the 
zinc channel, ZIP7 (ZIP is an abbreviation of ZRT, IRT-like Protein, while ZRT stands for 
Zinc Regulated Transporter and IRT for Iron Regulated Transporter)), located in the membrane 
of the endoplasmic reticulum (ER) (Taylor et al., 2012). Consequently, Zn2+ ions in ER stores 
were released, and cytosolic concentration of Zn2+ increased, triggering a cascade of signalling 
pathways including the activation of receptor tyrosine kinase and the phosphorylation of 
protein kinase B (also known as Akt) and extracellular signal-regulated kinases 1 and 2 
(ERK1/2). The end result of such action is enhanced cell proliferation. This finding offers a 
mechanistic explanation, if only partially, to the role of CK2 in regulating metal homeostasis. 
CK2 is also found to regulate epithelial Na+ channel activity (Bachhuber et al., 2008). The Na+ 
channel is a trimeric protein, composed of α, β and γ subunits. The phosphorylation sites for 
CK2 are located in the C terminus of β (βS631) and γ subunits (γT599). The channel’s activity was 
inhibited by the selective CK2 inhibitor 4,5,6,7-tetrabromobenzotriazole (TBB). Furthermore, 
phosphorylation of the channel by CK2 antagonises the inhibition of Nedd4-2, the E3-ubiquitin 
ligase, which causes channel ubiquitination and degradation. Intriguingly, CK2 was 
translocated to the cell membrane upon expression of the wildtype Na+ channel but not of the 
mutant channel lacking both of the phosphorylation sites. This notion also sheds light on the 
topic of CK2 distribution. There is likely a pulling force or an attraction between CK2 and its 
substrate, and evidence suggest that this attraction is structurally due to basic residues in key 
positions of CK2 recognising the acidic determinants in the substrate for phosphorylation. It is 
expected that more investigations will be carried out on this front. 
  
Another elegant study conducted on CFTR (cystic fibrosis transmembrane conductance 
regulator) provides more details on the mode of CK2 action (De Stefano et al., 2014; 
Venerando et al., 2011). Although CFTR is essentially a chloride channel, much can be learnt 
from its interaction with CK2. Inhibition of CK2 closes CFTR wildtype but not the cystic 
fibrosis mutant channel ∆F508-CFTR (Treharne et al., 2009). The deletion of phenylalanine 
(F), the 508th residue in CFTR, abolishes the interaction of CK2 with ∆F508-CFTR, suggesting 
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the phenylalanine residue serves as a docking site for CK2 action. Furthermore, ∆F508-CFTR 
mutant is often degraded before reaching the plasma membrane. As for the membrane-bound 
mutants, they are unstable. Application of the proteostasis regulator cysteamine and the CK2 
inhibitor, epigallocatechin gallate (EGCG) or CX-4945, can reduce the degradation of ∆F508-
CFTR, resulting in more mutant channels residing in the membrane (De Stefano et al., 2014).  
Such a study serves as an example for future investigations into the role CK2 in metal ion 
transport. 
 
Additionally, to understand cellular regulation of metal ions, we must differentiate the essential 
ions such as iron and zinc from the toxic ones like arsenic, chromium and aluminium. In the 
evolutionary sense, the cell has become accustomed to the essential ions and has built-in 
mechanisms to maintain their homeostasis for growth and survival. The cell’s response to the 
toxic metal ions is basically a detoxification process using the cell’s defense mechanisms. As 
reviewed previously, CK2 is involved in both categories of the metals. The key question is 
what senses the intracellular level of a particular ion. There is no absolute answer to this 
question thus far. However, it has been shown that in the presence of increased metal ions the 
transcription factor MTF-1 (metal transcription factor 1) is phosphorylated and this 
phosphorylation is reduced by inhibition of CK2.  Upon phosphorylation, MTF-1 activates 
metal responsive genes such as metallothioneins (Adams, Saydam, Steiner, Schaffner, & 
Freedman, 2002). Metallothioneins are a class of cysteine-rich, metal binding proteins that are 
thought to play a role in essential metal ion homeostasis and detoxification of toxic metal ions 
(Adams et al., 2002). This evidence suggests that CK2 plays a role in the detoxification of 
metals by activation of the metal transcription factor.  
 
The evidence for CK2’s role in metal homeostasis is emerging. As previously mentioned, the 
work by Taylor et al., 2012 demonstrates a role for CK2 in zinc homeostasis through regulation 
of the ER zinc channel ZIP7. There are 14 ZIP channels responsible for zinc uptake. There also 
exist 10 ZnT channels responsible for zinc efflux from the cytosol (Figure 1.3). Given that CK2 
is found to directly phosphorylate ZIP7 (Taylor et al., 2012), it is likely that it also 
phosphorylates other zinc transporters. As with the known interaction between CK2 and ZIP7, 
which leads to the elevated cytosolic Zn2+ level, the phosphorylation of other zinc transporters 
by CK2 may also have regulatory functions regarding metal ion homeostasis.    
23 
 
Table 1.2 shows the various zinc transporters and the possible residues that could be 
phosphorylated by CK2. The possible phosphorylation sites presented in the table are based on 
predictive software GPS 3.0 (http://gps.biocuckoo.org/). Additionally, a review of the online 
database PhosphositePlus (https://www.phosphosite.org/homeAction.action), a compendium 
of experimental evidence of phosphorylation sites in protein substrates of numerous kinases 
including CK2 (Hornbeck et al., 2015), reveals that experimental studies have confirmed the 
predictions in Table 1.2 for ZIP3 serine 125 (S125), serine 129 (S129) and serine 131 (S131) 
and ZIP7 serine 275 (S275) and serine 276 (S276).  According to a rodent study (Hoffert et al., 
2006), human ZIP12 serine 160 (S160) is likely phosphorylated.  
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Figure 1.3 Mammalian zinc homeostasis.  
14 ZIP importers are found in the plasma membrane and intraorganellar membranes. 10 ZnT efflux transporters also exist, found in the plasma 
membrane and intraorganellar membranes. Also shown is the mechanism of sequestration facilitated by metallothioneins. Metal transcription 
factor 1 (MTF-1) binds the Metal responsive element (MRE), resulting in production of metallothioneins (MTs) which bind excess Zn2+.     
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Table 1.2 Phosphorylated sites predicted in the zinc channels.  
Protein  Site  Exemplar Sequence  Score  Location of phosphorylation site  
ZIP1 None  - - - 
ZIP2 S87 MVQNRSASERNSSGD 10.179  Extracellular  
ZIP2 S91 RSASERNSSGDADSA 15.628  Extracellular  
ZIP3 S125 LETFNAGSDVGSDSE 10.216  Cytoplasmic  
ZIP3 S129 NAGSDVGSDSEYESP 16.602  Cytoplasmic  
ZIP3 S131 GSDVGSDSEYESPFM 12.602  Cytoplasmic  
ZIP4 None  - - - 
ZIP5 None - - - 
ZIP6 S100 HHDHDHHSDHEHHSD 11.864  Extracellular 
ZIP6 S106 HSDHEHHSDHERHSD 12.672  Extracellular 
ZIP6 S112 HSDHERHSDHEHHSE 12.662  Extracellular 
ZIP6 S118 HSDHEHHSEHEHHSD 12.807  Extracellular 
ZIP6 S124 HSEHEHHSDHDHHSH 12.309  Extracellular 
ZIP6 S183 RNVKDSVSASEVTST 10.324  Extracellular 
ZIP7 S275 RSTKEKQSSEEEEKE 16.548  Cytoplasmic  
ZIP7 S276 RSTKEKQSSEEEEKE 16.548  Cytoplasmic  
ZIP8 None - - - 
ZIP9 S132 IGNSHVHSTDDPEAA 11.066  Cytoplasmic 
ZIP10 None  - - - 
ZIP11 None - - - 
ZIP12 S160 DEDSSFLSQNETEDI 10.412  Extracellular 
ZIP12 S197 KKSGIVSSEGANEST 10.888  Extracellular 
ZIP12 S293 QDYSNFSSSMEKESE 11.826  Cytoplasmic  
ZIP12 S497 LALNSELSDQAGRGK 9.983  Extracellular 
ZIP12 S565 AIGAAFSSSSESGVT 10.276  Cytoplasmic  
ZIP12 S567 GAAFSSSSESGVTTT 10.409  Cytoplasmic  
ZIP13 None  - - - 
ZIP14 None  - - - 
ZNT1 None - - - 
ZNT2 S322 CQACQGPSD 10.147  Cytoplasmic 
ZNT3  S341 SAHLAIDSTADPEAV 9.921  Cytoplasmic 
ZNT4 S32 DTSAFDFSDEAGDEG 13.229  Cytoplasmic 
ZNT5 None - - - 
ZNT6 None  - - - 
ZNT7 None - - - 
ZNT8 S353 SLTIQMESPVDQDPD 10.017  Cytoplasmic 
ZNT9 None  - - - 
ZNT10 S446 TYGSDGLSRRDAREV 11.562  Cytoplasmic 
Note: The protein sequence of each zinc channel was analysed for phosphorylation by CK2 
using GPS3.0 software (Xue et al., 2008), using the high threshold option (reported false 
positive rate of <2%). This threshold correlates with a cut-off value of 9.84. The table 
shows the predicted residue position, the sequence, the score (higher score means more 
likely to be phosphorylated) and the location of the predicted phosphorylation sites. 
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Further from Table 1.2, a schematic view of the predicted phosphorylation sites in zinc 
channels are shown in Figure 1.4. It visualizes that many of the ZIP channels (influx to cytosol) 
and ZnT channels (efflux from cytosol) can be potentially phosphorylated by CK2. While some 
of these sites are likely not regulatory in nature (due to their extracellular location), some may 
indeed regulate the activity of the transporter as is seen in the case of ZIP7 (Taylor et al., 2012). 
 
Figure 1.4 Schematic view of the phosphorylation sites in ZIP and ZnT channels 
predicted to be phosphorylated by CK2. CK2 phosphorylation sites were predicted 
using GPS 3.0 software. Transmembrane domains are identified according to Uniprot 
(http://www.uniprot.org) and the original publications for ZIP2 (Wang, Zhou, Kuo, 
Zemansky, & Gitschier, 2002), ZIP3 (Wang et al., 2002), ZIP6 (Taylor et al., 2016; 
Wang et al., 2002), ZIP7 (Taylor et al., 2016; Wang et al., 2002), ZIP9, ZIP12 
(Schmitt-Ulms, Ehsani, Watts, Westaway, & Wille, 2009). The six TM domains of 
ZnT2, 3, 4, 8 and 10 are based on an atomic-resolution structure of YiiP (Huang & 
Tepaamorndech, 2013; Lu & Fu, 2007). TM denotes transmembrane (blue), E for 
extracellular (red), C for cytoplasmic (green), IO for intra-organellar, S for serine. 
 
1.5 Experimental approaches  
This study employs the well-established model organism S. cerevisiae. By using gene deletion 
mutants, I garner information about the function of genes in the regulation and toxicity of metal 
ions, particularly the genes encoding the subunits of protein kinase CK2. By crossing deletion 
mutants of CK2 genes with other genes of interest, double deletion mutants were produced, 
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this included double deletion mutants of CK2 genes (i.e. deletions of two subunits of CK2). By 
screening these mutants, I gathered information regarding the role of specific CK2 subunits 
and pathways involved in metal toxicity that interact with CK2. The use of a CK2 specific 
inhibitor allowed another avenue into exploring the cellular response to metals in a CK2 
compromised cell. The use of a redox active fluorescent probe allowed exploration of the role 
of CK2 in response to Cr6+. Inductively coupled plasma mass spectrometry allowed me to 
determine the cellular content of metals in CK2 deletion mutants allowing me to explore the 
role of CK2 in the influx/efflux of metal ions. Finally, after establishing the role for CK2 in 
metal ion regulation and toxicity in the yeast system, congruent findings were sought in 
mammalian tissue culture experiments where CK2 gene expression is quantified under metal 
ion treatment and the effect of CK2 inhibition and knockdown on the viability of the cells under 
metal ion treatment was quantified. Figure 1.5 shows a summary of the experimental 
approaches of this project.     
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Figure 1.5. Experimental approaches of this project.  
The initial stages of the project sought to understand the role of CK2 in metal toxicity through genetic and biochemical means employing the 
yeast model organism S. cerevisiae. The focus then shifted to seeking congruent findings in mammalian cell cultures using molecular and 
biochemical approaches.  
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1.6 Hypotheses and Aims  
On the basis of the above review of literature, the hypotheses for the experimental work 
conducted in this thesis were: 
1. Protein kinase CK2 regulates the toxicity of metal ions such as Al3+, Zn2+, As3+, 
Cr6+, Co2+ and Ca2+  
2. The individual subunits of protein kinase CK2 have discrete effects on metal ion 
toxicity 
3. CK2 interacts with proteins of molecular networks of the cell in response to metal 
toxicity       
4. The roles of CK2 in regulating metal toxicity in the model organism S. cerevisiae 
are conserved in mammalian cells    
 
Based on the above hypotheses the specific aims of this thesis are:  
1. To explore the role of protein kinase CK2 in metal toxicity using gene deletion 
mutants of S. cerevisiae 
2. To distinguish tetrameric CK2 functions from monomeric subunit functions under 
metal ion exposure   
3. To uncover the details for the role of protein kinase CK2 in arsenic toxicity via the 
genome-wide deletion mutant screening of S. cerevisiae 
4. To uncover the role of CK2 in chromium toxicity by genome-wide screening of S. 
cerevisiae gene deletion mutants 
5. To explore the role of CK2 in metal ion toxicity in mammalian neuronal cells 
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2 Materials and Methods 
2.1 General materials and reagents 
All generally required chemicals in this project were supplied by Sigma-Aldrich, Sydney, 
Australia. Specific chemicals and solvents were obtained from commercial suppliers detailed 
in the relevant procedures below, and they were of analytical grade or higher. Media and 
buffers were made with deionised water from a MilliQTM system (Millipore, Australia).  
 
2.2 Sterilisation 
All media, heat-stable solutions, glass and non-sterile plastic wares were sterilised by 
autoclaving at 121 ᵒC for 15 min. Heat-nonstable solutions, where sterility was required, were 
sterilised by filtration through a 0.2 µm filter. 
 
2.3 Experimental work using S. cerevisiae 
2.3.1 Yeast strains  
Unless otherwise stated, the yeast strains used were the BY4743 wildtype (MATa/MATα 
his3Δ0/his3Δ0; leu2Δ/leu2Δ0; met15Δ0/MET15; LYS2/lys2Δ0; ura3Δ0/ura3Δ0) and 
homozygous single-gene deletion mutants (genotype same as BY4743 with XXX::kanMX4/ 
XXX::kanMX4) from EUROSCARF (Institute of Molecular Biosciences, Frankfurt, Germany). 
 
2.3.2 Media and storage  
Minimal medium was used for the growth of yeast in all experiments except in cases where 
selection, based on nutrient requirements, was desired. Liquid minimal medium was composed 
of 20 g/L D-glucose, 1.7 g/L yeast nitrogen base (YNB) without ammonium sulfate or amino 
acids, 5 g/L ammonium sulfate and supplemented with the following: 10 mg/L adenine, 50 
mg/L L-arginine, 80 mg/L L-aspartic acid, 20 mg/L L-histidine HCl, 100 mg/L L-leucine, 50 
mg/L L-lysine HCl, 20 mg/L L-methionine, 50 mg/L L-phenylalanine, 100 mg/L L-threonine, 
50 mg/L L-tryptophan, 50 mg/L L-tyrosine, 140 mg/L L-valine, 20 mg/L uracil and 50 mg/L 
isoleucine. 
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YEPD media contained 10 g/L yeast extract, 20 g/L peptone and 20 g/L D-glucose. Prolonged 
storage of cells, was YEPD with the addition of 15% v/v glycerol. 
 
For the selection of heterozygous BY4743 diploids after mating BY4741 magic marker strains 
with BY4742 KanMX strains, synthetically defined selective media was used (SDsel). SDsel 
media contained D-glucose 20 g/L, YNB 1.7 g/L, glutamic acid 1 g/L, G418 200 mg/L and L-
histidine 120 mg/L. 
 
Rich YEPD, for the growth of the diploid results of mated haploid cells contained 10 g/L yeast 
extract, 30 g/L bacteriological peptone and 50 g/L D-Glucose.    
 
Sporulation medium contained potassium acetate (10 g/L), zinc acetate (0.5 g/L) and histidine 
(120 mg/L).  
 
All agar plates were made with the required medium supplemented with 5 g/L bacteriological 
agar.  
 
2.3.3 Generation of double deletion yeast mutants  
The homozygous double gene-deletion mutants generated in this study were derived by 
crossing a BY4741 magic marker URA3 strain MATa (ura3Δ0; leu2Δ0; his3Δ1; met15Δ0; 
can1Δ::LEU2-MFA1pr-HIS3/CAN1; xxx::URA3) (Tong et al., 2001) containing a given gene 
deletion to the BY4742 KanMX strain MATα (ura3Δ0; leu2Δ0; his3Δ1; lys2Δ0; xxx::KanMX) 
(Winzeler et al., 1999) which contains another gene deletion. The advantages of using the 
magic marker stains allows the ease of selection for the MATa mating type due to the 
can1Δ::LEU2-MFA1pr-HIS3 magic marker cassette without the use of dissection microscope 
and various tests associated with mating type and gene deletion. Specifically, the CAN1 gene 
is replaced with a magic marker cassette (can1Δ) and provides strains with resistance to L-
canavinine which is a toxic analogue of L-arginine. In addition, the magic marker cassette is 
maintained with a functional LEU2 gene. However, the selection for the MATa mating type is 
provided by the MFA1pr-HIS3 which is a HIS3 gene under the control of a mating pheromone 
a-factor promotor, thus only MATa can express HIS3. Selection of haploid cells was carried 
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out as described in Boone, Bussey, & Andrews, (2007). For example, the haploid ckb1∆ mutant 
from MATa BY4741 magic marker strain background was mated with the haploid ckb2∆ strain 
from the MATα BY4742 background by inoculating to an equivalent optical density of 0.01 of 
each mating type in YEPD, followed by incubation at 30 °C overnight with no shaking. Two 
rounds of single colony selection were performed on SDsel agar. This process selects for 
heterozygous BY4743 diploids MATa/α (ura3Δ0/ura3Δ0; leu2Δ0/leu2Δ0; his3Δ1/his3Δ1; 
lys2Δ/LYS; met15Δ0/MET15; can1Δ::LEU2-MFA1pr-HIS3/CAN1; ckb1Δ0::URA3/CKB1; 
ckb2∆0::KanMX/CKB2). The selection processes include using glutamic acid as a nitrogen 
source instead of ammonium sulfate during G418 selection as ammonium sulfate interferes 
with selection. G418 selects for the ckb2∆0::KanMX and inhibits the growth of BY4741, and 
the absence of uracil selects for ckb1Δ0::URA3 and prevents the growth of BY4742. L-histidine 
was supplemented because His3p is only expressed in MATa (MFA1pr-HIS3), therefore the 
combination selects for heterozygous diploids containing both deletions.   
 
After verification of growth on selective media, several viable individual colonies were pooled 
to sporulate. The heterozygous BY4743 diploid cells were grown in four successive cycles. 
Cell suspensions were washed with sterile water, then diluted (1:50) in sporulation medium 
and incubated at 25 °C for 5 days with shaking (150 rpm) followed by further incubation at 30 
°C for 3 days with shaking (150 rpm). Spore suspensions were germinated for homozygous 
haploid double deletion strains by streaking the spore containing suspension onto SDsel agar, 
which contains G418 as described above, with the addition of L-canavanine (25 mg/L) but 
lacking uracil and all amino acids including L-histidine. The addition of L-canavanine selects 
haploids using the magic marker cassette (can1Δ::LEU-MFA1p-HIS3) and prevents the growth 
of diploid heterozygous cells. Cells containing the magic marker cassette that are haploids can 
survive without leucine and histidine. The resulting double-deletion strains are haploid MATa, 
such as ckb1∆ ckb2∆ (ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; 
ckb2∆0::KanMX). A table of the double deletion mutants generated can be found in Appendix 
A. 
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2.3.4 Phenotypic screening for the effect of single deleted genes on metal 
toxicity 
Single colonies of the wildtype (BY4743) and the CK2 knockout mutants (cka1Δ, cka2Δ, 
ckb1Δ and ckb2Δ) were inoculated into minimal medium and incubated at 30 ᵒC, with shaking 
at 150 rpm in an orbital mixer incubator (Ratek) until the cultures reached optical density 600 
nm (OD600) of approximately 1. Cultures were then diluted in minimal medium to OD600 0.1 
and transferred into 96-well microtiter plates. The plated mutants and wildtype were then 
treated after 3 h incubation with 6 metals at varying concentrations: zinc sulphate (ZnSO4, 0, 
4, 8, 16, 25 and 32 mM), cobalt chloride (CoCl2, 0, 0.4, 0.8, 1.6, 3.2 and 6.4 mM), aluminium 
sulphate (Al2(SO4)3, 0, 0.4, 0.8, 1.6, 2.5 and 3.2 mM), sodium arsenite (NaAsO2, 0, 0.2, 0.4, 
0.8, 1.6 and 3.2 mM), chromium oxide (CrO3, 0, 0.05, 0.1, 0.2, 0.4 and 0.8 mM) and calcium 
chloride (CaCl2, 0, 40, 80, 160, 320 and 640 mM). The OD600 at the time of treatment (T0) was 
measured using a 96-well plate reader (Multiskan EX, Thermo Electron, USA) then the cultures 
were incubated at 30 ᵒC while shaking at 750 rpm (Ika MTS 2/4 digital microtiter shaker). 
OD600 was subsequently measured every 4 h for 24 h except sodium arsenite treatment which 
was measured until 48 h. The experiments were conducted 3 times with 8 replicates each.  
 
2.3.5 Phenotypic screening of CK2 double deletion mutants 
Single colonies of the BY4741 magic marker URA3 CK2 knockout mutants (cka1Δ, cka2Δ, 
ckb1Δ and ckb2Δ), BY4742 KanMX gene of interest knockout mutants, inter-CK2 double 
deletion mutants ckXX∆ ckXX∆ and CK2 mutants crossed with a subarray of genes of interest 
(Appendix A) were inoculated into minimal medium (pH 4.3) at 30 ᵒC, with shaking at 150 
rpm until the cultures reached OD600 of approximately 1. Cultures were then diluted to OD600 
0.1 and transferred into 96-well microtiter plates. After 3 h incubation, the BY4741 magic 
marker URA3 strains and inter-CK2 double deletion strains were treated with ZnSO4 (0, 5, 8, 
10, 16, 25 mM), CrO3 (0.2, 0.4 mM), Al(SO4)2 (0.8, 1.6 mM) and NaAsO2 (0.2, 0.4, 0.8 mM). 
The BY4742 KanMX gene of interest knockout mutants and the CK2 mutants crossed with the 
subarray of genes of interest were treated with ZnSO4 (5, 10 mM) and NaAsO2 (0.2 and 0.4 
mM). The OD600 was measured at T0 and subsequent 4 h intervals. 
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2.3.6 Quantification of metal ion content in yeast cells by inductively coupled 
plasma mass spectrometry (ICP-MS)  
Single colonies of strains were inoculated into pre-cultures and grown overnight at 30 ᵒC while 
shaking (150 rpm). Once the cultures achieved an OD600 value of approximately 1, they were 
diluted to an OD600 of 0.2 and returned to the incubator. Cultures were regularly monitored 
until reaching an OD600 of 0.8. The cells were then treated with aluminium sulfate (0.8 mM), 
zinc sulfate (16 mM), sodium arsenite (0.4 mM), and chromium trioxide (0.2 mM). 
Immediately after treatment 10 mL samples were taken as T0. Further sampling was carried out 
at 4 h intervals for a duration of 16 h. All samples were spun down at 10000 g immediately 
after being taken (Sorval RC6+, Thermo Scientific), washed with 5 mL of 0.2 µM 
ethylenediaminetetraacetic acid (EDTA), then washed with 5 mL sterile MilliQ water. The 
cells were then re-suspended in 1 mL MilliQ water and transferred to pre-weighed Eppendorf 
tubes for the final centrifugation at 20000 g for 5 minutes (Eppendorf 5424). The cell pellets 
were lyophilised and digested as follows. Dried samples were firstly suspended in 1 mL of 70% 
ultra-pure nitric acid (Sigma-Aldrich). The resultant suspensions were transferred to acid-
washed glass tubes and placed in a heating block at 120 ᵒC. After 12 h of digestion the 
temperature was raised to 180 ᵒC for acid evaporation. Acid only and water only controls were 
also included in each round of digestion. The digested samples, along with water and acid 
controls, were then re-suspended in 2 mL of 5% ultra-pure nitric acid and analysed using a 
NexION 300X ICP-MS (Perkin Elmer). 
 
2.3.7 Effect of CK2 inhibitor on the yeast gene deletion strains under metal ion 
treatment  
Single colonies of strains were inoculated in pre-cultures and grown overnight at 30 ᵒC while 
shaking (150 rpm). Upon reaching an OD600 value of approximately 1, the cultures were 
diluted to an OD600 of 0.1 and transferred to 96-well plates. After 3 h equilibration, the 
cultures were treated with 20 μM 4,5,6,7-Tetrabromo-2-azabenzimidazole (TBB). Although 
TBB is highly specific against CK2 and widely used in literature, the observed phenotype for 
the effect of its inhibition on yeast cells cannot be considered as due only to its inhibition of 
CK2. In a study on 33 kinases, a similar dose of TBB as used here was found to inhibit CK2 
activity by 85%, while only 3 off target kinases were inhibited, and to a much lesser extent 
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(averaging 39% inhibition) (Sarno et al., 2001). The off targets included phosphorylase 
kinase, glycogen synthase kinase 3β and cyclin-dependent kinase 2/cyclin A. Following a 
further 3 h incubation with the inhibitor, the cultures were treated with zinc sulfate (16 mM 
and 25 mM) and aluminium sulfate (0.8 mM and 1.6 mM). Immediately after the treatment 
the OD600 of the plates was measured. The plates were then returned to the shaking incubator 
(30 ᵒC, 150 rpm). OD600 was measured at 4 h intervals for 24 h. The experiments were 
conducted 3 times with 8 replicates each.  
 
2.3.8 Genome wide screening of S. cerevisiae against As3+ and Cr6+ 
Deletion mutants as well as the wildtype strain (BY4743) from EUROSCARF library plates, 
frozen in YEPD (10 g/L yeast extract, 20 g/L peptone and 20 g/L D-glucose) and 15% glycerol, 
were transferred to plates containing minimal medium (pH 4.3) (20 g/L D-glucose, 1.7 g/L 
yeast nitrogen base without ammonium sulphate, 5 g/L ammonium sulphate and 0.79 g/L, 10 
mg/L adenine, 50 mg/L L-arginine, 80 mg/L L-aspartic acid, 20 mg/L L-histidine HCl, 50 mg/L 
isoleucine, 100 mg/L L-leucine, 50 mg/L L-lysine HCl, 20 mg/L L-methionine, 50 mg/L L-
phenylalanine, 100 mg/L L-threonine, 50 mg/L L-tryptophan, 50 mg/L L-tyrosine, 140 mg/L 
L-valine, 20 mg/L uracil) and incubated at 30 °C for 3 h to allow growth to reach an OD600 of 
approximately 0.045 prior to addition of sodium arsenite (NaAsO2) or chromium trioxide 
(CrO3) for screening. 
 
BY4743 parent wildtype and the 4,873 deletion mutants were screened under two doses of 
sodium arsenite (NaAsO2) (0.2 and 0.4 mM) and two doses of chromium trioxide (CrO3) (0.05 
and 0.1 mM) as well as an equal volume of sterile MilliQ water (control). These concentrations 
were chosen based on a prior titration with a range of NaAsO2 concentrations (0.5-3.2 mM) 
and chromium trioxide (CrO3) concentrations (0.1-0.8 mM) using BY4743. The doses 0.2 mM 
NaAsO2 and 0.05 mM CrO3 were found to have no effect on wildtype (BY4743) growth. The 
lower growth of mutants than BY4743 under these doses is regarded as a sensitive phenotype. 
On the other hand, the doses of 0.4 mM NaAsO2 and 0.1 mM CrO3 reduced the growth of 
BY4743 by 50%. Therefore, 0.4 mM NaAsO2 and 0.1 mM CrO3 were used in this project to 
uncover resistant mutants with growth higher than the wildtype. OD600 at the time of treatment 
(T0) was measured using a 96-well plate reader (Multiskan EX, Thermo Electron, USA) then 
the cultures were incubated at 30 °C. At 16 h (T16) and 20 h (T20), cultures were re-suspended 
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and OD600 measured. Measurement at T16 has been found, in my experience, to correlate with 
the greatest divergence between treatment and control. T20 is the time when control cultures 
become stationary. In the final data analysis, only OD600 at T16 was used for each strain. The 
fold change in growth was calculated as a ratio of OD600 at T16 over OD600 at T0. Each strain’s 
phenotypic growth in this screen is expressed in a value calculated by dividing the ratio of the 
mutant’s growth over that of BY4743 in treatment by the ratio of mutant’s growth over that of 
BY4743 in control, as described in my publication (Johnson et al., 2016a). The ratio of mutant 
growth over that of the wildtype in treatment establishes the effect of arsenite or chromium on 
the growth of that mutant. For certain slow growing mutants, using such a ratio alone would 
result in false sensitive mutants. Therefore, the ratio in treatment is corrected with the ratio of 
mutant’s growth over that of BY4743 in control. The cut-off value of 0.5, denoting 50% growth 
reduction under treatment, was used to select sensitive mutants, which were at the value 0.5 or 
lower. The cut-off value of 2, representing 200% greater growth than the wildtype, was used 
for selecting resistant mutants, which were of 2 or higher. The sensitive and resistant mutants 
identified from the initial screen were further screened for confirmation. The mutants were 
picked from EUROSCARF stock plates and screened against 0.2 mM NaAsO2 for arsenite 
sensitivity and against 0.4 and 0.8 mM NaAsO2 for arsenite resistance and 0.05 mM CrO3 for 
chromium sensitivity and 0.1 and 0.2 mM CrO3 for chromium resistance. The data was 
processed in the same manner as the initial screen. 
 
2.3.9 Gene annotation of the identified deletion mutants to As3+ or Cr6+ 
For the annotation of biological processes and pathways that play a role in the detoxification  
of Cr6+ and As3+ mutants that were found to be sensitive to the toxicants were analysed using 
a range of web-based resources. The same process was used to uncover the biological processes 
and pathways involved in metal toxicity for the genes deleted in tolerant mutants. Functions of 
the corresponding genes of the Cr6+ and the As3+ sensitive and tolerant mutants were annotated 
and analysed using Saccharomyces Genome Database (http://www.yeastgenome.org), MIPS, 
Gene Ontology, BioGRID (http://www.thebiogrid.org) and FunSpec 
(http://funspec.med.utoronto.ca). 
 
37 
 
2.3.10   Determination of oxidative stress in CK2 mutants under metal ion 
treatment using flow cytometry 
CK2 gene deletion mutants and the BY4743 wildtype were transformed with Grx1-roGFP on 
a pAG416GPD vector according to the protocol by Liu, Lanham, Buchan, & Kaplan, (2017). 
The redox probe measures changes in oxidized glutathione (GSSG) against a backdrop of 
reduced glutathione (GSH) as described by Gutscher et al., (2008). The expression clone was 
generously provided by Doctor Gabriel Perrone. Single colonies of the transformants were 
inoculated into flasks and grown to an OD600 of approximately 1. Cultures were subsequently 
diluted to an OD600 of 0.1 and treated with Al
3+
 (0.4, 0.8, 1.6, 3.2 mM), Zn
2+ (4, 8, 16, 32 mM), 
Cr6+ (0.05, 0.1, 0.2, 0.4 mM), As3+ (0.2, 0.4, 0.8, 1.6 mM), Co2+ (0.8, 1.6, 3.2, 6.4 mM) and 
Ca2+ (160, 320 mM). Cells were run on a FACSCanto II flow cytometer (BD Biosciences, 
Australia) and excited at 405 and 488 nm and the emission spectra were gathered at 510 and 
530 nm. The probe works by differential excitation and emission in different redox 
environments. Under the oxidative condition in which GSH is oxidised to GSSG, the probe 
changes its excitation maximum from 488 nm to 405 nm based on a redox relay. By 
determining the ratio of emission signals detected under the two excitation signals in treatment 
and control conditions one can infer the redox state of the cell. Cells were measured at 0 h (just 
prior to treatment) at 10 min, 2 h and 4 h. 
 
2.4 Experimental work using mammalian cell lines 
2.4.1 Cell lines 
Two cell lines were used in this project, as shown in Table 2.1. Neuro2a mouse neuroblastoma 
cells were generously provided by Doctor Sindy Kueh.  SH-SY5Y cells were purchased from 
CellBank Australia.  
 
 
 
 
 
 
38 
 
Table 2.1 Mammalian cell lines used in this project 
Cell type Source  Growth mode  Morphology  Karyotype  
Neuro2a Albino mouse 
neuroblastoma     
Adherent  Neuronal/amoeboid-
like 
2n 
SH-SY5Y Human 
Neuroblastoma   
Adherent  Neuroblast  Not specified  
 
2.4.2 Media for mammalian cells 
Neuro2a mouse neuroblastoma cells were grown in complete DMEM medium (Growth 
medium) which was made from high glucose DMEM (Life Technologies, Australia), 
supplemented with 10% foetal bovine serum (FBS) (Life Technologies, Australia) and 1% 
antibiotics (penicillin/streptomycin) (Life Technologies, Australia). 
 
SH-SY5Y neuroblastoma cells were grown in complete DMEM/F12 Hams (Growth medium) 
(Sigma-Aldrich, Australia) supplemented with 10% foetal bovine serum (FBS) (Life 
Technologies, Australia) and 1% antibiotics (penicillin/streptomycin) (Life Technologies, 
Australia). 
 
The freezing medium used for cryogenic storage was made from DMEM for Neuro2a cells, or 
DMEM/F12 Hams for SH-SY5Y cells, supplemented with 20% FBS and 10% dimethyl 
sulfoxide (DMSO, Sigma-Aldrich). 
 
2.4.3 Cell culture conditions 
All aspects of cell culture, such as passaging cells and changing media, were carried out 
aseptically in a class II biological safety cabinet (Gelaire AS-2252.2). The cabinet was exposed 
to UV light for 30 min and wiped down with 80% ethanol immediately prior to and post use. 
Exteriors of materials were sprayed with 80% ethanol before entering the sterile cabinet. Tips, 
bottles and heat-stable solutions were sterilised by autoclaving for 20 min at 121 ᵒC (Tuttnauer 
3150EL, Australia). Certain heat-sensitive reagents were filtered through a 0.2 µm filter. 
 
Approximately 1.0 × 105 cells were seeded into a 25 cm2 tissue culture flask (Greiner Bio-One, 
Germany) with 6 mL complete DMEM for Neuro2a or 6 mL complete DMEM/F12 Hams for 
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SH-SY5Y and incubated at 37 ᵒC, 5% CO2 (Thermo Scientific HERA 150). Cultures were 
observed daily under an inverted microscope (Olympus CKX41) to monitor the health and 
confluence. When cultures reached 80% confluence, the cells were passaged into new flasks 
such as from one 25 cm2 flask to one 75 cm2 flask, or from one 75 cm2 flask to three 75 cm2 
flasks. Passaging was carried out by washing cultures with 3 mL (for 25 cm2 flasks) or 5 mL 
(for 75 cm2 flasks) phosphate-buffered saline (PBS) (137 mM NaCl, 2.7 mM KCl, 10 mM 
Na2HPO4 and 2 mM KH2PO4 at pH 7.4), trypsinisation with 1-2 mL trypsin (Life Technologies, 
Australia) and incubation at 37 ᵒC with 5% CO2 for approximately 5 min. After detachment of 
cells, the cells were resuspended in 5-10 mL complete DMEM or complete DMEM/F12 Hams. 
Cell suspensions were then carefully pipetted up and down multiple times to achieve a 
homogenous suspension. Cell suspensions were then aliquoted into new 75 cm2 flasks in a final 
volume of 13 mL medium containing 3 x 105 cells and flasks were returned to the incubator 
for growth.  
 
Cells for experiments in microtitre plates were prepared from the 80% confluent 75 cm2 flasks 
according to the above cell maintenance procedures. Briefly, when cultures reached 80% 
confluence they were washed with 5 mL PBS, trypsined and counted on a hemocytometer 
(Hawksley BS. 748). The suspended cells were seeded in microtitre plates at 7000 cells per 
well. Experiments conducted in this plate format were conducted when the cell cultures reached 
80% confluence.  
 
2.4.4 Freezing and storage 
Preparation of frozen stocks was accomplished by growing cells in 75 cm2 tissue culture flasks 
in complete media until 80% confluence. Neuro2a and SH-SY5Y cells were then washed with 
5 mL PBS, trypsinised with 2 mL of trypsin and incubated at 37 ᵒC, 5% CO2 for 5 min. Once 
cells were detached, 10 mL of complete DMEM was added to the flask and the cells were 
suspended by pipetting. The cell suspension was then transferred into 50 mL Falcon tubes 
(Sigma-Aldrich, Australia) and centrifuged (Allegra X-15R) at 900 g for 5 min. The 
supernatant was aspirated and cells were resuspended in 3 mL of freezing medium. 1 mL 
aliquots of suspension were transferred to cryovials (Greiner Bio-one, Germany) and placed in 
a styrofoam container (Sigma-Aldrich, Australia). Cryovials were gradually brought to -196 
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°C by placing the insulated styrofoam container at -80 °C (Thermo Scientific -80C ULT) for 
12 h, followed by transferring the vials to the liquid nitrogen storage at -196 °C. 
 
2.4.5 Synthesis of aluminium maltol  
Due to the insolubility of aluminium sulfate under neutral or basic pH in mammalian tissue 
culture media, aluminium maltol (Al(mal)3) was used in tissue culture experiments. Al(mal)3 
was made from AlCl3 hexahydrate and 3-hydroxy-2-methyl-4H-pyran-4-one (maltol) as per the 
method described in Bertholf et al., (1989). In brief, to produce 10-15 g of Al(mal)3 15.5 g 
maltol and 9.9 g of AlCl3.6H2O were dissolved in 160 mL deionized water with mild heating. 
When the material had dissolved the pH was adjusted to 8.3 and the solution was heated to 65 
ᵒC with gentle stirring to produce a divided precipitate. The solution was then cooled and the 
resultant off-white crystals were filtered, washed with acetone several times and dried 
overnight in a vacuum desiccator.      
 
2.4.6 Determination of IC25 and IC50 of metal ions  
Neuro2a and SH-SY5Y cells were seeded into 96 well plates in 190 μl of complete media 
containing 7000 cells per well. Plates were incubated at 37 ᵒC with 5% CO2 for 32 h (Neuro2a) 
or 48 h (SH-SY5Y). After incubation cells were treated with 10 μl stock solutions of 20X metal 
salts that had been filter sterilised. Neuro2a cells were treated with CaCl
2 
(0, 0.1, 0.2, 0.4, 0.8, 
1, 2 and 5 mM), ZnSO₄ (0, 125, 150, 160, 180, 200, 220, 240 and 260 μM), CoCl
2 
(0, 150, 200, 
220, 240, 260, 280, 300, 320 and 340 μM), Al(mal)3
 
(0, 25, 50, 75, 100, 125, 125, 150, 160, 
170, 180, 190, 200 μM), NaAsO
2 
(0, 5, 10, 15, 20, 25, 30, 35 and 40 μM) and CrO
3 
(0, 5, 10, 
15, 20 and 40 μM). SH-SY5Y cells were treated with ZnSO₄ (0, 25, 50, 100, 150, 175, 200, 
225, 250, 275, 300 and 375 μM), Al(mal)3 (0, 5, 10, 20, 50, 100, 125, 150, 175, 200, 225 and 
250 μM), CrO3 (0, 1, 2.5, 5, 7.5, 10, 12.5, 15, 17.5, 20, 30, 40, 50, 60, 70, 80, 90 and 100 μM) 
and NaAsO2 (0, 2.5, 5, 7.5, 10, 12.5, 15, 17.5, 20, 22.5, 25, 30, 40, 50, 60, 70, 80, 90 and 100 
μM). After treatment Neuro2a and SH-SY5Y cells were incubated for 6 h, before an MTT(3-
(4,5-dimethyliazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide) (Sigma-Aldrich) colorimetric 
assay was conducted. For SH-SY5Y cells Al(mal)3 toxicity was also determined for 24 h and 
48 h incubation times before the MTT assay was performed.  The assay was carried out by 
adding 50 μl of 5 mg/mL MTT (in PBS) to each well followed by 2 h incubation. After 2 h, 
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medium and MTT was aspirated and the resultant formazan crystals in each well were 
dissolved in 100 μl DMSO. Plates were then shaken gently and optical absorbance at 570 nm 
was measured using a spectrophotometer (Multiskan EX, Thermo Electron, USA). The 
differences in metal exposure time for the Al(mal)3 experiments reflects the different mode of 
action investigated for Al(mal)3 compared to the acute toxicity studied for the other metals. 
 
2.4.7 Harvesting and purifying RNA for quantitative polymerase chain reaction 
(qPCR)   
Cells were grown in 75 cm2 flasks to 80% confluence whereupon 1 mL of TRIzolTM reagent 
(Thermofisher) was added directly to the flask. The solution was pipetted up and down several 
times to homogenise the lysate then transferred to 2 mL Eppendorf tubes. The resultant lysate 
was incubated for 5 min at room temperature to allow complete dissociation of the 
nucleoproteins complex. 200 µL of chloroform was added, followed by a further 3 min 
incubation. Samples were then centrifuged for 15 min at 12,000 g at 4 ᵒC to separate it into 
three phases. The RNA containing upper phase was transferred to a new tube by careful 
pipetting, without touching the white layer in the middle. To precipitate the RNA, 0.5 mL of 
isopropanol was added to the RNA containing tube and incubated. After 10 min incubation the 
sample was centrifuged for 10 min at 12,000 g at 4 oC. The supernatant was then discarded and 
1 mL 75% ethanol added. The sample was vortexed for 5 sec then centrifuged for 5 min at 
7500 g at 4 oC. The supernatant was aspirated and the pellet allowed to air dry for about 20 
min. The pellet was resuspended in 30 µL RNase-free water by pipetting up and down several 
times. The resulting RNA was then stored at -80 oC. Quantification and determination of purity 
was accomplished by NanoDrop based on the A260/A280 ratio and the peak shapes at 260 and 
280 nm.   
 
2.4.8 cDNA synthesis  
cDNA was prepared using High-Capacity cDNA reverse transcription kits (Thermo Fisher 
Scientific) according to manufacturer’s instructions. Briefly, reagents and samples were 
thawed on ice. RNA samples were mixed by gently pipetting up and down and diluted to 0.1 
µg/µL. Sufficient Master mix was prepared for all samples to be run on the day separately. 
For each single 20 µL reaction, 10 µL of Master mix was required and consisted of 2 µL 10X 
42 
 
reverse transcription buffer, 0.8 µL 25X dNTP mix, 2 µL 10X reverse transcription random 
primers, 1 µL Multiscribe™ reverse transcriptase, and 4.2 µL DEPC treated water. The master 
mix was mixed by gently pipetting. 10 µL of master mix was combined with 10 µL of 0.1 
µg/µL sample. Reaction tubes were mixed by gently pipetting and briefly spun down to push 
solution to the bottom and to eliminate air bubbles. Reaction mixtures were run on a Veriti 96 
well thermal cycler (Applied Biosystems) according to the protocol in Table 2.2  
 
Table 2.2 Thermal cycler settings for cDNA synthesis 
 Step 1 Step 2 Step 3 Step 4 
Temperature °C  25 37 85 4 
Time  10 min 120 min 5 min Until collection 
 
Once the cycling finished, samples were validated for cDNA by measuring the UV absorbance 
(A260/A280). 
 
2.4.9 QPCR 
Real time quantitative polymerase chain reaction was carried out using TaqMan real time PCR 
assays (Thermo Fisher Scientific) according to manufacturer’s instructions. Samples were 
thawed on ice and diluted to contain 100 ng/µL cDNA. Reagents were also thawed on ice. Each 
20 µL reaction contained 1 µL 20X TaqMan assay (primers and probe), 10 µL TaqMan gene 
expression master mix, 1 µL of template and 8 µL DEPC treated water (9 uL for the no template 
control). Samples were mixed by gentle pipetting and spun down briefly. Each sample was run 
in triplicate for all assays. Assays containing specific primer probe combinations targeted to 
CK2α, CK2α’, CK2β, GAPDH (endogenous control) and ACTβ (endogenous control). The 
thermal cycler settings are shown in Table 2.3 and Figure 2.2 gives an overview of how the 
reaction works.     
 
Data generated was analysed by the 2-ΔΔCT method (Schmittgen & Livak, 2008) where the cycle 
threshold for the gene of interest in control conditions is normalised to the cycle threshold of 
the endogenous control in control conditions (ΔCTc). The cycle threshold of the gene of 
interest under experimental conditions is normalised to the cycle threshold of the endogenous 
control under experimental conditions (ΔCTe). ΔCTe is then normalised to ΔCTc to give 
ΔΔCT. The expression fold change is given by raising 2 to negative ΔΔCT.     
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Table 2.3 Parameters for the qPCR thermal cycler   
Stage  Temp (°C) Time (mm:ss)  
Hold  50 2:00 
Hold  95 10:00 
Cycle  
(40 cycles) 
95 0:15 
60 1:00 
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Figure 2.2 Schematic explanation of the principle underlying TaqMan technology 
After double stranded DNA melts, the reaction is cooled to the annealing temperature where 
the primers and probe bind to the target. Taq polymerase then catalyses the extension of the 
primer along the template strand. When it reaches the probe it displaces the reporter. Once 
the reporter is no longer near the quencher it is able to fluoresce. Upon each cycle greater 
levels of reporter are liberated from their proximity to the quencher and therefore each cycle 
is characterised by an increase in fluorescence. As each cycle represents a doubling of 
template this increase follows an exponential trajectory.   
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2.4.10 siRNA knock down of CK2 expression  
SMARTpool siRNA targeting mouse CK2 (CK2α, CK2α’ and CK2β) and ON-TARGETplus 
siRNA targeting human CK2 (CK2α, CK2α’ and CK2β) were purchased from Dharmacon, 
USA. Each siRNA assay purchased was a mixture of four sequences targeting different 
segments of the CK2 target transcripts. The sequences for each CK2 subunit are shown in Table 
2.4. Stock siRNA (10 µM) was prepared in siRNA buffer (pH 7.3) containing 300 mM 
potassium chloride, 31 mM HEPES and 2.1 mM magnesium chloride. For transfection of cells 
with siRNA, two Eppendorf tubes were prepared for each transfection. Tube 1 contained 20 µl 
of 10 µM siRNA and 480 µl OPTI-MEM (Life Technologies), tube 2 contained 20 µl 
lipofectamine 2000 transfection reagent (Invitrogen) and 480 µl OPTI-MEM. After 5 min 
incubation at room temperature, the contents of tube 1 was transferred into tube 2 and left at 
room temperature for 20 min (siRNA transfection mixture). A mock tube with no siRNA 
containing 980 µl OPTI-MEM with 20 µl lipofectamine was prepared as a control. The use of 
such a mock control containing no siRNA allowed for control of the transfection protocol. A 
limitation should be acknowledged here for not using another negative control, i.e. a nonsense 
(non-targeting) siRNA. Cells were cultured in 25 cm2 flasks for 32 h until 80% confluent. Cells 
were washed with PBS, trypsinised and suspended in 5 mL complete media. After counting 
cells 5 tubes for each cell line were prepared with 2 x 106 cells in 5 mL complete media. Tube 
1 were designated CK2α siRNA, tube 2 CK2α’ siRNA, tube 3 CK2β siRNA, tube 4 mock 
control and tube 5 untreated control. The cells were spun down at 900 g for 5 min and the 
supernatant was aspirated and discarded. The cells were then washed with 5 mL PBS and again 
spun down with the supernatant again removed and discarded. Cell pellets were suspended in 
1 mL of the appropriate siRNA transfection mixtures previously prepared (described above) 
and mixed by gentle pipetting. After 15 min in the siRNA transfection mixture cells were 
transferred into 9 mL OPTI-MEM, mixed and aliquoted into 96-well plates at 100 µl per well. 
The plates were incubated at 37 ᵒC, 5% CO2 for 76 h. IC25 and IC50 of the metal ions in 5 µl 
were added to the treatment wells followed by incubation at 37 ᵒC, 5% CO2. After 5 h 
incubation an MTT assay was performed (as described in Section 2.4.6) to determine cell 
viability. Knockdown efficiency was verified using qPCR as described in 2.4.7-2.4.9.  
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Table 2.4 siRNA targets and sequences for mouse and human CK2 subunits   
Cell type  CK2 subunits Target sequences 
Mouse 
Neuro2a 
CKα UGAAUUAGAUCCACGUUUC, GCAAUUGUACCAGACGUUA, CAGAAAGCUUCGGCUAAUA, AGACUAUGACAUUCGAUUU 
CKα’ GCAAGUAUAGUGAAGUAUU, CAACAGAGAUUGACCGCCA, GGUGGAACAAAUAUCAUUA, GAACUAUAUGGUUAUCUGA 
CKβ CAGCUGAGAUGCUUUAUGG, CCAAGUGCAUGGACGUGUA, GGUAAUGAAUUCUUCUGUG, GCAGGGAGACUUUGGCUAC 
Human 
SH-SY5Y 
CKα GCAUUUAGGUGGAGACUUC, GGAAGUGUGUCUUAGUUAC, GCUGGUCGCUUACAUCACU, AACAUUGUCUGUACAGGUU 
CKα’ GAGUUUGGGCUGUAUGUUA, GGGACAACAUUCACGGAAA, GAUAGAUCACCAACAGAAA, UUAAGCAACUCUACCAGAU 
CKβ CCAAGUGCAUGGAUGUGUA, GCAAUGAAUUCUUCUGUGA, GCAAGGAGACUUUGGUUAC, CAACCAGAGUGACCUGAUU 
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2.5   Statistical analysis  
Where statistical analysis was used, means were compared to identify significant differences. 
Where means of two different groups needed to be compared a student t test was used; where 
multiple groups were compared ANOVA was used.  
Where sample size was less than 25 the assumption of normal distribution was checked by a 
probability plot. If not normally distributed a non-parametric comparison was used (Mann-
whitney). The statistical analysis for experimental data was carried out in SPSS or Minitab 
statistical software. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
48 
 
3 Unravelling the role of protein kinase CK2 in metal 
toxicity by the gene deletion mutants of Saccharomyces 
cerevisiae 
3.1 Introduction 
As described in Chapter 1.4, protein kinase CK2 is a ubiquitous serine/threonine kinase in 
eukaryotes. It has two catalytic subunits designated as α and α’, and one regulatory β subunit 
in mammalian cells. The kinase exists both as tetrameric holoenzymes (αα’ββ, ααββ, α’α’ββ) 
and as monomers (Schnitzler et al., 2014). In contrast to mammalian cells, Saccharomyces 
cerevisiae has two catalytic genes (CKA1 and CKA2) encoding Cka1p (orthologous to 
mammalian α) and Cka2p  (orthologous to mammalian α’) and two regulatory genes (CKB1 
and CKB2) encoding Ckb1p and Ckb2p subunits, which could form Cka1pCka2pCkb1pCkb2p, 
Cka1pCka1pCkb1pCkb2p and Cka2pCka2pCkb1pCkb2p tetramers apart from the individual 
subunits.  
The work of this chapter is a follow-up of the initial dataset for Al3+ toxicity obtained by Tun et 
al., (2014) in our laboratory using the unbiased genome-wide screening of deletion mutants. A 
key finding of the dataset is that the deletion of CKA2 (cka2Δ) renders the yeast mutant resistant 
against Al3+. Herein I further investigated the role of CK2 in metal toxicity for an expanded 
panel of metals including zinc, chromium, arsenic, cobalt, calcium and aluminium. Molecular 
intricacy for CK2’s involvement is unravelled by the individual deletion mutants of CK2 
subunits and their double deletion mutants, as well as the biochemical quantification of metal 
ion contents in the cells after individual metal treatments using inductively-coupled plasma 
mass spectrometry (ICP-MS). 
 
3.2 Results 
3.2.1 Phenotypic response of CK2 deletion mutants to metal ion treatment  
As detailed in 2.3.4, the response of CK2 gene deletion mutants to metal toxicity was 
determined as shown in Figure 3.1-3.6. The premise for such an approach being that, after 
establishing the phenotype of the wild-type under exposure to the various metal treatments, 
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observation of the phenotypic response of the CK2 mutants would shed light on the distinct 
roles of the individual CK2 subunits to metal toxicity. 
 
3.2.2 The protective effect of CKA2 deletion under Al3+ exposure 
At lower doses of aluminium, the effects of the metal appear to extend the lag phase (by 4 h 
for cka1∆, ckb1∆ and ckb2∆ and less than 4 hours for BY4743 at 0.4 and 0.8 mM Al3+) and 
decrease the slope of the log phase of all strains tested except for cka2∆. For example, the 
average growth for BY4743, cka1∆, ckb1∆ and ckb2∆ is reduced to approximately 33% at the 
12 h time point when compared to the untreated control while cka2∆ is only reduced to 
approximately 90% untreated control. This indicates that, at these lower doses (0.4 and 0.8 
mM), the cka2∆ strain is experiencing very little Al3+ related stress or toxicity. The absence of 
the adverse effect on the growth of the cka2∆ mutant may be indicative of an absence of 
intracellular Al3+ accumulation at these doses. However, the injurious effect of Al3+ is indeed 
observed in cka2∆, but only at much higher doses tested (>1.6 mM). Despite the negative 
effects at higher doses, the protective effect of CKA2 deletion on growth under Al3+ treatment 
can clearly be seen across the whole range of concentrations used (Figure 3.1). At 2.5 mM Al3+ 
the cka2∆ grows 75% as well as the untreated control while BY4743 does not grow at all (at 
the 24 h time point). Of the subunits of protein kinase CK2, only cka2∆ exhibits this phenotype. 
The result therefore demonstrates that the presence of CKA2 facilitates the toxicity of 
aluminium, either directly e.g. by enhancing Al3+ uptake or indirectly e.g. by hindering the 
detoxification of intracellular Al3+. These two possibilities were further explored by double 
deletion mutant studies and ICP-MS.   
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Figure 3.1. Growth phenotypes of BY4743 and CK2 deletion mutants under Al3+ exposure.  
Yeast strains, including the wildtype BY4743 and four deletion mutants for individual CK2 subunits (cka1∆, cka2∆, ckb1∆ and ckb2∆), were 
grown at 30 °C, 150 rpm in minimal medium for 24 h. At 0 h (T0) cultures were treated with a range of Al2(SO4)3 concentrations (0.4, 0.8, 1.6, 2.5 
and 3.2 mM). The control was treated with an equivalent volume of H2O. OD600 was measured at 4 h intervals. Error bars, which are too small to 
be seen, represent SEM of triplicate experiments, each experiment consisted of 8 replicates.
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3.2.3 CKA2 deletion provides a protective effect against Zn2+ toxicity  
While the effect of CKA2 deletion on growth under Al3+ treatment was clear against a range 
of concentrations, the effect of CKA2 deletion under Zn2+ is different in that its protective 
effect is very narrow, prominent only at 25 mM. This dose may seem high, considering the 
Zn2+ concentration required for optimal growth is 1/10th of this (Simm et al., 2007). However, 
S. cerevisiae was found to have an intracellular concentration of Zn2+ of four times this dose 
(100 mM) under certain conditions (Simm et al., 2007). At 25 mM Zn2+, all strains except 
cka2∆ barely exit the lag phase and the cka2∆ mutant has a clearly extended doubling time 
(Figure 3.2, 25 mM Zn2+). This indicates that the mutant is experiencing Zn2+ related stress 
but has a capability to overcome such stress due to the deletion of CKA2. It stands to reason 
that zinc, being essential to cellular function, has numerous intracellular homeostatic 
mechanisms in terms of its transport and sequestration. Due to the adverse effects of excess 
zinc, which may include oxidative stress, (Jain et al., 2010) the equilibrium of the labile, 
bound and sequestered Zn2+ is under tight control and slight perturbations could result in 
toxicity to the cell.  
 
The alike yet contrasting responses of the cka2∆ mutant to these two metals, Al3+ and Zn2+, is 
suggestive of differential roles of the subunit CKA2. These differences likely relate to the 
different ways the cell responds to the metals. That is, Al3+, having no biological function, 
has no specific transporters for its uptake into the cell. It can therefore be considered as a 
cellular mistake when it is allowed into the cell and it is possible that cka2p is facilitating this 
uptake.  In contrast, Zn2+ is required by the cell, this means there are ample routes for its 
uptake and necessitates further and more intricate intracellular processing mechanisms. CKA2 
deletion may either inhibit Zn2+ uptake, or favourably facilitate effective detoxification of 
Zn2+, hence protect the cells from zinc toxicity and increase the cell growth at the high Zn2+ 
concentration of 25 mM. These two possibilities will be further explored in the follow-up 
experiments.
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Figure 3.2 Growth phenotypes of BY4743 and CK2 deletion mutants under Zn2+ exposure 
Yeast strains, including the wildtype BY4743 and four deletion mutants for individual CK2 subunits (cka1∆, cka2∆, ckb1∆ and ckb2∆), were 
grown at 30 °C, 150 rpm in minimal medium for 24 h. At 0 h (T0) cultures were treated with a range of ZnSO4 concentrations (4, 8, 16, 25 and 32 
mM). The control was treated with an equivalent volume of H2O. OD600 was measured at 4 h intervals. Error bars, which are too small to be seen, 
represent SEM of triplicate experiments, each experiment consisted of 8 replicates.
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3.2.4 Sodium arsenite elucidates a possible distinct role for the CKB2 subunit of 
CK2 
Kinetically, the phenotypic responses to As3+ (Figure 3.3) show that all strains experience an 
extended lag phase at 1.6 mM, indicating the extended cellular preparation required for 
adaption and growth in the presence of As3+. At this concentration, the regulatory subunit, 
CKB2 deletion, allows growth to markedly exceed that of the wildtype. At this dose all CK2 
subunit deletions confer greater viability when compared to the wildtype. While CKA2 deletion 
provides a protective effect, it is the lowest of the CK2 subunit deletions. Due to the difference 
in phenotypes between cka1∆ and cka2∆ the results indicate discrepancies in the need for 
Cka1p (encoded by CKA1) and Cka2p (encoded by CKA2) in the presence of As3+. The deletion 
of the two regulatory subunits (CKB1 and CKB2) showed a similar phenotype as cka1Δ. 
Another interesting observation is that ckb2∆ begins to grow at the 3.2 mM dose, albeit at a 
slower rate compared to lower doses at 24 h, while the other mutants do not. As has been 
mentioned, tetramer formation requires the presence of both regulatory subunits. This late stage 
growth cannot therefore be a result of a lack of CK2 tetramer activity, or a similar effect would 
be observed in ckb1∆, but rather a lack of a distinct function associated with the Ckb2p 
monomer. This could also account for the discrepancies of growth between the ckb2∆ mutant 
and the cka1∆ and ckb1∆ mutants at the 1.6 mM dose of sodium arsenite. 
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Figure 3.3 Growth phenotypes of BY4743 and CK2 deletion mutants under As3+ exposure 
Yeast strains were grown at 30 °C, 150 rpm in minimal medium for 36 h. At 0 h (T0) cultures were treated with a range of sodium arsenite 
concentrations (0.2, 0.4, 0.8, 1.6 and 3.2 mM). The control was treated with an equivalent volume of H2O. OD600 was measured at 4 h intervals. 
Error bars represent SEM of triplicate experiments, each experiment consisted of 8 replicates.
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3.2.5 Deletion of CK2 subunits increases Cr6+ tolerance   
At lower concentrations of chromium trioxide (0.05, 0.1 and 0.2 mM) deletion mutants of CK2 
genes are indistinguishable from the wildtype (Figure 3.3). However, at 0.4 mM all CK2 gene 
deletion mutants (cka1∆, cka2∆, ckb1∆ and ckb2∆) grow better in the presence of chromium 
trioxide, while at 0.8 mM the protective effect of the CK2 gene deletions is abolished. In terms 
of growth kinetics the effect of Cr6+ appears to induce earlier entry into stationary phase 
possibly as a response to oxidative stress induced by Cr6+.  Interestingly CKB1 and CKB2 
deletion provide the greatest tolerance indicating a possible adverse effect of the tetramer under 
chromium exposure, because deletion of any regulatory genes (CKB1 or CKB2) leads to no 
formation of CK2 tetramers (Kubiński et al., 2007).  
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Figure 3.4 Growth phenotypes of BY4743 and CK2 deletion mutants under Cr6+ exposure 
Yeast strains were grown at 30 °C, 150 rpm in minimal medium for 24 h. At 0 h (T0) cultures were treated with a range of CrO3 concentrations 
(0.05, 0.1, 0.2, 0.4 and 0.8 mM). The control was treated with an equivalent volume of H2O. OD600 was measured at 4 h intervals. Error bars, 
which are too small to be seen, represent SEM of triplicate experiments, each experiment consisted of 8 replicates.
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3.2.6 Cobalt chloride exposure requires tetramer activity  
As shown in Figure 3.5, at the lower doses (0.4 mM, 0.8 mM and 1.6 mM), the catalytic subunit 
deletions show a similar growth profile to the wildtype (particularly cka1∆) while ckb1∆ and 
ckb2∆ appear more sensitive, with ckb2∆ experiencing an extended lag phase at the two lower 
doses. At 1.6 and 3.2 mM the regulatory subunit deletions show distinct phenotypes from the 
catalytic deletion and wildtype strains. This indicates that lacking the tetramers of CK2 
sensitises yeast to cobalt chloride exposure. 
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Figure 3.5 Growth phenotypes of BY4743 and CK2 deletion mutants under Co2+ exposure 
Yeast strains were grown at 30 °C, 150 rpm in minimal medium for 24 h. At 0 h (T0) cultures were treated with a range of CoCl2 concentrations 
(0.4, 0.8, 1.6, 3.2 and 6.4 mM). The control was treated with an equivalent volume of H2O. OD600 was measured at 4 h intervals. Error bars, which 
are too small to be seen, represent SEM of triplicate experiments, each experiment consisted of 8 replicates.
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3.2.7 Phenotypes of CK2 mutants are indistinguishable from the wildtype under 
Calcium chloride treatment. 
Treatment with calcium chloride showed that CK2 gene deletion provided no discernable 
phenotypic effect when exposed to the metal salt (Figure 3.6). This served as a valuable 
negative control showing that the anion Cl- was benign regarding the cellular response of CK2 
deletion mutants to treatment of metal salts. It also is indicative of a lack of a general osmotic 
stress response at salt concentrations as high as 80 mM, because no apparent effect was shown 
by 80 mM CaCl2.  
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Figure 3.6 Growth phenotypes of BY4743 and CK2 deletion mutants under Ca2+ exposure 
Yeast strains were grown at 30 °C, 150 rpm in minimal medium for 24 h. At 0 h (T0) cultures were treated with a range of CaCl2 concentrations 
(40, 80, 160, 320 and 640 mM). The control was treated with an equivalent volume of H2O. OD600 was measured at 4 h intervals. Error bars 
represent SEM of triplicate experiments, each experiment consisted of 8 replicates.
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3.2.8 Phenotypic response of CK2 double deletion mutants to metal toxicity 
Exhibiting different phenotypes by mutants under identical treatment allows elucidation of 
functions of the deleted genes. This notion is demonstrated by the results of single deletion 
mutants of CK2 as just described. As CK2 is functional as individual subunits (Cka1p, Cka2p, 
Ckb1p, Ckb2p), or in tetrameric holoenzymes (Cka1pCka1pCkb1pCkb2p, 
Cka1pCka2pCkb1pCkb2p, Cka2pCka2pCkb1pCKb2p), double deletion mutants of CK2 will 
dissect the roles of CK2 subunits which may be distinct or possibly contrasting under certain 
metal stress.  
 
The growth responses under metal ion exposure of double deletion mutants of CK2 
(cka1∆ckb1∆, cka1∆ckb2∆, cka2∆ckb1∆, cka2∆ckb2∆, ckb1∆ckb2∆) were determined, as 
shown below. The double deletion mutants were generated using two haploid yeast strains, i.e. 
BY4741 and BY4742, following the protocol in Chapter 2.3.3. Single deletions of each CK2 
subunit were crossed on a BY4741 with each of the single deletion mutants on BY4742 
generating cka1∆ckb1∆, cka1∆ckb2∆, cka2∆ckb1∆, cka2∆ckb2∆, ckb1∆cka1∆, ckb1∆cka2∆, 
ckb1∆ckb2∆, ckb2∆cka1∆, ckb2∆cka2∆, ckb2∆ckb1∆. Note the double deletion cka1∆cka2∆ 
is lethal and therefore would not be viable. Two doses of each metal were chosen for each of 
the metals in the study as well as an equal volume solvent control. The concentrations of metals 
used were as follows: 0.8 and 1.6 mM aluminium sulfate, 16 and 25 mM zinc sulfate, 0.8 and 
1.6 mM sodium arsenite, 0.2 and 0.4 mM chromium trioxide and 0.4 and 0.8 mM cobalt 
chloride. For the purposes of presenting the data the background BY4741 (haploid) single 
deletion mutant are shown, however, while not shown, the BY4742 (haploid) foreground single 
deletion mutants exhibited the same growth profiles under each treatment. 
 
3.2.9 Deleting CKA1 with CKB1 reduces viability under control conditions   
The single deletion backgrounds exhibited growth analogous to their diploid counterparts in 
Figures 3.2.2 – 3.2.7. Of the double deletion mutants, a combination of CKA1 deletion and 
CKB1 deletion reduces viability indicating the loss of each is additive (Figure 3.7). Double 
deletions of CKA2 (cka2∆ckb1∆, cka2∆ckb2∆; or ckb1∆cka2∆, ckb2∆cka2∆) exhibit no 
reduction in growth. Losing both regulatory subunits appears to have no adverse effects under 
the control conditions.
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Figure 3.7 Growth phenotypes of single deletion backgrounds and double CK2 deletion mutants grown in minimal media.  
Yeast were grown at 30 °C, 150 rpm in minimal medium for 24 h. At 0 h (T0) cultures were treated and OD600 was measured at 4 h intervals. 
Experiments consisted of 8 replicates. Data points represent the average of 3 independent experiments with error bars being the standard error of 
the mean.   
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3.2.10 The protective effect of CKA2 deletion under Al3+ stress is independent of 
the regulatory subunits.   
By examining the growth data of double deletion mutants in the presence of Al3+, it becomes 
clear that lacking the CKA2 subunit is beneficial in a manner independent of the ckb1p and 
ckb2p. When considering the 24 h time point, in the presence of aluminium sulfate the cka2∆ 
mutant grew 95.8% [0.8 mM Al2(SO4)3] and 97.4% [1.6 mM Al2(SO4)3] when compared to its 
untreated control (cka2∆ in Figure 3.8 and Figure 3.9 compared to cka2∆ in Figure 3.7). cka2∆, 
when coupled with the regulatory deletions, does have markedly reduced growth, cka2∆ckb1∆ 
showing 60.2% [0.8 mM Al2(SO4)3] and 50.4% [1.6 mM Al2(SO4)3] of untreated control and 
cka2∆ckb2∆ 49.2% (0.8 mM) and 42.1% (1.6 mM) of untreated control. This reduction of 
growth can be wholly attributed to the phenotypic response of the regulatory subunit deletion 
alone, as ckb1∆ is 55.1% (0.8 mM), 39.3% (1.6 mM) of untreated control and ckb2∆ 50.3% 
(0.8 mM), 38.1% (1.6 mM) of untreated control. Indeed, the growth of the double deletion 
mutants at the 1.6 mM dose is either equal to or greater than the growth of the single regulatory 
mutants indicating a possible attenuation of the deleterious effects of the regulatory deletion 
alone when coupled with cka2∆ (Figure 3.9). Likewise, when considering the reciprocal double 
deletions, ckb1∆cka2∆ and ckb2∆cka2∆ the picture becomes clear. ckb1∆cka2∆ attained a 
growth of 49.1% of its untreated growth in 0.8 mM aluminium sulfate compared to ckb1∆’s 
55.1% (0.8 mM), and 44.3% in 1.6 mM compared to ckb1∆’s 39.3% (1.6 mM) which again is 
close to (in the case of 0.8 mM) or greater than (in the case of 1.6 mM) the growth of the single 
regulatory deletion, while the ckb2∆cka2∆ attained a growth of 39.3% (0.8 mM) and 46% (1.6 
mM) of its untreated control. At the 1.6 mM treatment, this outstrips the growth of the single 
CKB2 deletion. This therefore leads to the conclusion that the attenuation of growth observed 
in CKA2 double deletions in the presence of Al3+ is attributable to the deletion of the regulatory 
subunits and that the resistance of the cka2 deletion mutant is independent of the effects of the 
regulatory subunits.   
 
In 0.8 mM Al2(SO4)3, lacking the CKA1 subunit reduces the growth to 80.2% (at the 24 h time 
point) of the untreated mutant, lacking CKB1 reduces the growth to 55.1% of the untreated 
control and lacking CKB2 reduces the growth to 50.3% of the untreated control. When cka1∆ 
is coupled with a regulatory deletion (cka1∆ckb1∆ or cka1∆ckb2∆ or ckb1∆cka1∆ or 
ckb2∆cka1∆), in all cases except cka1∆ckb1∆, this reduction in growth is somewhat 
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potentiated. The cka1∆ckb2∆ mutant, when combining the single deletion growth’s, one would 
expect a reduction to 40.3% untreated, while the observed value is 27.7% of the untreated 
control, the ckb1∆cka1∆ mutant is 21.2% of the untreated control (expected 44.2%) and the 
ckb2∆cka1∆ mutant is 19% of the untreated control (expected 40.3%). This data demonstrates 
that 1. the double deletion’s growth is markedly reduced in the presence of Al3+ and 2. In 3 of 
the 4 cases the addition of a regulatory deletion to the cka1∆ reduces the viability of the cell 
beyond what can be expected from the addition of single deletion responses to Al3+. While this 
process is (admittedly) naïve, it does demonstrate that the deletion of CKA1 in conjunction with 
a regulatory subunit is injurious to a cell beyond simply ∆1+∆2. 
  
A final point of interest is that cells lacking both regulatory subunits ckb1∆ckb2∆ or 
ckb2∆ckb1∆ show growth equal to or greater than single regulatory deletions at the 1.6 mM 
dose (Figure 3.9). 
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Figure 3.8 Growth phenotypes of single deletion backgrounds and double CK2 deletion mutants grown in minimal media plus 0.8 mM 
aluminium sulfate. Yeast strains were grown at 30 °C, 150 rpm in minimal medium for 24 h. At 0 h (T0) cultures were treated with 0.8 mM 
Al2(SO4)3 and OD600 was measured at 4 h intervals. Data points represent the average of 3 independent experiments, each of which consisted of 8 
replicates, with error bars representing the standard error of the mean.      
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Figure 3.9 Growth phenotypes of single deletion backgrounds and double CK2 deletion mutants grown in minimal media plus 1.6 mM 
aluminium sulfate. Yeast strains were grown at 30 °C, 150 rpm in minimal medium for 24 h. At 0 h (T0) cultures were treated with 1.6 mM 
Al2(SO4)3 and OD600 was measured at 4 h intervals. Data points represent the average of 3 independent experiments, each of which consisted of 8 
replicates, with error bars representing the standard error of the mean.     
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3.2.11 Tolerance conferred by CKA2 deletion against Zn2+ is reduced when 
coupled with a regulatory subunit deletion 
As shown previously, CKA1 deletion mutant (cka1Δ) was sensitive to Zn2+, CKA2 deletion 
mutant (cka2Δ) was resistant to Zn2+. In this section, the CKA2 double deletions also exhibit a 
sensitive phenotype against Zn2+ (Figure 3.10 and Figure 3.11). This suggests that not having 
CKA2-encoded cka2p is not the reason for resistance. That is, a loss of Cka2p function is not 
the reason for the resistance of CKA2 deletion mutants against Zn2+, but rather the Cka2p 
subunit could possibly interfere with the function of CKA1-encoded Cka1p in the detoxification 
process. The reduction of resistance associated with an cka2∆ckb1∆ (30% growth of untreated 
and 29% growth of a cka2∆ in 25 mM ZnSO4) and cka2∆ckb2∆ (26% untreated and 25% of 
the cka2∆ at the 25 mM ZnSO4) is likely due to the loss of Cka1pCKa1pCkb1pCkb2p 
tetramers. Additionally, cka2∆ckb1∆ and cka2∆ckb2∆ show a similar reduction in growth 
when compared to untreated controls (24% and 31.7% respectively) which could be due to the 
same reason. What is intriguing is that lacking both regulatory subunits is somewhat beneficial 
(Figure 3.10 and Figure 3.11) under Zn2+ exposure. Compared to untreated, the double 
regulatory deletion mutants (ckb1∆ckb2∆, ckb2∆ckb1∆) grow half as well at 25 mM ZnSO4, 
however, they grow to a similar extent, or in the case of ckb2∆ckb1∆ better than the background 
single deletions. This suggests that having two monomeric catalytic subunits may enable a cell 
to cope with a zinc insult and that having a single regulatory subunit may in fact interfere with 
the detoxification process. In any case, the key finding is that Cka1p containing tetramers 
(Cka1pCka1pCKb1pCkb2p) are the main iteration of CK2 required for zinc detoxification.  
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Figure 3.10 Growth phenotypes of single deletion backgrounds and double CK2 deletion mutants grown in minimal media plus 16 mM zinc 
sulfate. Yeast strains were grown at 30 °C, 150 rpm in minimal medium for 24 h. At 0 h (T0) cultures were treated with 16 mM ZnSO4 and OD600 
was measured at 4 h intervals. Data points represent the average of 3 independent experiments, each of which consisted of 8 replicates, with error 
bars representing the standard error of the mean. 
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Figure 3.11 Growth phenotypes of single deletion backgrounds and double CK2 deletion mutants grown in minimal media plus 25 mM zinc 
sulfate. Yeast strains were grown at 30 °C, 150 rpm in minimal medium for 24 h. At 0 h (T0) cultures were treated with 25 mM ZnSO4 and OD600 
was measured at 4 h intervals. Data points represent the average of 3 independent experiments, each of which consisted of 8 replicates, with error 
bars representing the standard error of the mean.     
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3.2.12  Arsenic treatment may require regulatory subunit monomers 
As mentioned above deletion of both regulatory subunits has no adverse effect on the growth 
phenotype when compared to the single regulatory deletions in the control condition.  Against 
Al3+ and Zn2+ the double regulatory deletions also either experience no adverse effects beyond 
the single deletion background or they in fact out-grow them. It is therefore quite interesting 
that, under both 0.8 mM As3+ (Figure 3.12) and 1.6 mM As3+ (Figure 3.13), the double 
regulatory deletions experience the greatest decrease in viability when compared to the single 
backgrounds and the untreated control. From the single deletion studies, it was shown that 
single deletion of the regulatory subunit CKB2 resulted in greater viability. As tetramer 
formation requires both regulatory subunits we can therefore assert that this increase in viability 
is either due to loss of tetramer function (unlikely as the effect observed at 3.2 mM was absent 
in CKB1 deletion) or due to increased monomers of ckb1p (but not due to increased catalytic 
monomer presence as this would be observed in a Ckb1∆ as well). The decrease in viability 
under As3+ stress when both regulatory subunits are deleted is therefore not related to tetramer 
function and indicates that the regulatory subunits have functions outside the tetramer. Indeed, 
the contrasting phenotypes of the regulatory single deletions and the regulatory doubles may 
be an indication that monomeric regulatory subunits are favored in As3+ replete environments. 
i.e. the increased viability of the CKB2 deletion may mean that ckb1p is not bound up in a 
regulatory dimer and therefore better able to undertake its “moonlighting function”. The 
breakdown is as follows. In the wildtype we have both beta monomers. Some are free, and 
some are dimerized. In a regulatory subunit single deletion all beta subunits are free to perform 
monomeric functions therefore these mutants are better off than the wildtype under As3+ stress. 
In a double regulatory deletion mutant there are no monomeric beta subunits at all and therefore 
it is worse off than the wildtype. Chapter 4 will further explore the role of CK2 in response to 
As3+.  
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Figure 3.12 Growth phenotypes of single deletion backgrounds and double CK2 deletion mutants grown in minimal media plus 0.8 mM sodium 
arsenite. Yeast were grown at 30 °C, 150 rpm in minimal medium for 24 h. At 0 h (T0) cultures were treated with 0.8 mM NaAsO2 and OD600 was 
measured at 4 h intervals. Data points represent the average of 3 independent experiments, each of which consisted of 8 replicates, with error bars 
representing the standard error of the mean.     
72 
 
 
 
Figure 3.13 Growth phenotypes of single deletion backgrounds and double CK2 deletion mutants grown in minimal media plus 1.6 mM sodium 
arsenite. Yeast strains were grown at 30 °C, 150 rpm in minimal medium for 24 h. At 0 h (T0) cultures were treated with 1.6 mM NaAsO2 and 
OD600 was measured at 4 h intervals. Data points represent the average of 3 independent experiments, each of which consisted of 8 replicates, with 
error bars representing the standard error of the mean.    
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3.2.13 Tolerance to chromium trioxide correlates with lacking the CK2 tetramer 
The most notable aspect of the phenotypes of CK2 double deletion mutants under chromium 
exposure is that deletion of both regulatory subunits results in approximately equal growth 
compared to the single regulatory subunit deletions (Figures 3.14 and 3.15). Because the 
greatest tolerance conferred by CK2 single subunit deletion is shown by deletion of CKB1 
and CKB2 and this phenotype is retained when both regulatory subunits are deleted, the 
increased growth could be due to a lack of tetramer formation because a tolerant phenotype is 
observed in all tetramer lacking strains (ckb1Δ, ckb2Δ, ckb1Δckb2Δ and ckb2Δckb1Δ) 
Chapter 5 will further explore the role of CK2 in Cr6+ tolerance.     
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Figure 3.14 Growth phenotypes of single deletion backgrounds and double CK2 deletion mutants grown in minimal media plus 0.2 mM 
chromium trioxide. Yeast were grown at 30 °C, 150 rpm in minimal medium for 24 h. At 0 h (T0) cultures were treated with 0.2 mM CrO3 and 
OD600 was measured at 4 h intervals. Experiments consisted of 8 replicates. Data points represent the average of 3 independent experiments with 
error bars the standard error of the mean.
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Figure 3.15 Growth phenotypes of single deletion backgrounds and double CK2 deletion mutants grown in minimal media plus 0.4 mM 
chromium trioxide. Yeast were grown at 30 °C, 150 rpm in minimal medium for 24 h. At 0 h (T0) cultures were treated with 0.4 mM CrO3 and 
OD600 was measured at 4 h intervals. Experiments consisted of 8 replicates. Data points represent the average of 3 independent experiments with 
error bars the standard error of the mean.  
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3.2.14 Quantification of intracellular metal ion content of CK2 deletion mutants 
by ICP-MS 
To further understand the phenotype of deletion mutants under metal ion exposure, biochemical 
measurement of metal ion contents was carried out for aluminium and zinc. One can 
hypothesise that the tolerant phenotype against a given metal ion can be due to two possible 
mechanisms. The first of these is that the mutants do not allow the toxicant into the cell. The 
second mechanism is that the mutants acquire an increased ability to combat excessive 
intracellular metal ions. This combat may take the form of detoxification e.g. reduction of 
oxidative metals, sequestration of labile metal into subcellular compartments or metal binding 
proteins (like metallothioneins) or export of the metal out of the cell. In the case of metals such 
as aluminium this mechanism is the second line of defence, i.e. the primary barrier has been 
breached, time for damage control. For essential metals such as zinc this constitutes the 
ramping up of an existing process, because the cells have inherent mechanisms for zinc 
homeostasis. The protein that is absent in a deletion mutant whose tolerance is based upon this 
mechanism, when present, likely hinders the cell’s detoxification response. To determine 
which of these mechanisms is responsible for the tolerant phenotypes of CKA2 deletion mutants 
against Al3+ and Zn2+, ICP-MS was performed. The results demonstrate the similar level of 
cellular Zn2+ for cka1Δ, cka2Δ and BY4743, whilst ckb1Δ and ckb2Δ contain 50% or 100% 
more intracellular Zn2+ at the final time point respectively. In terms of cellular Al3+, it is 
conspicuous that cka2Δ has markedly reduced intracellular Al3+, which explains its resistant 
phenotype. In contrast, the level of Al3+ in cka1Δ is highly elevated (Figure 3.16). 
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Figure 3.16 Intracellular metal ion content determined by ICP-MS.  
Cells were treated with 0.8 mM Al2(SO4)3 and 16 mM ZnSO4. Samples were taken at 4 h intervals for 16 h. Results represent the average of 8 
replicates. Error bars represent standard error. Note: Y axis varies across treatments.   
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3.2.15 Effect on the phenotype of CK2 gene deletion mutants under Al3+ and Zn2+ 
by an inhibitor of protein kinase CK2 
CK2 activity in yeast cells can be performed by either catalytic monomer (Cka1p or Cka2p) or 
by any of the tetramers (Cka1pCka2pCKb1pCKb2p, Cka1pCka1pCkb1pCkb2p, 
Cka2pCKa2pCkb1pCkb2p). By employing a CK2 inhibitor, a further layer of information 
could be gathered for elucidation of CK2’s role in regulating metal toxicity. For example, in 
the cka2Δ mutant, CKA1-encoded Cka1p is still present, in the form of Cka1p or 
Cka1pCka1pCkb1pCKb2p. Hence, a CK2 inhibitor such as TBB (4,5,6,7-tetrabromo-1H-
benzotriazole) can explore the role of Cka1p. Such an objective could not be fulfilled by further 
deletions, since deletion of both CKA2 and CKA1 is not viable. TBB is an analogue of ATP, 
which can inhibit phosphorylation of either CK2 monomers or tetramers.  
 
The selective inhibitor (TBB) of CK2 completely abolished the resistance phenotype of cka2∆ 
against Zn2+, indicating that Cka1pCka1pCkb1pCkb2p and/or Cka1p is responsible for Zn2+ 
tolerance. In contrast, TBB did not abolish the resistance of cka2∆ against Al3+, only causing 
a minor reduction in the resistance level, indicating that CKA2 (Cka2p) is mainly responsible 
for Al3+ toxicity (Figure 3.17). 
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Figure 3.17 Growth phenotypes of the cka2∆ mutant treated with 16 mM ZnSO4 or 0.8 mM Al2(SO4)3 in the presence of 20 μM TBB.  
cka2∆ mutant was treated with 16 mM ZnSO4 or 0.8 mM Al2(SO4)3 in the presence of 20 μM TBB and OD600 was measured at 4 h intervals. The 
OD600 of the Zn
2+ treated cells was checked at 3 later time points to see if the effect of inhibition had worn off.  Data are the average of 3 
experiments, each of which contained 8 replicates. Error bars represent standard error. 
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3.2.16 Further evidence for the prominent role of CKA1 in Zn2+ sequestration 
In Figure 3.16, the data demonstrate that there is no significant decrease of zinc content in the 
cka2Δ mutant, unlike the dramatic reduction of aluminium content for the same mutant. This 
reveals that the tolerant phenotype of cka2Δ against zinc is due to its efficient detoxification of 
the metal. By using CK2 specific inhibitor TBB, as shown in Figure 3.17, Cka1p is 
demonstrated to play a prominent role in zinc detoxification, as TBB abolishes the tolerance of 
cka2Δ against zinc because of its inhibition of CKA1-encoded Cka1p still present in the mutant.  
 
There are two vacuolar zinc transporter genes, ZRC1 and COT1, in yeast, which are responsible 
to sequester excess zinc into vacuoles (Claus & Chavarría-Krauser, 2012) .  In the absence of 
ZRC1 the job falls to COT1, and in the absence of COT1 the role is on ZRC1. The data shown 
in Figures 3.18 and 3.19, highlight that zrc1Δ mutant is more viable when CKA2 is deleted, 
and that cot1Δ mutant shows the same phenotypic pattern. The data also show that both ZRC1 
and COT1 mutants are inviable when the tetramer is absent (Fold change of 1) in control 
conditions and that under Zn2+ stress both ZRC1 and COT1 show a similar, markedly reduced 
phenotype as single deletions and as double deletions with CKA1. This similar phenotype is 
suggestive of the two proteins sharing the same pathway. This data indicates that, under control 
conditions, the Zn2+ vacuolar sequestration mechanisms are linked to the CK2 tetramer as 
deletion of one of these transporters alongside a deletion of a regulatory CK2 subunit results in 
no growth.  
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Figure 3.18. Growth fold change of ck2∆zrc1∆ double deletion mutants at the 16 h time point.  
The Single deletion background strain and the CK2 double deletion strains were screened against 5 mM Zn2+, 10 mM Zn2+ or an equal volume of 
H2O.  Data represents the average of three independent experiments, each of which contained 8 replicates. Error bars represent SEM.  
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Figure 3.19. Growth fold change of ck2∆cot1∆ double deletion mutants at the 16 h time point.  
The Single deletion background strain and the CK2 double deletion strains were screened against 5 mM Zn2+, 10 mM Zn2+ or an equal volume of 
H2O.  Data represents the average of three independent experiments, each of which contained 8 replicates. Error bars represent SEM.
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3.3 Discussion  
The key aspect for the complexity of protein kinase CK2 is its functionality as both tetramers 
and individual monomers. More and more evidence demonstrates that both catalytic and 
regulatory individual subunits have distinct biological functions (Bibby & Litchfield, 2005; 
Domanska et al., 2005; M. Faust & Montenarh, 2000; Janeczko, Masłyk, Szyszka, & Baier, 
2011; Kubiński et al., 2007). Therefore, there are seven functional entities of CK2 in yeast, 
including three tetramers (Cka1pCka2pCkb1pCkb2p, Cka1pCka1pCKb1pCKb2p, 
Cka2pCka2pCKb1pCkb2p), two individual catalytic (Cka1p, Cka2p) and two regulatory 
monomers (Ckb1p, Ckb2p). This chapter demonstrates three major findings: (1) individual 
CK2 subunits have distinct functions in regulating metal toxicity; (2) CKA2 (Cka2p) is 
involved in Al3+ uptake, while CKA1 (Cka1p) is a major regulator for Zn2+ sequestration; and 
(3) ZRC1 and COT1 are involved in Zn2+ sequestration and are possibly regulated by Cka1p.   
 
Metal toxicity is related to the uptake of metal ions, hence the metal content in the cell. In this 
chapter, the cellular metal contents for Al3+ and Zn2+ were quantified using ICP-MS. The data 
reveal two disparate mechanisms. One is exemplified by Al3+. The Al3+ content was markedly 
lower in cka2∆ than cka1∆. Such contrasting findings in the two mutants explain their divergent 
phenotypes shown in Figure 3.1 under exposure to aluminium sulphate, which leads to the 
conclusion that Cka2p is involved in Al3+ uptake. CKA2 deletion reduces Al3+ transport across 
the plasma membrane and in turn results in increased cell growth. The cka1∆ mutant still 
possesses CKA2 in either monomeric or tetrameric forms which can facilitate uptake of Al3+, 
therefore leading to higher Al3+ content and lower growth. As no membrane-bound Al3+ 
transporter has been reported to date, the exact mode of regulation for Al3+ uptake by CKA2 
(Cka2p) remains to be investigated. Because Al3+ is associated with neurodegenerative 
disorders such as Alzheimer’s disease (Tomljenovic, 2011) , the involvement of CKA2 in Al3+ 
uptake, as demonstrated in this study, provides an insight into the potential role of Cka2p 
(CK2α’ in mammals) in the development of Alzheimer’s disease.  
 
The other mechanism for CK2’s regulation is exemplified by Zn2+. As shown in Figure 3.2 
under a high dose of Zn2+, cka2∆ mutant exhibited resistance to Zn2+ toxicity. Further analysis 
by ICP-MS (Figure 3.16) demonstrated that the Zn2+ contents in cka2∆ and cka1∆ mutants 
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were at a similar level to the wildtype. Such an observation suggests that their divergent 
phenotypes against Zn2+ might be underpinned by the perturbed distribution of Zn2+ inside the 
cell. The resistance of cka2∆ could be due to better sequestration of excess cytosolic Zn2+ into 
vacuoles, which might be regulated by CK2. Following this line of reasoning, we carried out 
the follow-up experiment using the selective inhibitor TBB of CK2. The resultant findings 
(Figure 3.17) showed that TBB abolished the resistant phenotype of cka2∆ against Zn2+. 
Because there are two molecular forms of catalytic CK2 in cka2∆, i.e. 
Cka1pCka1pCkb1pCKb2p (tetramer) and Cka1p (monomer), it is therefore reasoned that the 
Cka1p encoded by CKA1 in either tetrameric or monomeric form is the key player in regulating 
Zn2+ sequestration and hence preventing the metal toxicity. Additionally, the ICP-MS data 
(Figure 3.16) shows that deletion of either regulatory subunit results in greater intracellular 
Zn2+ than the wildtype. This suggests a possible role for the tetramer at the plasma membrane.  
 
The finding in Figure 3.10 and 3.11 further demonstrates that CKA1 tetramer 
(Cka1pCka1pCkb1pCkb2p) plays a major role against Zn2+ toxicity. The result shows that the 
resistance of CKA2 deletion (cka2∆) against Zn2+ is markedly reduced when coupled with the 
deletion of CKB1 or CKB2. Because the deletion of any one of the regulatory subunit disrupts 
the formation of CKA1 tetramers (Cka1pCka1pCkb1pCkb2p) in cka2∆ (Kubiński et al., 2007), 
it is likely that the lack of (Cka1pCka1pCkb1pCkb2p) in the double deletion mutants resulted 
in the reduced resistance against Zn2+. 
 
Unlike Al3+, Zn2+ is essential to the cell. Over the course of evolution, organisms built up an 
elaborate system of Zn2+ transport proteins and metallothioneins for zinc homeostasis, allowing 
availability of intracellular Zn2+ when the cell requires it and the 
compartmentalising/sequestering of Zn2+ when it is excessive (Sekler et al., 2003). 
Metallothioneins are the key players in “mopping up” excess cytosolic Zn2+, therefore, 
essential for the detoxification of Zn2+. Previous studies demonstrate that metallothioneins 
proteins are found to be highly elevated in cells exposed to excess Zn2+ (Suhy et al., 1999; 
Cousins, 1983).   Significantly, both the activity of Zn2+ transporters and the expression of 
metallothioneins are linked to the activity of CK2 in mammalian cells, i.e. the mammalian ZIP7 
channel is directly phosphorylated by CK2 (Taylor et al., 2012; Taylor et al., 2008)  and 
metallothionein gene expression is significantly decreased upon CK2 inhibition (Adams et al., 
2002). However, there are so many unanswered questions on how CK2 regulates Zn2+ 
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transporters, as there are 24 zinc transporters found in the mammalian cell, including 14 ZIP 
(ZRT/IRT-like protein) and 10 ZnT (zinc transporter) (Colvin, Fontaine, Laskowski, & 
Thomas, 2003; Guerinot, 2000). In yeast, Zrt1p, Zrt2p, Zrt3p and Yke4p are the orthologues 
of mammalian ZIP (Colvin et al., 2003; Kumánovics et al., 2006) whilst Zrc1p, Cot1p, Msc2 
and Zrg17p are the orthologues of mammalian ZnT (MacDiarmid, Gaither, & Eide, 2000).  
 
In yeast, Zn2+ ions are transported across the plasma membrane into the cytoplasm by Zrt1p 
and Zrt2p, to supply zinc to the requirement of zinc binding proteins in the cytoplasm, 
endoplasmic reticulum and Golgi apparatus. Excess zinc is both buffered by metallothioneins 
and sequestered in vacuoles by Zrc1p and Cot1p, therefore preventing zinc toxicity. The stored 
zinc in vacuoles can be transported into the cytoplasm via Zrt3p in the time of need. The 
experimental condition of this study mimics acute zinc toxicity. Therefore, the survival of the 
yeast cells under Zn2+ exposure depends upon their detoxification capacity. The results (Figure 
3.2, 3.16 and 3.17) demonstrate that CKA1 is a key player in regulating Zn2+ sequestration. It 
is plausible to conceive that Zrc1p and Cot1p are phosphorylated by CKA1 (Cka1p). By use 
of a bioinformatic tool, GPS 3.0 (http://gps.biocuckoo.org/), for identifying CK2 substrates, 
we found that both Zrc1p and Cot1p contain signature sequences (S/TXXE/D) for protein 
kinase CK2. Additionally, three studies identified that serine 396 (S396) of ZRC1 was 
phosphorylated (Holt et al., 2009; Gerber et al., 2007; Smolka et al., 2007), which supports the 
bioinformatics prediction by GPS 3.0.  This also lends support to the notion that the zinc 
transporters could be regulated by Cka1p. The findings with the double deletion mutants 
(Figure 3.10 and 3.11) provide additional evidence that Cka1p might interact with Zrc1p and 
Cot1p. Taken together the findings shown in Figures 3.2, 3.10, 3.11, 3.16, 3.17, 3.18 and 3.19, 
a mechanism for CK2’s regulation of zinc toxicity is proposed in Figure 3.20.  
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Figure 3.20 Mechanistic diagram for CK2’s regulation of Zn2+ toxicity. Under high dose of 
Zn2+, the yeast cells transport the metal ions into cytosol via plasma membrane-bound 
transporters such as Zrt1p and Zrt2p. Zn2+ ions in cytosol are sequestered into vacuole via 
Zrc1p and Cot1p which are likely regulated by CK2α (Cka1p). Metallothioneins are involved 
in buffering the excess Zn2+ in cytosol. 
 
Both CK2 and zinc have not been the hot topics du jour in recent memory, likely due to their 
being around for a long time. CK2 was discovered in 1954 (Burnett & Kennedy, 1954), whilst 
zinc initially drew researchers’ attention in 1869 (Maret, 2012; Raulin, 1869). However, their 
prominence has never receded, which is reflected by the intensive research activities on them 
to date. The link of CK2 with Zn2+ transport has direct bearing to cancer research. It is known 
that dysregulation of zinc homeostasis is a hallmark for two major types of cancer, namely 
breast and prostate cancers. Zn2+ is hyper-accumulated in breast cancer cells (Alam & Kelleher, 
2012). Its accumulation in cytoplasm was found to correlate with the regulation of ZIP such as 
ZIP7 by CK2 (Taylor et al., 2012; Taylor et al., 2008). However, which subunit of CK2 is more 
responsible for such regulation remains to be delineated. In terms of prostate cancer, Zn2+ is 
significantly decreased (Franklin et al., 2005; Song & Ho, 2009), and the regulation of zinc 
transporters in prostate cancer is unclear. Perhaps the link to the aberrant zinc levels of different 
cancerous tissues lies in the differential activity of CK2 subunits and their differing activities 
towards different substrates (e.g. zinc transporters). By dissecting the particular roles of CK2 
subunits in regulating zinc levels for cancer cells, as this study has done for S. cerevisiae, it 
may then be possible to tailor specific inhibitors against a particular subunit (CK2α or CK2α’) 
of CK2. A subunit specific inhibitor may allow for a targeted therapy, whereby the CK2 
function causing the pathology can be inhibited while other essential functions of CK2 remain 
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unaffected. This form of inhibition (differentiating between subunits) for the purpose of 
substrate selectivity is already a potential strategy being explored for the treatment of cancer 
(Prudent & Cochet, 2009). Considering the wide application of kinase inhibitors in treating 
various cancers, and the importance of CK2 in oncogenesis (Trembley et al., 2009), it will not 
be long before the advent of therapeutic inhibitors against CK2 in the clinic. Indeed, CX-4945 
which inhibits CK2 activity is currently in clinical trials.  
 
3.4 Conclusions 
This study investigated the role of CK2 in metal toxicity using both single and double gene-
deletion mutants. The phenotypic observations were complemented by the metal contents 
measured by ICP-MS. The findings demonstrate the link between CK2 and metal toxicity and 
highlight the intriguing differentiation for the regulation of zinc and aluminium toxicity by 
CK2. The potential role of Cka1p (CK2α) in regulating zinc sequestration discovered herein 
will provide a basis for further investigations in both S. cerevisiae and mammalian cells to 
tackle the question of how CK2 regulates zinc homeostasis. 
 
While much of the discussion of this chapter has been devoted to the role of CK2 in zinc and 
aluminium toxicity the focus will now shift to understanding the role of CK2 in arsenic toxicity 
and to elucidating the global cellular response to arsenic.  
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4 Molecular details for the role of protein kinase CK2 in 
arsenic toxicity uncovered via the genome-wide deletion 
mutant screening of Saccharomyces cerevisiae 
4.1 Introduction 
Arsenic mining and its industrial applications, as well as the natural occurrence of this 
metalloid in ground and drinking water, as detailed in 1.2.4, present a serious concern to human 
health. The past research has linked arsenic with cancers, neurodegenerative and cardiovascular 
diseases. Therefore, it is pressing to understand its cellular effects, as such an understanding 
could provide a basis upon which life-saving interventions are developed.  
 
The discoveries of Chapter 3, demonstrating a link between arsenic toxicity and the protein 
kinase CK2, presented a novel direction for understanding this toxicant. Deletion of CKA1, 
CKB1 and CKB2 conferred upon the mutant strains clear tolerance to the metalloid, when 
compared to the wildtype strain BY4743, at a dose of 1.6 mM.  Most intriguing of the findings 
was the delayed but marked tolerance of CKB2 deletion to 3.2 mM sodium arsenite (NaAsO2), 
a concentration that rendered the other strains completely inviable (Figure 3.3).  
 
This chapter presents further details for the role of CK2 in arsenic (As3+) toxicity. By screening 
a genome wide deletion collection against NaAsO2 I aimed to uncover pathways that may 
interact with protein kinase CK2 in the cellular response to arsenic. While previous genome 
wide screening utilising NaAsO2 has been published (Thorsen et al., 2009; Zhou et al., 2009), 
both screens were skewed towards uncovering sensitive phenotypes and were performed by 
quantifying colony size of spotted strains on agar plates. While these studies demonstrated 
some valuable, congruent findings, the dosage ranges used were conspicuously divergent with 
one study using 0, 75, 100 and 150 µM and the other using 0, 750 and 1000 µM NaAsO2.  
Further, of the few tolerant strains uncovered by Zhou et al. (Zhou et al., 2009), ckb2 was 
prominently featured as the 8th most tolerant, but this finding was not elaborated upon. 
 
The findings herein not only reveal more details for the role of CK2 in arsenic toxicity, but also 
provide a general overview of the cellular responses to arsenic by phenotypes of both tolerant 
and sensitive deletion mutants.                
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4.2 Results 
The phenotypic growth of deletion mutants and the wildtype under As3+ treatment was 
measured as optical density at 600 nm over a period of 16 h.  According to their growth profile, 
75 mutants were found sensitive to As3+, whilst 39 mutants were resistant. The functional 
categories of the genes corresponding to the sensitive and resistant phenotypes are shown in 
Figure 4.1. These genes are listed in Tables 4.1 and 4.2. The functional annotation for each 
gene is described in Appendix B and C. The complete data set, which is too large to include, 
can be found as Electronic Supplementary Information 1 in Johnson et al. (2016a). 
90 
 
 
 
  
  
Figure 4.1. Functional categories of the genes corresponding to the sensitive and resistant phenotypes and number of genes associated with 
each category. (A) Functional categories of the genes in 75 sensitive deletion mutants. The functional classifications are based on gene ontology 
and molecular function in SGD, where A represents genes related to protein translation, B for signal transduction, C for protein modification, 
transport and sorting, D for transcriptional regulation, E for membrane-bound proteins/transporters, F for metabolism, G for genomic maintenance 
and stability, H for structural proteins, I for cell cycle and J for uncharacterised or dubious ORFs.  The details for the functional groups (A-J) are 
provided in Table 4.1. (B) Functional category of the genes in 39 resistant deletion mutants, where A represents genes related to protein translation, 
B for signal transduction, C for membrane bound or associated proteins/ transporters and D for uncharacterised or dubious ORFs. The details for 
the functional groups (A-D) are provided in Table 4.2.
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Table 4.1. Functional analysis of the genes deleted in the As3+ sensitive mutants 
Functional category No. of genes Genes involved in As(III) tolerance 
Protein translation 5 CBS1, NCL1, DEG1, LHP1, NAB6 
Signal transduction 9 HOG1, PBS2, SSK1, SSK2, SLT2, PDE2, REG1, ARL1, LTE1  
Protein modification, 
transport and sorting 
17 BUL1, PFD1, LST7, LST4, PAC10, RBL2, CSF1, PAC2, CIN2, SEC22, YKE2, TUB3, 
VPS71, ARL1, VPS72, VPS13, ARL1 
Transcriptional 
Regulation 
13 SAS4, YAP1, ARR1, YAP3, RPN4, STP1, ADA2, RSC1, NGG1, MED1, IRA2, MNE1, 
URE2 
Membrane bound 
proteins/transporters 
9 ARR3, TAT1, LAS21, SEC22, FIT3, FET5, FIT2, MAL31, YPK9  
Metabolism 9 TPS1, IDP1, ERG4, GPM2, TPS2, SLC1, CYS3, ELO3, OPI3 
Genomic maintenance 
and stability 
8 HNT3, VPS71, SWC3, VPS72, RXT3, RTT107, ADA2, NGG1 
Structural proteins 3 SEH1, TUB3, JNM1 
Cell cycle 3 JNM1, SHE1, KAR9 
Uncharacterised or 
Dubious 
5 BSC1, YDL057W, API2, YOR338W, YDL050C  
 
Table 4.2. Functional analysis of the genes deleted in the As3+ resistant mutants 
Functional category No. of genes Genes involved in As(III) sensitivity 
Protein translation  23 RPS9B, RPS16A, RPS14A, RPS18A, RPL29, TMA22, RPS1B, RPS21B, TMA23, 
RPS28B, RPL37A, RPL6B, RPS29A, RPL43A, RPL16B, RPS29B, RPS17B, RPL13B, 
RPL37B, BUD31, RPS22B, RPL36B, URM1 
Signal transduction  4 CKB1, CKB2, PHO4, PHO81 
Membrane 
associated  
3 FPS1, ASK10, SNF3 
Uncharacterised  9 YLL044W, YIL014C-A, YLR444C, YLR111W, YGL088W, YDR417C, YLR402W, 
YLR184W, YML009C-A 
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4.2.1 The sensitive mutants against As3+ and their corresponding genes 
By the means of web-based resources as described in Section 2.3.9, and manual examination 
of the available annotation for each gene, the 75 genes of the corresponding deletion mutants 
were categorised into 10 groups based on the functions of their encoded proteins (Table 4.1). 
Highly represented are the genes involved in signal transduction, transcriptional regulation, 
protein modification/transport/sorting, membrane-bound proteins/transporters, metabolism 
and stress response (Figure 4.1A). Because deletion of these genes confers sensitivity, their 
presence is therefore necessary for combating arsenic toxicity.  
 
Group A (Figure 4.1 A) contains five genes related to protein translation. CBS1 encodes a 
protein that regulates the translation of the mitochondrial gene COB which encodes 
apocytochrome b, a member of the electron transport chain. The sensitive phenotype of cbs1∆ 
against As3+ indicates the significance of CBS1 in response to As3+.  NCL1 is a 
methyltransferase gene. The enzyme can methylate cytosine in tRNAs and therefore regulate 
protein translation. It was previously shown to be involved in oxidative stress response and 
mutants lacking Ncl1p are hypersensitive to oxidative stress (Chan et al., 2012). The finding 
here demonstrates NCL1 is also required against As3+ toxicity. The other three genes, LHP1, 
NAB6 and DEG1, are relevant to RNA binding and modification. Their sensitive phenotype 
against As3+ points to the necessity of these genes for survival under As3+ exposure. 
 
Group B (Figure 4.1A) contains genes that are involved in signal transduction. The presence 
of HOG1, PBS1, SSK1 and SSK2 highlights the prominence of mitogen-activated protein 
kinase (MAPK) signalling pathway. HOG1 was originally found to be involved in high 
osmolarity glycerol (HOG) response. It encodes a MAPK. The gene, PBS2, is for the MAPK 
kinase (MAPKK), which phosphorylates and hence activates MAPK. The kinase (MAPKKK) 
further upstream of Pbs2p is encoded by SSK2. Ssk2p interacts with Ssk1p, leading to 
autophosphorylation and activation of Ssk2p which phosphorylates Pbs2p.  This screening data 
set shows that the deletion mutants of HOG1, PBS2, SSK1 and SSK2 are highly sensitive to 
As3+. The functions of the other genes, PDE2, REG1, ARL1, LTE1 and SLT1, are diverse and 
detailed in Appendix B. Their deletion renders the mutants sensitive to As3+ toxicity.  
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The composite of group C (Figure 4.1A) reflects the essentiality of protein folding (PAC2, 
PAC10, PFD1, YKE2, RBL2 and CIN2), transport (ARL1, LST7, LST4, VPS13, SEC22 and 
VPS71) and degradation (BUL1) in response to As3+. This is of no surprise as the ability of 
As3+ to compromise protein folding by coordinating to the cysteine residues of unfolded 
proteins has been shown (Ramadan, Rancy, Nagarkar, Schneider, & Thorpe, 2008).  The 
misfolded proteins, due to the toxic effect of As3+ need to be transported to the proteasome for 
degradation. Interruption of this process by gene deletion would be detrimental to cell survival. 
Therefore, the deletion mutants in this group showed sensitivity to As3+.  
 
Group D represents genes related to the regulation of transcription. ARR1 is required for 
transcription of the membrane bound exporter of As3+ encoded by ARR3. The sensitivity of 
arr1∆ along with the sensitive phenotype associated with YAP1 and RPN4 demonstrates their 
critical role in response to As3+. The hypersensitivity of YAP3 deletion mutant highlights that 
a third member of the YAP family, together with YAP1 and ARR1 (also known as YAP8), is 
required for regulating As3+ detoxification.  
 
Group E includes the genes encoding membrane-bound proteins. The presence of ARR3 is 
expected as Arr3p is an As3+ exporter, essential for the yeast cell’s defence against As3+. Also, 
within this group are genes related to iron homeostasis (FET5, FIT1 and FIT3). Their sensitive 
phenotype demonstrates the significant role of iron homeostasis in response to As3+ exposure. 
The sensitivity of mutants in Group F indicates certain metabolic processes are important in 
response to As3+. For instance, TPS1 and TPS2 are involved in trehalose biosynthesis. It is 
known that trehalose plays a role in stress response and supressing protein aggregation (Pereira, 
Eleutherio, & Panek, 2001). This study demonstrates that their deletion confers sensitivity to 
As3+. 
 
The genes related to the maintenance of genomic stability in Group G indicate the need for 
chromatin remodelling in response to As(III) insult. Of the genes involved in chromatin 
remodelling (SWC3, RXT3, NGG1, SAS4, ADA2, VPS72, RSC1, VPS71), three genes (SWC3, 
VPS72, VPS71) are part of the Swr1p complex which exchanges histone variant H2AZ (Htz1p) 
for chromatin-bound histone H2A, important for regulating gene expression (Mizuguchi et al., 
2004). The sensitive phenotype of these mutants indicates these genes are a part of molecular 
mechanisms involved in dealing with arsenic exposure. 
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4.2.2 The resistant mutants against As3+ and their corresponding genes 
The resistant mutants, as listed in Table 4.2, are those with two-fold or greater growth than the 
wildtype BY4743 against 0.4 mM NaAsO2. The detailed annotation of the genes is provided 
in Appendix C. 
 
The corresponding genes of the resistant mutants are over-represented by ribosomal genes and 
genes involved in protein translation (Figure 4.1B). Their encoded proteins are components of 
translational machinery in the cell. Deletion of these genes would slow down protein synthesis 
and hence cell growth. This could allow the cell to adapt and survive the As3+ insult and 
therefore lead to the resistant phenotype. The presence of signalling genes (CKB1, CKB2, 
PHO4, PHO81) on the list of deletion mutants resistant to arsenite indicates possible signalling 
pathways regulating the entry of As3+. CKB1 and CKB2 encode the regulatory components 
(Ckb1p and Ckb2p) of the tetrameric, pleotropic serine/threonine protein kinase CK2. Since it 
was previously shown that CK2 does not form tetramers in the absence of either of the 
regulatory subunits (Kubiński et al., 2007), the resistant phenotype of ckb1∆ and ckb2∆ 
demonstrates the likelihood that the tetrameric holoenzyme CK2 is associated with As3+ uptake 
and toxicity. Ckb1p and Ckb2p could also be directly involved in regulating the uptake of As3+ 
by interacting with the other signalling proteins such as those in Hog1p MAPK pathway. This 
idea is further explored using double deletion mutants in the subsequent section. Both PHO4 
and PHO81 are related to phosphate transport, with the former encoding a transcription factor 
Pho4p required in phosphate limited environments, and the latter coding for a protein that 
regulates phosphate transporters. The increased tolerance to As3+ of these two mutants 
demonstrates that phosphate transporters could serve as the route of As3+ entry. Similarly, the 
resistance associated with fps1∆ and snf3∆ is linked to their roles as membrane-bound 
transporters for glycerol (Fps1p, known as aquaglyceroporin) and hexose (Snf3p). Ask10p is a 
positive regulator of Fps1p.  Deletion of ASK10 would abolish the positive regulatory effect 
and result in deactivation of aquaglyceroporin, and hence the resistance to As3+ shown by 
ask10∆. 
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4.2.3 Double deletion mutants against 0.2 mM arsenic  
To further explore the interactions of CK2 subunits with the genes whose deletion resulted in 
distinct phenotypes in the presence of arsenic, double deletions were generated according to 
section 2.3.3. They were of a CK2 subunit gene and different genes that showed prominent 
phenotypes in the tolerant and sensitive lists generated in the screen. In total 64 double deletion 
mutants were used in the investigation of sensitive mutants and 32 for the tolerant mutants.  
 
Tolerant single and double deletion mutants were screened against 0.4 mM NaAsO2 while 
sensitive single and double deletion mutants were screened against 0.2 mM NaAsO2. Each 
mutant (tolerant and sensitive) were also screened against an equal volume of H2O. To calculate 
the relative growth of a mutant compared to itself in the solvent control, the OD600 was 
measured at 0 h (T0) and 16 h (T16). The relative growth was then calculated by dividing the 
treated (0.2 mM for sensitive single and double deletion mutants and 0.4 mM for tolerant single 
and double deletion mutants) by the corresponding untreated control. A value of 1 therefore 
indicates that the mutant grew to the same level in treatment as it did in control. The growth of 
the genes as single deletion mutants is also shown so comparisons between the double deletion 
mutants and the single deletion mutants can be performed. The experiments were conducted in 
triplicate with at least 3 replicates, all data shown represents the average and are shown in Table 
4.3 and 4.4. 
 
In Chapter 3 the interesting phenotype of the double deletion mutants ckb1∆ckb2∆ and 
ckb2∆ckb1∆ was that under all metals but arsenic the double regulatory deletion was relatively 
healthy when compared to the other double deletions, while in arsenic treatment it was less 
viable. In this chapter, this finding was confirmed. Intriguingly, while ckb1∆ and ckb2∆ show 
tolerance to arsenic as shown in Table 4.3 and Table 4.4 (growing 91% and 98% as well as 
control in 0.2 mM and 75% and 95% as well as control in 0.4 mM respectively). The double 
deletion mutants ckb1∆ckb2∆ and ckb2∆ckb1∆ showed sensitivity similar to the HOG pathway 
and YAP single gene deletion mutants at the 0.2 mM dose shown in table 4.3 (25% 
ckb1∆ckb2∆, 27% for ckb2∆ckb1∆, 37% hog1∆ and 22% yap1∆). This indicates that having 
monomeric ckb1p or ckb2p (present in ckb1∆ and ckb2∆ as they are unable to dimerize) is 
beneficial in arsenic replete environments while having neither is markedly disadvantageous.   
While ckb1∆ssk2∆, ckb2∆ssk1∆ and ckb2∆slt2∆ did not grow, the other CK2 double deletion 
mutants had similar growth in 0.2 mM as the MAP kinase gene deletions or even the YAP gene 
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deletions. While this indicates no causal relationship, it is certainly correlative of CK2 genes 
occupying spaces within the same arsenic response pathway/s as the MAP kinases and/or YAP 
transcription regulation genes. When taken with the fact that CK2 regulatory double deletions 
show a similar sensitivity to MAP Kinase single gene deletions, one begins to suspect that the 
ckb1p or ckb2p have auxiliary functions outside the CK2 tetramer that are related to the MAP 
kinase pathway. 
 
One further point of interest is that the divergent phenotypes of arr1∆ and arr3∆ compared to 
arr1∆ckb1∆, arr1∆ckb2∆, arr3∆ckb1∆ and arr3∆ckb2∆ demonstrate that the resistance 
conferred to As3+ by deletion of CKB1 and CKB2 is not related to the efflux of the toxicant via 
the arsenic resistance system encoded for by ARR3 and ARR1 because the resistance of the 
ckb1∆ and ckb2∆ is not abolished when the ARR1 and ARR3 genes are deleted with these CK2 
genes.        
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Table 4.3 Growth of double deletion mutants and single deletion backgrounds in 0.2 mM 
NaAsO2  
Name  
Single 
deletion 
CKA1 CKA2 CKB1 CKB2 
ARR1 0.38 0.315 0.361 0.902 0.737 
ARR3 0.405 0.388 0.542 0.774 0.75 
BUL1 0.467 0.612 0.633 0.304 0.457 
CKA1 0.627 NA SL 0.668 0.762 
CKA2 0.69 SL NA 0.762 0.66 
CKB1 0.905 0.822 1.107 NA 0.252 
CKB2 0.988 0.887 1.174 0.271 NA 
FET5 0.455 0.539 0.565 0.809 0.808 
FIT2 0.469 0.348 0.55 0.682 1.141 
FIT3 0.493 0.463 0.367 0.485 0.231 
HOG1 0.369 0.282 0.348 0.236 0.446 
PBS2 0.442 0.438 0.729 0.414 0.341 
SLT2 0.499 0.476 0.632 0.336 NG 
SSK1 0.397 0.498 0.847 0.536 NG 
SSK2 0.405 0.685 0.512 NG 0.184 
YAP1 0.224 0.26 0.459 0.104 0.239 
YAP3 0.195 0.069 0.109 0.265 0.219 
Note: Data represents the average of three independent experiments. SL- synthetically lethal, 
NA-not applicable (e.g. cannot cross a cka1∆ with a cka1∆), NG- mutant did not grow in 
control. Growth is normalised to untreated. Red indicates low growth, yellow average and 
green is growth approaching or exceeding that of untreated.  
 
4.2.4 Double deletion mutants against 0.4 mM arsenic  
The phenotype of several genes on the tolerant mutant list, including SNF3, FPS1, ASK10, 
PHO81 and PHO4, indicates that they play a role in arsenic transport. If the resistance 
conferred by deletion of CKB1 or CKB2 was due to interactions with these transporters one 
would expect that the phenotypes of these transporters as single deletions would match the 
phenotypes when their deletion is accompanied with a CKB1 or CKB2 deletion. As Table 4.4 
shows this in fact, is what is observed with the fps1∆ and ask10∆ deletion mutants.     
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Table 4.4 Growth of double deletions and single deletion backgrounds in 0.4 mM As3+  
 
Single 
deletion 
CKA1 CKA2 CKB1 CKB2 
ASK10 0.83 0.886 0.848 0.794 0.882 
CKA1 0.748 NA SL 0.124 0.129 
CKA2 0.58 SL NA 0.193 0.098 
CKB1 0.753 0.657 0.744 NA 0.097 
CKB2 0.946 0.786 0.903 0.12 NA 
FPS1 0.796 0.514 0.743 0.832 0.908 
PHO4 0.841 0.228 0.325 NG NG 
PHO81 0.775 0.35 0.568 0.11 NG 
SNF3 0.731 0.278 NG NG NG 
Note: Data represents the average of three independent experiments. SL- synthetically lethal, 
NA-not applicable (e.g. cannot cross a cka1∆ with a cka1∆), NG- mutant did not grow in 
control. Growth is normalised to untreated growth. Red indicates low growth, yellow average 
growth and green is growth approaching or exceeding that of untreated.  
 
4.3 ICP-MS of CK2 deletion mutants under As3+ exposure.  
In chapter 3 Figure 3.3 we saw that deletion of all CK2 subunits resulted in greater viability 
than the wildtype at 1.6 mM As3+. At 0.4 mM we see that all CK2 deletions result in lower 
intracellular As3+ than the wildtype with CKB1 and CKB2 deletions providing the greatest 
reduction. The double deletion data indicates that the resistant growth phenotype of ckb1∆ and 
ckb2∆ is independent of the As3+ efflux system (Table 4.3) and that resistance conferred by 
CKB1 deletion and CKB2 deletion may be related to the ASK10/FPS1 uptake system. The 
reduced intracellular As3+ content of CKB1 and CKB2 deletion mutants appears to be a result 
of less uptake through the FPS1 transporter, possibly mediated by the HOG1 pathway. 
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Figure 4.2 Intracellular As3+ content of CK2 deletion mutants in 0.4 mM NaAsO2 over a 
period of 16 h. Preparation and analysis of samples was carried out according to Chapter 2.3.6. 
Data represents the average of three independent experiments. Error bars represent SEM.  
 
4.4 Discussion 
This genome-wide screen of the individual deletion mutants for 4,873 non-essential genes 
reveals both sensitive and resistant mutants against arsenite. The sensitive mutants demonstrate 
that the deleted genes are essential to combat As3+ toxicity. The term “essential gene” here is 
used to describe the requirement of a given gene under As3+ exposure, it has no relevance to 
the other term, “non-essential genes” used in yeast genetics to describe the genes whose 
deletion results in cells viable in normal growth conditions. As demonstrated by the sensitive 
mutants, 75 genes are required for the yeast cell’s survival upon exposure to As3+. The number 
of resistant mutants (39) uncovered in this study is striking, compared to the finding of five 
resistant mutants in another genome-wide screen against As3+ (Zhou et al., 2009). The 
difference in findings between my study and that performed by Zhou et al. (2009) are likely 
accounted for by the differing methodologies. For example, the use of a liquid plate-based 
assay in my study compared to spotting strains on agar and scoring colony size likely accounted 
for much of this discrepancy. The use of agar as a growth medium necessitates that the culture 
is exposed to the toxicant from the moment of inoculation. Contrastingly, the liquid based assay 
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allowed me to apply the toxicant into the cultures as they were exiting the lag phase. This 
difference in initial exposure to the toxicant provides one possible basis for the differing results.  
  
The hypersensitivity shown by arr1∆ and arr3∆ evidently demonstrates that arsenic-specific 
detoxification genes, ARR1 (also known as ACR1) and ARR3 (ACR3), are at the forefront of 
the survival mechanism against As3+. ARR3 encodes a plasma membrane-bound As3+ 
transporter to efflux the toxic metalloid from the cytosol to the extracellular space (Bobrowicz, 
Wysocki, Owsianik, Goffeau, & Ułaszewski, 1997; Maciaszczyk-Dziubinska, Wawrzycka, 
Sloma, Migocka, & Wysocki, 2010; Wysocki, Bobrowicz, & Ułaszewski, 1997), whilst ARR1 
encodes the transcription factor to regulate the expression of Arr3p in response to As3+ insult 
(Maciaszczyk, Wysocki, Golik, Lazowska, & Ulaszewski, 2004). The deletion mutant of 
ARR2, which is the gene for As5+ reductase, did not show sensitivity. This is due to the As3+ 
salt used in the screen, therefore As5+ was not the dominant arsenic species although some 
arsenite ions could be oxidised to arsenate. The hypersensitive phenotype of yap3∆ uncovered 
here is novel, suggesting the necessity of this transcription activator gene in response to arsenic 
toxicity. The finding is conceivable since the other members of the Yap family are heavily 
involved in regulating molecular responses against oxidative stress (Yap1p) and cadmium 
toxicity (Yap2p) (Azevedo, Nascimento, Labarre, Toledano, & Rodrigues-Pousada, 2007; 
Fernandes, Rodrigues-Pousada, & Struhl, 1997; O’Doherty et al., 2013). In fact, Arr1p also 
belongs to the Yap family, and is referred to as Yap8p (Rodrigues-Pousada, Menezes, & 
Pimentel, 2010). This discovery of Yap3p in regulating arsenic detoxification is significant in 
answering the question of how the cell senses the toxic metalloid. As Yap1p possesses two 
redox centres, one for reactive oxygen species and the other for thiol-reactive chemicals, such 
as heavy metals (Azevedo et al., 2007), we think that Yap3p, as well as Yap1p, may act as an 
arsenic sensor and regulate the downstream detoxification response. This involves upregulating 
the expression of vacuolar ATPase Ypk9p, as deletion of its corresponding gene (YPK9) 
resulted in sensitivity to As3+, in addition to its previously observed sensitivity to cadmium, 
manganese, nickel and selenium (Schmidt, Wolfe, Stiller, & Pearce, 2009). Based on the higher 
sensitivity of yap3∆ than yap1∆ (yap3∆ grew less than 50% of yap1∆ in 0.2 mM As3+), it is 
likely that Yap3p plays a more direct role in combating As3+ toxicity, whilst Yap1p might be 
more involved in regulating the antioxidant response. 
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The hypersensitive phenotype of MAPK deletion mutant hog1∆ under 0.2 mM As3+ is in 
agreement with the previous genome-wide screens (Thorsen et al., 2009; Zhou et al., 2009). 
However, further details were revealed in this exercise by the sensitivity of pbs2∆, ssk1∆, 
ssk2∆, ckb1∆ and ckb2∆. PBS2 and SSK2 encode MAPKK and MAPKKK respectively, 
upstream of MAPK for its phosphorylation and activation, while the protein encoded by SSK1 
regulates Ssk2p. Hence, deletion of PBS2, SSK1 and SSK2 would disrupt Hog1p activity and 
its signalling pathway, which explains their sensitivity to the metalloid. In contrast, deletion of 
CKB1 or CKB2, the two regulatory subunits of protein kinase CK2, results in resistance against 
As3+. In ckb1∆ or ckb2∆ mutants, the tetrameric protein kinase CK2 cannot be formed 
(Kubiński et al., 2007). That the absence of tetrameric holoenzyme CK2 gives rise to resistance 
to arsenite indicate that the tetrameric CK2 may be involved in As3+ uptake. Moreover, the 
individual subunits in ckb1∆ (Cka1p, Cka2p and Ckb2p) and ckb2∆ (Cka1p, Cka2p and Ckb1p) 
can function independently. Therefore, it is likely Ckb2p in ckb1∆, and Ckb1p in ckb2∆ that 
account for their resistant phenotypes, because neither cka1∆ nor cka2∆ displayed a 
pronounced resistant phenotype in the genome wide screen. This notion was further explored 
by double deletion mutant studies. The phenotype of the double deletion mutants (Figure 3.12 
and 3.13) uncovered that the tolerance of a single regulatory subunit deletion is abolished in a 
double regulatory deletion under arsenic exposure. This is in contrast to the relative viability 
of the double regulatory deletion in the presence of other metals (Figures 3.8, 3.9, 3.10, 3.11, 
3.14 and 3.15). This indicates that having monomeric ckb1p or ckb2p (present in ckb1∆ and 
ckb2∆ as they are unable to dimerize) is beneficial in arsenic replete environments while having 
neither is markedly disadvantageous. This indicates that either the CK2 tetramer is a reason for 
sensitivity, or that ckb1p or ckb2p subunits have individual functions outside the tetramer that 
are bolstered by their unrestricted nature when their dimer binding partner is absent. Under the 
second of these two possibilities the reasoning can be extended. For example, in ckb1∆, 
dimerization does not occur. This leaves ckb2p free to interact with possible detoxification 
pathways. The same reasoning applies to ckb2∆, however the greater resistant phenotypes for 
ckb2∆ (Figure 3.3) would mean that the ckb1p monomer is more effective in the hypothesised 
pathways. The finding again highlights the involvement of protein kinase CK2 in metal 
toxicity, in addition to our previous finding that the catalytic subunit Cka2p is closely related 
to aluminium toxicity (Johnson et al., 2017; Tun et al., 2014). Interestingly, ckb2∆ did show a 
high level of resistance against As3+ in the genome-wide screen conducted by Zhou et al. (Zhou 
et al., 2009), but it was not explicitly highlighted.  
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Considering that both Hog1 MAPK pathway and CK2 are involved in regulating arsenic 
toxicity, it is possible that they may be linked. This means that Ckb1p or Ckb2p may regulate 
MAPK, MAPKK or MAPKKK. Indeed, according to the protein-protein interaction database 
(www.thebiogrid.org), CKB1 and PBS2 interact at the genetic level. 
 
That the sensitivity of arr1Δ and arr3Δ is attenuated by double deletion with CKB1 or CKB2 
suggest that the tolerance conferred by deletion of CKB1 or CKB2 is not due to their bolstering 
of this efflux pathway. Conversely the similar phenotype of the double deletion of the As3+ 
importer gene FPS1 and CKB1 or CKB2 suggest that the tolerance conferred by CKB1 or CKB2 
deletion is related to uptake via the Fps1p importer possibly mediated by the Hog1 pathway.   
 
The ICP-MS data suggests that the resistance to As3+ by deletion of CKB1 or CKB2 is due to 
decreased cellular levels of the metal supports the idea that Ckb1p and Ckb2p may block uptake 
via the Fps1p transporter. Indeed, previous evidence indicates that MAPK phosphorylation 
targets Fps1p leading to its ubiquitination, endocytosis and degradation (Mollapour & Piper, 
2007).     
 
Protein damage is the key mode of action for As3+ toxicity. This is demonstrated by the 
sensitive phenotype of bul1∆ and the other mutants involved in protein transport and sorting. 
Because BUL1 encodes a ubiquitin-binding protein for protein ubiquitination (Andoh, Hirata, 
& Kikuchi, 2000), it is therefore required by the cell to clear the damaged protein. Chemically, 
trivalent arsenite readily reacts with the thiols of cysteine residues in proteins, resulting in 
misfolding and loss of protein activity (Hughes, 2002). Such toxicity can also be extended to 
free cysteine and glutathione, which are the part of sulphur metabolism. In fact, our data 
demonstrate deletion of CYS3 confers sensitivity to As3+. Cys3p (cystathionine γ-lyase) 
catalyses the formation of cysteine from cystathionine, hence its deletion interrupts sulphur 
metabolism and in turn affect the level of cysteine and glutathione.  
 
Metal toxicity starts with the prerequisite step, cellular uptake of metal ions. Disruption of the 
uptake process should lead to resistance. This notion is supported by this study. Firstly, as 
mentioned in the outset of this study, trivalent arsenite (As3+) structurally resembles glycerol, 
and enters the cell via the membrane-bound glycerol channel Fps1p (Wysocki et al., 2001). 
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Our finding that fps1∆ is indeed resistant to arsenite serves as a valuable quality control, 
demonstrating the validity of this screen. Furthermore, this screen revealed that ask10∆ is 
highly resistant to As(III) toxicity. ASK10 encodes Ask10p (also known as Rgc2p), which is 
an activator of Fps1p (Beese, Negishi, & Levin, 2009). Because Ask10p is required for the 
opening of Fps1p, its deletion abolishes Fps1p channel activity, therefore leading to reduced 
arsenite uptake and in turn resistance.  
 
Apart from the Fps1p-mediated arsenite uptake, this study uncovered two additional entry paths 
for the metalloid, i.e., via glucose transporter (SNF3) and phosphate transporters. The 
underlying reason for these transporters to take up arsenic as “mistaken identity” instead of 
their intended cargoes is also due to the chemistry of arsenite. Apart from the polyhydroxylated 
form, As(OH)3, analogous to glycerol, polymerisation of three As(OH)3 is predicted to form a 
six-membered ring structure which seems to be similar to the six-membered ring structure of 
hexose sugars (Liu, Boles, & Rosen, 2004). Therefore, arsenite can gain entry into the cell via 
glucose transporters. This explains the finding here that deletion mutant snf3∆ displayed 
tolerance to arsenite. The fact, that mammalian glucose transporter, GLUT1, also facilitates 
arsenite entry into the cell (Liu et al., 2006), demonstrates the commonality between the yeast 
model and mammals. The structural similarity amongst arsenate (AsO4) and phosphate (PO4) 
explains the involvement of phosphate transporters in arsenate uptake. The entry of arsenate 
by phosphate transporters is deduced according to the resistant phenotype of pho4∆ and 
pho81∆, which encode transcription factor Pho4p and its regulator - cyclin-dependent kinase 
inhibitor Pho81p (Kaffman, Herskowitz, Tjian, & O'shea, 1994). Deletion of both genes would 
lead to lower expression of phosphate transporters, therefore the resistant phenotype against 
arsenite exposure. The involvement of phosphate transporters implies that some of the applied 
As3+ during the treatment were oxidised to the pentavalent form and those As5+ ions could be 
taken up via these transporters, contributing to cytotoxicity.   
 
Deletion of ribosomal genes and those related to ribosomal biogenesis confers arsenite 
resistance. In yeast, there are 78 ribosomal proteins encoded by 137 ribosomal genes, with 59 
of these proteins encoded by a pair of paralogous genes (Planta & Mager, 1998; K. K. Steffen 
et al., 2012). Forty-six proteins are in the 60S large subunit and 32 in the 40S small subunit of 
the yeast ribosome. Deletion of ribosomal genes slows down the protein translation process, 
and in turn cell growth. The resistance against arsenite shown by 19 deletion mutants of 
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ribosomal genes, representing approximately 14% of 137 ribosomal genes, demonstrates that 
slowed protein synthesis confers resistance to adversary arsenite exposure. This notion is 
further supported by the findings of Pan et al. (2010) and Dilda et al. (2008). Additionally, the 
ribosomal proteins could serve as the targets of arsenicals in wildtype strains (Szinicz & Forth, 
1988). Since such damaged proteins would cause cytotoxicity, their deletion is in fact beneficial 
in an arsenic-rich environment.  
 
Although previous studies using yeast deletion mutants have led to a significant advance in our 
understanding of the metal uptake, toxicity mechanisms and cellular detoxification of As3+, the 
molecular details of these key aspects are still to be defined. So scarce is the knowledge of how 
toxic metals, like arsenic, are sensed by the cell and how the sensing is linked to specific 
cellular responses. As the mammalian cell senses growth factors via their receptors, the yeast 
cell has transporters/receptors (transceptors) to sense its nutrients (e.g. phosphate). Such 
sophisticated built-in systems are the result of lengthy adaptation and evolution. In contrast to 
nutrients, organisms such as yeast do not have such innate transceptors per se to sense toxic 
metals like arsenite. Rather, the cell has to organise its defence upon an insult. This study 
highlights the uptake routes for arsenic as “mistaken identity” via glycerol channel, hexose 
transporter and phosphate transporters. The phenotype of three YAP transcription factor genes 
(ARR1/YAP8, YAP1, YAP3) demonstrates their critical role in organising cellular defences, 
likely by sensing intracellular As3+ and activating specific genes for exporting As3+ to the 
extracellular space and other detoxification processes. The Hog1 pathway, possibly in 
conjunction with CK2, is essential to shut down uptake transporters like Fps1p. This overall 
mechanistic network is illustrated in Figure 4.3. 
 
 
  
 
Figure 4.3 The proposed mechanistic response against arsenite in S. cerevisiae. Upon 
exposure to As3+ (grey spheres), the metalloid enters the cell via glycerol transporter Fps1p and 
hexose transporter Snf3p. Some As3+ might be oxidised to As5+ (black sphere) which then 
enters the cell through phosphate transporters. The sudden increase of intracellular arsenite can 
attack Yap1p and Yap3p, which initiates downstream regulation, including activation of gene 
expression for ARR3, BUL1 and the other detoxification genes as well as activation of Hog1p 
MAPK pathway which can in turn deactivate Fps1p, and also possibly trigger interaction 
between regulatory subunits (Ckb1p and Ckb2p) of protein kinase CK2 with the components 
of MAPK pathway. --- dashed line denotes possible interactions. 
 
4.5 Conclusions 
The data here provide additional details for the role of protein kinase CK2 in arsenic toxicity 
and cellular detoxification, by demonstrating that Ckb1p (encoded by CKB1) and Ckb2p 
(encoded CKB2) could be involved in regulating the uptake of As3+ by interacting with the 
signalling proteins such as those in the Hog1p MAPK pathway. The fact that yeast cells have 
specific built-in molecules such as ARR1 and ARR3 for As3+ efflux strongly suggests such 
detoxification apparatuses has been developed along the evolutionary timeline of thousands of 
years. A recent finding demonstrates, similarly, that human populations in the arsenic 
contaminated Andean highlands have acquired genetic adaptation by developing a particular 
detoxification mechanism (Schlebusch et al., 2015). Such commonality between these two 
species again reinforces the potential usefulness of this study. Apart from CK2 genes, the other 
uncovered genes relevant to the metalloid’s detoxification and uptake provide valuable 
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knowledge for dealing with arsenic-related health and environmental problems. The proposed 
regulatory mechanism for the yeast cell, in response to arsenic exposure, highlights the key 
findings of this screen, and further demonstrates the value of yeast deletion collections as tools 
in toxicological investigation. As demonstrated by the engineered arsenic-accumulating plant 
using bacterial detoxification genes (Dhankher et al., 2002),  the yeast genes revealed here such 
as CKB2 and ASK10 could also be targeted for developing arsenic resistant yeast strains or 
plant varieties for bioremediation.  
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5 Understanding the role of CK2 in chromium toxicity by 
genome-wide screening of S. cerevisiae gene deletion 
mutants 
5.1 Introduction 
Since its discovery in 1797 by Louis Nicholas Vauquelin (Lennartson, 2014), the benefits of 
chromium have been exploited in many areas such as leather tanning, electroplating, stainless 
steel production and clinical orthopaedics. While chromium usage affords inarguable benefits 
it is nonetheless a toxicant that has severe adverse effects on living organisms, such as the 
development of lung cancer in humans exposed to chromium in an industrial context 
(Beveridge, Pintos, Parent, Asselin, & Siemiatycki, 2010; Coyle et al., 2006). The apparent 
enigma of chromium as a beneficial yet toxic metal is exemplified by the two prominent 
oxidation variants of the metal, the hexavalent Cr6+ and the trivalent Cr3+. Cr6+ is considered to 
be highly toxic whilst Cr3+ is regarded as a micronutrient used in many health supplements (Liu 
et al., 2015; Urbano et al., 2012; Wu et al., 2016).      
 
By demonstrating a link between CK2 and metal ion toxicity and homeostasis, Chapter 3 
provided a basis for further exploring the role of the kinase CK2 in the toxicity of chromium 
(Cr6+), like what was done in Chapter 4, which uncovered the details of CK2 in arsenic toxicity 
and its detoxification by the cell. This chapter aims to reveal the big picture of Cr6+ toxicity 
and the cellular response to the metal ion through genome-wide screening of S. cerevisiae 
deletion mutants, and to obtain details of CK2 in Cr6+ toxicity and its detoxification.  
 
The homozygous diploid deletion set obtained from EUROSCARF as used in Chapter 4, was 
screened with two concentrations of CrO3, one benign and the other sub-lethal. Both sensitive 
and resistant mutants in response to Cr6+ exposure were revealed. Functional analysis of the 
genes deleted in those mutants provides detailed understanding of Cr6+ toxicity and cellular 
detoxification, and within such context, the role of CK2 in Cr6+ toxicity and cellular 
detoxification is described and discussed.     
 
In chapter 3, evidence is reported linking CK2 to chromium toxicity (Figure 3.4). Interestingly 
the data indicate that the adverse effects associated with Cr6+ may be linked to the tetramer 
108 
 
function as deletion of the regulatory subunits provide the greatest tolerance to the metal. When 
the double deletion data is observed (Figures 3.14 and 3.15), one can see that this tolerance 
observed in all CK2 tetramer lacking mutant strains. The purpose of this chapter is to determine 
pathways or individual genes that may be linked to the role of CK2 in chromium toxicity and 
homeostasis.  
 
5.2 Results 
The phenotypic growth of 4783 gene deletion mutants along with the wildtype (BY4743) under 
two doses of Cr6+ revealed both sensitive and resistant mutants against Cr6+. Here, a sensitive 
mutant denotes that deletion of the gene impairs at least 50% of the growth of BY4743 upon 
exposure to 0.05 mM CrO3, a non-toxic dose to the wildtype. Therefore, the deleted gene is 
required for combating the metal’s toxicity. Conversely, a resistant mutant reveals that the gene 
deletion increases its growth relative to that of the wildtype BY4743 under Cr6+ treatment and 
hence the deleted gene is likely involved in the metal’s uptake or in synergistic actions which 
enhance Cr6+ toxicity. The complete data set, which is too large to include, can be found as 
Electronic Supplementary Information 1 in Johnson et al. (2016b). A total of 206 mutants were 
found to be sensitive to Cr6+, while 66 mutants were resistant. Figure 5.1 shows the functional 
categories of the genes corresponding to the sensitive and resistant phenotypes. The individual 
genes are listed in Tables 5.1 and 5.2. The functional annotation for each gene is contained in 
Appendix D and E.
  
 
  
Figure 5.1 Functional categories of the genes corresponding to the sensitive and resistant phenotypes and number of genes associated with 
each category. (A) Functional categories of the genes in 206 sensitive deletion mutants. The functional classifications are based on gene ontology and molecular function in 
SGD, where A represents genes related to protein modification transport and sorting, B for genomic maintenance and stability, C for transcriptional regulation, D for protein 
translation, E for membrane associated proteins, F for metabolism, G for cell cycle, H for signal transduction, I for structural proteins and J for uncharacterised or dubious 
ORFs.  The details for the functional groups (A-J) are provided in Table 5.1. (B) Functional category of the genes in 66 resistant deletion mutants, where K represents genes 
related to protein translation, L for modification, M for metabolism, N for cell cycle, O for membrane associated proteins, P for signal transduction, Q for transcriptional 
regulation and R for uncharacterised or dubious ORFs. The details for the functional groups (K-R) are provided in Table 5.2.
Table 5.1 Functional analysis of the genes deleted in the Cr6+ sensitive mutants 
Functional category No. of genes Genes 
Protein modification, 
transport and sorting 
(A) 
53 AGE2, APL5, ATG11, BLM10, BUL1, COG8, DID2, DID4, DOA4, DRS2, DYN3, ELO2, ELP6, FYV10, GET4, GYL1, 
JID1, LDB19, NCS2, PEP12, PER1, PEX19, PHO86, PMT5, RIM13, SBH2, SEC22, SEM1, SKY1, SLY41, SNF7, SNF8, 
STP22, TOM7, UBP11, UBP3, UBP6, URE2, VAM6, VPS1, VPS4, VPS8, VPS16, VPS25, VPS28, VPS29, VPS33, 
VPS36, VPS41, VPS53, VPS54, VTA1, VTC1 
Genomic maintenance 
and stability (B) 
25 BEM4, CHZ1, DPB3, ESC1, GAS1, LEO1, MMS1, MRC1, PAT1, RAD18, RAD27, RAD50, RAD51, RAD52, RAD54, 
RAD59, REV1, RRM3, RTT107, RXT3, SAP30, SGS1, SRS2, TPP1, YEN1 
Transcriptional 
regulation (C) 
25 ACA1, AFT1, BDF2, BUD31, CCR4, ELP4, ELP6, FIR1, FKH2, GAS1, GCR2, HAC1, HCM1, MED1, MTF1, POP2, 
SNF1, SNU66, SPT21, SRB5, SRB8, STB5, THI3, URE2, XRN1 
Protein translation (D) 25 ASC1, CCR4, DEG1, EFM2, ELP4, ELP6, HBS1, IKI3, MRPL24, MRPL33, MTG1, NCS2, POP2, RPL15B, RPL20A, 
RPL34A, RPL42B, RPS17A, RPS24A, RPS27B, SKI2, SKI3, SLM3, SLZ1, XRN1 
Membrane associated 
proteins (E) 
21 ALG9, DRS2, FCY2, FET3, FET5, FIT2, FIT3, FPS1, IMP1, ISC1, 
MDM31, PEP3, PKR1, PMR1, RAS2, SAM3, VAM6, VMA3, VPH1, YAT2, YFL040W 
Metabolism (F) 15 AAH1, AGX1, CBR1, GCR2, GPM2, ICL1, NPC2, PFK1, PFK2, PYK2, SER3, THI21, YHM2, VPS4, YFL040W 
Cell cycle (G) 15 BIM1, BUB1, CLB2, CLB5, CSM1, CTS1, ELM1, FAR7, GAS1, KAR9, LTE1, MEI4, NUR1, SMI1, SRS2 
Signal transduction 
(H) 
5 BCK1, GPA2, PTP3, SLT2, TUS1 
Structural proteins (I) 2 BIL1, NUP133 
Uncharacterised or 
dubious (J) 
37 AEP2, AIM29, CIR2, CTL1, FMP32, GDS1, HUR1, HVG1, IRC4, NAB6, PAU5, YBR277C, YCR087C-A, YCR087W, 
YDL050C, YDL068W, YDR048C, YDR442W, YER034W, YER084W, YER087C-A, YFH7, YFL006W, YFL015C, 
YFL032W, YFL043C, YHL005C, YIM1, YIM2, YLR312C-B, YLR374C, YML002W, YPR059C, YPR123C, YPR150W, 
YPR174C, ZRG8 
 
Table 5.2 Functional analysis of the genes deleted in the Cr6+ resistant mutants 
Functional category No. of genes Genes 
Protein translation (K) 14 CBP6, CTK2, MRN1, MRP2, MRPL13, MRPL49, MRPS9, PBP2, RPL21A, RPL34B, RPL4A, RPS1B, RPS9B, TMA23 
Protein modification 
(L) 
12 APM3, DCR2, EMC2, GEA1, MBA1, MMS2, MSW1, NPL4, NTA1, PNG1, VPS55, VPS71 
Metabolism (M) 9 APA1, GDH2, IFA38, OSM1, PDB1, PHO3, SHB17, URA1, UTR1 
Cell cycle (N) 4 DCR2, MMS4, RIF1, YOX1 
Membrane associated 
proteins (O) 
5 GUP2, ICE2, MMM1, SSU1, SUL1 
Signal transduction (P) 4 CKA1, CKB1, CKB2, DCR2 
Transcriptional 
regulation (Q) 
2 CTK2, YOX1 
Uncharacterised or 
dubious (R) 
20 APD1, BUD26, GEP5, GEP7, ICS2, SVL3, UIP5, YBR139W, YBR226C, YCL026C, YER119C-A, YJR018W, YJR056C, 
YJR061W, YKR032W, YMD8, YOR139C, YOR309C, YPL080C, YSY6 
111 
 
5.2.1 Genes corresponded to the sensitive deletion mutants  
Through bioinformatic analysis by means of web-based resources and manual examination of 
the annotation for each gene, the 206 genes that correspond to the Cr6+ sensitive mutants were 
categorised into 11 groups based on the functions of their encoded proteins.  
 
Of the 52 genes in group A (Figure 5.1 A), 28 are involved in vacuolar protein sorting and 
transport (APL5, ATG11, COG8, DID2, DID4, DRS2, GET4, PEP12, PHO86, SBH2, SLY41, 
SNF7, SNF8, TOM7, VTA1, SEC22, VPS4, VPS8, VPS16, STP22, VPS25, VPS28, VPS29, 
VPS33, VPS36, VPS41, VPS53 and VPS54). Nine of the 28 genes (DID2, SNF8, STP22, VPS1, 
VPS16, VPS25, VPS28, VPS33 and VPS36) are required for protein targeting to the vacuole. 
Fourteen genes in Group A are associated with protein degradation in the context of Cr6+ 
exposure, including DID4, SNF7, SNF8, STP22, VPS25, VPS28 and VPS36, as well as 5 other 
genes (DOA4, SEM1, UBP3, UBP6, UBP11) which are involved in the ubiquitin dependent 
degradation of proteins. BLM10 is required for activation of the proteasome and RIM13 codes 
for a cysteine protease. Additionally, Group A also contains genes that code for proteins 
involved in protein urmylation (ELP6, NCS2 and URE2), a ubiquitin like pathway (Goehring, 
Rivers, & Sprague, 2003). Considering the results together, the genes in Group A clearly 
demonstrate that vesicular and vacuolar protein sorting is a part of the cell’s molecular 
responses to Cr6+ exposure. It also reflects that protein damaged by Cr6+ is a key facet of Cr6+ 
toxicity. 
 
There are 25 genes in Group B, including 14 genes related to DNA repair (MMS1, MRC1, 
RAD18, RAD27, RAD50, RAD51, RAD52, RAD54, RAD59, SGS1, SRS2, TPP1, REV1 and 
YEN1). Of these 14 genes, 5 are members of the RAD52 epistasis group (RAD50, RAD51, 
RAD52, RAD54 and RAD59), which means they are required to work together in the repair of 
Cr6+-induced DNA lesions, particularly double stranded breaks (Symington, 2002). This 
finding demonstrates that Cr6+ toxicity is linked to DNA damage. Other subsets of this group 
include genes involved in telomere maintenance, chromatin remodelling and histone 
modification. The sensitive phenotype of these gene deletion mutants confirms the concept 
derived from the previous studies that Cr6+ can cause genotoxicity and is carcinogenic (Wise, 
Holmes, & Wise Sr, 2008).  
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Group C contains 25 genes related to the regulation of DNA transcription. Genes of particular 
interest include the transcription factor STB5, related to multidrug resistance and oxidative 
stress response (Akache & Turcotte, 2002; Larochelle, Drouin, Robert, & Turcotte, 2006);  
AFT1, involved in the regulation of iron homeostasis (Yamaguchi-Iwai, Dancis, & Klausner, 
1995; Yamaguchi-Iwai, Stearman, Dancis, & Klausner, 1996); HAC1 which regulates the 
unfolded protein response (Mori, Kawahara, Yoshida, Yanagi, & Yura, 1996); CCR4 and 
POP2, involved in transcription regulation of a number of genes in association with resistance 
to DNA damage, possibly through regulation of RAD51 and RAD52 (Liu et al., 1998; Schild, 
1995). 
 
Of the 21 genes whose deletion resulted in a sensitive phenotype in Group D associated with 
membrane-bound proteins, 4 genes are involved in iron transport (FET5, FET3, FIT2 and 
FIT3). The sensitive phenotype of these mutants is compatible with the finding for aft1∆, as 
previously mentioned, the deletion of transcription factor AFT1 results in sensitivity to Cr6+. 
Additionally, the deletion of VMA3, another gene involved in iron and copper homeostasis, 
also conferred sensitivity to Cr6+. These results demonstrate the essentiality of iron homeostasis 
for combating Cr6+ toxicity and are reminiscent of similar findings under arsenite, nickel and 
cobalt treatment (Alkim, Benbadis, Yilmaz, Cakar, & Francois, 2013; Johnson et al., 2016a; 
Kucukgoze et al., 2013). 
 
Group E (Figure 5.1 A) contains 25 genes related to protein translation. Of these 25 genes, five 
genes encode proteins that participate in tRNA modification of the nucleoside at the wobble 
position (IKI3, ELP4, ELP6, NCS2 and SLM3) and one gene (DEG1) for tRNA:pseudouridine 
synthase which is involved in maintenance of translation efficiency and normal cell growth. 
The sensitive phenotype of these genes against Cr6+ demonstrates that Cr6+ exposure can cause 
inefficiency and inaccuracies in translation. This is in agreement with the key finding of the 
previous yeast-based high throughput screen (Holland et al., 2007). Six of the 25 genes are 
involved in the degradation of RNA (SKI2, SKI3, XRN1, POP2, CCR4 and HBS1) while 10 
genes code for structural components of ribosomes (RPL34A, RPS24A, RPS27B, RPL42B, 
RPS17A, RPL15B, MRPL24, RPL20A, MRPL33 and ASC1) and another gene encoding for a 
protein involved in assembly of the large ribosomal subunit (MTG1) for protein translation. 
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Group F comprises 15 genes involved in metabolic processes such as glycolysis (GPM2, PFK1, 
PFK2 and PYK2), and amino acid biosynthesis (SER3). GPM2 is the gene for 
phosphoglycerate mutase which converts 3-phosphoglycerate to 2-phosphoglycerate in 
glycolysis, while PYK2, a paralog of PYK1, encodes pyruvate kinase, which catalyses the 
formation of pyruvate from phosphoenolpyruvate, the final step of glycolysis. PFK1 and PFK2 
encode α and β subunits of heterooctameric phosphofructokinase respectively, which is a 
critical regulator for glycolysis. Deletion of either PFK1 or PFK2 would abolish glycolysis, 
and then in turn disrupt the initiation of cell cycle (Newcomb, Diderich, Slattery, & Heideman, 
2003). It becomes clear, therefore, that the sensitive phenotype of gmp2∆, pyk2∆, pfk1∆ and 
pfk2∆ demonstrates the requirement of glycolysis for the cellular response to Cr6+ insult. The 
essential role of SER3 for 3-phosphoglycerate dehydrogenase in combating Cr6+ toxicity is also 
revealed here, likely due to its ultimate involvement in cysteine biosynthesis because 3-
phosphoglycerate dehydrogenase encoded by SER3 catalyses the transition from 3-
phosphoglycerate to 3-phosphohydroxypyruvate, the first and rate-limiting step in serine 
biosynthesis, and serine is a precursor of cysteine. Additionally, dysfunction in sterol transport 
and metabolism renders the cell sensitive to Cr6+ as evidenced by the deletion of three sterol-
related genes (NPC2, YFL040W and VPS4). As perturbation of glycolysis exacerbates Cr6+ 
toxicity and adversely affects cell cycle, it is expected that genetic deletion of certain cell cycle 
genes could also lead to Cr6+ sensitivity. This is indeed confirmed by the sensitive phenotype 
of the cell cycle gene deletion mutants in Group G which is comprised of 15 genes. 
 
Group H, which contains genes related to signal transduction comprises three genes (PTP3, 
SLT2 and BCK1) involved in mitogen-activated protein kinase (MAPK) signalling cascade, 
indicating the involvement of this regulatory pathway in response to Cr6+. PTP3 is the gene for 
phosphotyrosine phosphatase and SLT2 encodes a MAPK, whilst BCK1 is for a MAPK kinase 
kinase (MAPKKK). The finding here is in agreement with the previous data collected in human 
and mouse experiments, showing that Cr6+ sensitivity is linked to the MAPK signalling cascade 
(Chen, Ovesen, Puga, & Xia, 2009; Tessier & Pascal, 2006). The sensitive phenotype of PTP3 
deletion mutant demonstrates the importance of regulating the MAPK pathway in response to 
Cr6+. This finding is supported by a previous study which showed direct binding  of Cr5+ and 
Cr6+ to cysteine residues at the active site of  Ptp3p phosphatase (Mulyani, Levina, & Lay, 
2004).  Two other genes in signal transduction were also identified, including GPA2, which is 
involved in nutrient sensing and TUS1 involved in cell wall integrity. 
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5.2.2 Genes corresponded to the resistant deletion mutants  
Of the 14 genes in Group K related to protein translation, the deletion of 9 genes encoding 
ribosomal proteins exhibited a resistant phenotype against Cr6+. Three genes are for the 
cytosolic large ribosomal subunit (RPL4A, RPL21A and RPL34B), two for the cytosolic small 
ribosomal subunit (RPS9B, RPS1B), two for the mitochondrial large ribosomal subunit 
(MRPL49, MRPL13) and another two encoding the mitochondrial small ribosomal subunit 
(MRPS9, MRP2). Considering that there are 78 ribosomal proteins coded by 137 ribosomal 
genes (Planta & Mager, 1998; Steffen et al., 2012), these chromium resistance-related 
ribosomal genes represents approximately 6.6% of the total. Interestingly, individual deletion 
mutants of RPS9B and RPS1B are also found to be resistant to arsenite as shown in Chapter 4 
and my previously published (Johnson et al., 2016a). 
 
Disruption of tricarboxylic acid cycle or Kreb’s cycle in energy metabolism confers resistance 
to Cr6+, as is evidently reflected by the genes in Group M. PDB1 encodes pyruvate 
dehydrogenase which is part of the pyruvate dehydrogenase complex. The resistant phenotype 
of pdb1∆ is in fact congruous to the abovementioned involvement of glycolysis in combating 
Cr6+ toxicity. The loss of PDB1 blocks the entry of pyruvate into Kreb’s cycle, leaving 
glycolysis as the major process for energy production. Such a diversion is essential to Cr6+ 
detoxification. The resistance conferred by PDB1 deletion could also be explained by the fact 
that dihydrolipoamide dehydrogenase, another component of the multi-subunit pyruvate 
dehydrogenase complex, was found to act as a Cr6+ reductase in bacteria (Opperman & van 
Heerden, 2008). Deletion of PDB1 would render the enzyme complex dysfunctional, allowing 
dihydrolipoamide dehydrogenase solely for the reduction of Cr6+. The resistance of GDH2 and 
OSM1 deletion mutants further show that perturbation of the Kreb’s cycle is beneficial to the 
cell in the context to Cr6+ exposure. 
 
The resistance of SUL1 deletion mutant manifested in this screen against Cr6+ demonstrates 
that the sulfate transporter encoded by SUL1 is indeed the transporter of Cr6+ by which the 
metal ion enters the cell and unleashes toxicity. Its deletion abolishes such an entry route and 
therefore leads to resistance. The finding is in agreement with the previous studies (Pereira et 
al., 2008; Roberts & Marzluf, 1971). Due to the competition between Cr6+ and sulfate for their 
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entry into the cell, the requirement for sulfur by the cell is impaired and a plausible conservation 
measure for the cell is to reduce the efflux of sulfur compounds such as sulfite. The deletion of 
SSU1 which encodes the sulfite transporter serves this very purpose and therefore ssu1∆ is in 
fact shown to be resistant to Cr6+. The significance of the intracellular sulfite could also reside 
in its reduction to sulfide, as sulfide could participate in the reduction of Cr6+. 
 
Group P is concerned with genes encoding proteins for signal transduction. Of the 4 genes in 
this group, three are members of CK2 (CKA1, CKB1 and CKB2). The findings here further 
demonstrate that deletion of CK2 subunits results in resistance to Cr6+. This unbiased genome-
wide approach again confirmed the involvement of protein kinase CK2 in regulating Cr6+ 
toxicity.  
 
Additionally, the ICP-MS result (Figure 5.2) shows that the intracellular chromium in cka1∆, 
ckb1∆ and ckb2∆ at 16 h is 16%, 24% and 48% lower than the wildtype BY4743, respectively. 
The data for each time point were confirmed to be normally distributed and a one-way ANOVA 
with Tukey comparison was conducted to analyse the chromium contents for each mutant and 
BY4743. The chromium contents in cka1∆, ckb1∆ and ckb2∆ at 16 h are significantly lower 
than the wildtype (p<0.001), whilst the chromium content in cka2∆ is significantly higher than 
BY4743 (p<0.001). 
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Figure 5.2 Chromium content of protein kinase CK2 mutants and the wildtype quantified by 
ICP-MS. The deletion mutants for individual subunits of protein kinase CK2 were treated with 
0.2 mM CrO3, along with the wildtype BY4743 as the control. The treated yeast samples were 
collected at 4 h intervals from T0 to T16, and followed with digestion in nitric acid and 
quantification by ICP-MS. The cellular chromium content is expressed as microgram per 
milligram of dry yeast cells. Data points represent the average of four experiments. Error bars 
represent standard error of the mean. At the 16 h time point cka1∆, ckb1∆ and ckb2∆ were 
found to contain significantly less intracellular Cr6+ than the wildtype (p < 0.001) while cka2∆ 
was found to contain significantly more (p < 0.001). 
 
5.2.3 Oxidation state of CK2 deletion mutants and the wildtype under CrO3 
treatment.  
The involvement of CK2 in chromium toxicity, as shown by the resistance conferred by the 
mutants cka1∆, ckb1∆ and ckb2∆, is likely due to decreased uptake in the deletion mutants (as 
shown in the ICP-MS data, Figure 5.2). Alternatively, the action of cka1p, ckb1p and ckb2p or 
the tetramer may hinder some intracellular process of detoxification, so their deletion would 
abolish such hindrance and lead to better growth of the deletion mutants. In the case of Cr6+ a 
well-attested method of toxicity is the production of ROS in the reduction process of Cr6+ 
(Guttmann, Poage, Johnston, & Zhitkovich, 2008; Ning & Grant, 2000; Quievryn, Goulart, 
Messer, & Zhitkovich, 2001). The potential DNA damage revealed by Group B sensitive 
117 
 
mutants and the adverse role of citric acid cycle shown by Group M resistant mutants 
demonstrate that oxidative stress is part of the mechanism for Cr6+ toxicity. The mutagenic 
effects of Cr6+ are closely linked to its reduction. Reduction of Cr6+ in mammals has been 
shown to rely on cysteine, ascorbic acid, thiols and glutathione (Guttmann et al., 2008; Suzuki 
& Fukuda, 1990). Depletion of glutathione is known to increase the toxicity of Cr6+ in  rat 
osteoblast cells at the 3 h time point (Ning & Grant, 2000). It was therefore worthwhile to 
check the cellular oxidation state of the CK2 mutants, cka1∆, cka2∆, ckb1∆ and ckb2∆ under 
chromium stress.  
 
The cytosolic demand for GSH in the wildtype BY4743 and the CK2 mutants undergoing Cr6+ 
exposure was determined using the redox probe GRX1-roGFP2 (Chapter 2.3.10), under the 
doses 0.05, 0.1, 0.2, 0.4 mM at 10 minutes, 2 h and 4 h.     
The data in Figure 5.4 indicates that ckb1∆ or ckb2∆ do not undergo an oxidative shift while 
cka1∆ does but only at the 0.4 mM dose. In contrast cka2∆ also experiences a significant shift 
at the 0.1 mM and 0.4 mM doses similar to the wildtype. This data is in agreement with the 
ICP-MS data from Figure 5.2 which shows that only CKA2 deletion results in increased 
intracellular Cr6+ while deletion of the other subunits results in a lower intracellular level of the 
metal ion than the wildtype.  
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Figure 5.3 Oxidation states of BY4743 and CK2 deletion mutants after Cr6+ exposure. Transformants containing the GRX1-roGFP2 probe were 
treated with 0, 0.05, 0.1 and 0.4 mM CrO3. Cultures were incubated at 30 °C, 150 rpm and measured at 10 minutes, 2 hours and 4 hours. Data 
shows the ratio of fluorescence at 510 nm under 405 nm excitation to that of 488 nm. Greater fluorescence at 488 (a larger ratio) indicates greater 
oxidation state at the 4 h time point. Data represents the average of 3 experiments. A one-way ANOVA was run with a post hoc Tukey analysis. 
*p < 0.05, **p < 0.01.  
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5.3 Discussion  
Along with chromium’s industrial usage, its pollution becomes a health hazard to humans. The 
international agency for research on cancer has identified it as a major carcinogen (Scharf et 
al., 2014). Somewhat mystically, Cr3+ has been widely used in nutritional supplements and can 
be readily found on the shelves of pharmacies and health supplement shops, although 
controversy regarding its effectiveness and risk is still debated (Wu et al., 2016). As the 
molecular details of chromium’s effects on human health are incomplete, this study, by means 
of S. cerevisiae genome-wide deletion mutants, reveals in-depth details on Cr6+ toxicity, 
detoxification, uptake and molecular regulation. The data produced in this chapter not only 
indicates a role for CK2 in the facilitation of Cr6+ uptake and toxicity but also presents a wide-
ranging summary of the molecular details of Cr6+ toxicity and contains novel findings 
concerning the general cellular response to Cr6+.  
 
My data clearly indicates that the deletion of CKA1, CKB1 and CKB2 leads to Cr6+ resistance, 
indicating these CK2 subunits regulate Cr6+ toxicity. Further, the findings by ICP-MS show 
significantly lower intracellular chromium in cka1∆, ckb1∆ and ckb2∆ mutants (Figure 5.2). 
This reveals that Cka1p, Ckb1p and Ckb2p in fact regulate Cr6+ uptake. These results, for the 
first time, identify CK2 as a molecular regulator in Cr6+ toxicity. Interestingly, the deletion of 
CKA2 results in significantly higher chromium accumulation in the cell, indicating this 
catalytic subunit has a discrete function from the other three subunits. The flow cytometry data 
shown in Figure 5.3 support the ICP-MS data and indicate that the cell undergoes greater 
oxidative stress commensurate with the intracellular level found in the ICP-MS experiments. 
That is, the lower levels found in CKA1, CKB1 and CKB2 deletion mutants correlate with a 
lower level of oxidative stress. 
 
The general findings reported here show that DNA and proteins are the key molecular targets 
of Cr6+, and that multiple biological processes are involved in Cr6+ detoxification, including 
protein degradation pathways, DNA repair, glycolysis, signal transduction, DNA transcription 
and translation. Significantly, it also uncovers that disruption of Kreb’s cycle is beneficial to 
the cell’s survival against Cr6+ toxicity and protein kinase CK2 is a key regulator for Cr6+ 
uptake. 
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The carcinogenicity of Cr6+ is indirectly confirmed by this study using S. cerevisiae, because 
DNA damage, reflected by the high enrichment of DNA repair genes in the sensitive 
phenotype, is a prominent feature for Cr6+ toxicity. I, for the first time, relate these specific 
DNA repair genes (Table 5.1) directly to Cr6+-induced DNA damages. A possible mode of 
action for Cr6+ on DNA could be pinpointed according to the existing findings such that Rad18p 
repairs DNA lesions located at stalled replication forks (Tateishi, Sakuraba, Masuyama, Inoue, 
& Yamaizumi, 2000), and that RAD27, encoding a multi-functional nuclease, is involved in 
processing Okazaki fragments during DNA replication and base excision repair (Hansen, 
Friedberg, & Reagan, 2000). Double-stranded breaks could result from Cr6+ exposure as 
RAD52, RAD54, RAD57 and RAD59 all participate in repairing breaks in double-stranded DNA 
(Symington, 2002). Furthermore, dma∆ sensitivity to Cr6+ treatment adds support to the notion 
that DNA damage is a mode of action by Cr6+, because DMA2 encodes ubiquitin-protein ligase 
shown to be involved in down-regulation of the conserved kinase Swe1p and important for the 
survival of budding yeast cells during DNA replication stress (Raspelli, Cassani, Lucchini, & 
Fraschini, 2011). 
 
Interruption of sulfur metabolism is clearly a facet of Cr6+ toxicity. The fact that Cr6+ enters the 
cell via the plasma membrane-bound sulfate transporter (Sul1p) evidently implies the potential 
disruption of sulfur metabolism by Cr6+ (Pereira et al., 2008). In addition, the reactive 
intermediates Cr5+ and Cr4+ as well as the free radicals generated from the reduction of Cr6+ 
can directly attack glutathione, free cysteine and cysteine residues in proteins (Guttmann et al., 
2008; Ning & Grant, 2000; Quievryn et al., 2001). Such disruption can affect gene translation 
(Holland et al., 2007).  It is also noteworthy that hydrogen sulfide, an intermediate metabolite 
of sulfur metabolism, was demonstrated to be able to detoxify Cr6+ (Ali et al., 2013; Sahinkaya, 
Kilic, Altun, Komnitsas, & Lens, 2012). Together, these results demonstrate the importance of 
sulfur metabolism to combating Cr6+ toxicity in yeast. However, whether this finding is 
applicable to humans remains to be investigated. 
 
It is plausible to assume that after the reduction of Cr6+ to Cr3+, the cell must have a 
detoxification system to remove excess Cr3+ to the extracellular space for survival. As shown 
in Table 5.1 Group A, vesicular and vacuolar transport as well as the ubiquitination and protein 
degradation pathway are heavily involved in response to Cr6+ exposure. It is likely that proteins 
are part of the detoxification mechanism by acting as a frontline sacrifice, and they are damaged 
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in the process by the active intermediates [Cr5+ and Cr4+], the end product Cr3+ and the free 
radicals. The damaged proteins are then destroyed via the ubiquitin-proteasome system. A 
second mechanism of removing the damaged proteins by routing from Golgi to the 
endosomal/vacuolar system for degradation may also exist in S. cerevisiae (Arvan, Zhao, 
Ramos-Castaneda, & Chang, 2002). This notion is based on the sensitive phenotype of the 
deletion mutant of BUL1 which encodes a ubiquitin-binding component of the Rsp5p E3-
ubiquitin ligase complex involved in post-Golgi endosomal-vacuolar protein sorting (Forsberg, 
Hammar, Andréasson, Molinér, & Ljungdahl, 2001). 
 
As is known, the reduction process of Cr6+ is the sine qua non of the metal’s toxicity, which 
generates the intermediate species [Cr5+ and Cr4+] and could also produce free radicals through 
a Fenton-like reaction if hydrogen peroxide (H2O2) is proximal to the reduction hotspots 
(Urbano et al., 2012). H2O2 can be generated in the cell by superoxide dismutase which is 
essential to detoxify the free radical superoxide (O2
●-) derived from the reduction of molecular 
oxygen by leaked electrons. Mitochondria are the subcellular organelle for potential leakage of 
electrons and H2O2 generation a result of respiratory metabolism. Therefore, it makes sense 
that disruption of the Kreb’s cycle in pdb1∆ confers resistance to Cr6+, and that glycolysis is 
essential for combating Cr6+ toxicity as shown by pfk1∆ and pfk2∆. The deactivation of 
pyruvate dehydrogenase leads to an added benefit, allowing dihydrolipoamide dehydrogenase, 
a component of the multi-subunit pyruvate dehydrogenase complex, to moonlight as a Cr6+ 
reductase (Opperman & van Heerden, 2008). 
 
It is intriguing to draw a similarity between the yeast cell’s response to Cr6+ and the metabolic 
phenotype of cancerous cells known as the Warburg effect or aerobic glycolysis. The results 
here demonstrate that for combating Cr6+ toxicity glycolysis is needed whilst the Kreb’s cycle 
is not. This is exactly reminiscent of the cancer cell metabolism where glycolysis is dominant 
under aerobic conditions. Therefore, it is possible that Cr6+ toxicity in yeast could serve as a 
valuable model for cancer research. 
 
An intriguing detoxification mechanism for Cr6+ employed by the bacterium Acidiphilium 
cryptum can lend an explanation to the role of iron in chromium toxicity. The bacteria reduce 
the ferric iron (Fe3+) to ferrous (Fe2+), the ferrous ion then passes the electron to Cr6+, leading 
to the reduction of Cr6+ to Cr3+ (Cummings et al., 2007). Such a process produces no harmful 
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free radicals and no organic reductants, such as glutathione and cysteine are consumed. 
Deletion of iron-transport related genes (AFT1, FET3, FET5, FIT2 and FIT3) would interrupt 
iron homeostasis, therefore limiting iron’s potential role in Cr6+ detoxification. Hence, aft1∆, 
fet3∆, fet5∆, fit2∆ and fit3∆ are sensitive to Cr6+ exposure. This finding is complementary to 
the transcriptomic evidence of Jin et al.(Jin et al., 2008), where they found the genes involved 
in iron homeostasis are up-regulated upon treatment of Cr6+. The role of iron in countering Cr6+ 
toxicity further expands the spectrum of iron homeostasis in the cell’s molecular response 
against lipid peroxide, cisplatin and arsenic (Johnson et al., 2016a; O’Doherty et al., 2013; 
Wang, Higgins, Aldrich-Wright, & Wu, 2012). 
 
The presence of genes for ribosomal proteins in both sensitive and resistant mutants reveals the 
dichotomous nature of ribosomal proteins in response to Cr6+ exposure. As is known, in dealing 
with stress or adversary environments one strategy employed by the cell is to slow down the 
growth and repair the damages (O’Doherty et al., 2013). This may explain the resistant 
phenotype of the nine resistant mutants, where the deletion of ribosomal genes would attenuate 
protein translation and hence cell growth. However, the 10 sensitive mutants of ribosomal 
genes reflect that certain ribosomal proteins are essential in response to Cr6+. Amongst these 
10 ribosomal genes, RPL42B is the paralog of the essential ribosomal gene RPL42A identified 
under normal growth conditions by Steffen et al. (2012). Although the underlying molecular 
basis for these 10 ribosomal genes required for the cell’s response against Cr6+ is unclear, I 
think that the deletion of the ribosomal genes in Table 5.1 Group D might disrupt the protein 
translation process and in turn lead to sensitivity against Cr6+, because  the past genomic studies 
demonstrate Cr6+ provokes errors in the mRNA translation process (Holland et al., 2007; 
Moreno-Martinez, Vallieres, Holland, & Avery, 2015). 
 
Finally, the sensitive phenotype of the mutants with the deletion of MAPK pathway-related 
genes (PTP3, SLT2 and BCK1) demonstrates the requirement of this signalling cascade for the 
cell’s survival in the context of Cr6+ challenge. This agrees with similar findings in other 
organisms such as mice (Chen et al., 2009).  
 
Together with my previous work for the involvement of CK2 in aluminium and arsenic toxicity 
(Johnson et al., 2016a; Tun et al., 2014), it is clear that CK2 is a critical player in regulating 
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chromium toxicity, apart from its currently recognised role in regulating cell growth and 
proliferation.  
 
 
Figure 5.4 Proposed molecular mechanism for Cr6+ toxicity. The hexavalent chromium Cr6+ 
in the form of the chromate anion (CrO4
2-) enters the cell via sulfate transporter (Sul1p). Cr6+ 
is then reduced by the ferrous ion (Fe2+), sulfide (H2S), glutathione (GSH) and Cr
6+ reductase, 
producing intermediates Cr5+ and Cr4+ and possibly reaction oxygen species like the hydroxyl 
radical (OH●). As a result, DNA and proteins are damaged, and protein synthesis is 
interrupted; detoxification pathways and signalling cascades are triggered for the cell’s 
survival. 
 
5.4 Conclusion  
In summary, the findings garnered in this study revealed multifaceted molecular mechanisms 
of Cr6+ toxicity, detoxification, uptake and molecular regulation (Figure 5.3). It is certain that 
the in-depth molecular details of the dataset reported here are relevant to understanding 
chromium-related problems in the environment, agriculture and human health. The close 
correlations in regard to Cr6+ toxicity between S. cerevisiae and mammalian cells, such as DNA 
damage and alteration of energy metabolism, highlight the value of the yeast model organism 
in cancer research. The discovery of protein kinase CK2 in regulating Cr6+ toxicity provides a 
basis for further investigations into its substrates and interactive partners in the regulation of 
metal uptake. 
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6 Exploring the role of CK2 in metal ion toxicity in 
mammalian neuronal cells  
6.1 Introduction 
Up to this juncture, it is clear that the topic of the role of CK2 in metal ion toxicity is relatively 
nascent. My discoveries, based on the model organism S. cerevisiae as described in the 
previous chapters, provide a foundation for studies of CK2 and metal ions in mammalian cells 
with potential for further understanding of metal ion-linked cancers and neurodegenerative 
diseases. Recent studies into the link between CK2 and zinc homeostasis in the human breast 
cancer cell line MCF-7 (Taylor et al., 2012) demonstrate that the extension of my study from 
the simple yeast model to mammalian cells, as reported in this chapter, was sound. The above-
mentioned study showed that the intracellular cytosolic zinc concentration was increased due 
to the phosphorylation of endoplasmic reticulum zinc channel ZIP7 by CK2. The 
phosphorylation results in the gated release of Zn2+ from intracellular stores in the endoplasmic 
reticulum. In this chapter I focused on the yet unexplored role of CK2 in the regulation of metal 
toxicity in neuronal cells. CK2 plays an integral role in neuronal biology. For example, it is a 
critical player in embryonic neural tube formation (Lou et al., 2008). The greatest abundance 
of CK2 is found in brain tissue when compared to the rest of the body, and in adult rat tissues 
its activity is highest in the brain and testis (Blanquet, 2000). Many CK2 substrates exist in 
synaptic and nuclear compartments. CK2 is involved in long-term potentiation in the 
hippocampus, and neurotrophins stimulate activity of CK2 in the hippocampus (Blanquet, 
2000; Perez et al., 2010). It is suggested that CK2 may play a role in neuronal adaptations to a 
changing environment through modulating synaptic connections, regulate specific neuronal 
activities and participate in survival and death decision making events (Blanquet, 2000). CK2 
has also been linked to various neurodegenerative diseases, particularly AD (Aksenova et al., 
1991). Experimental evidence demonstrates that metal ions are involved in amyloid plaque 
formation (Bolognin et al., 2011; Bush, 2000; Tomljenovic, 2011). Therefore, there is a 
likelihood that CK2 up-regulation could lead to metal ion accumulation and hence trigger 
amyloid aggregation. 
 
In this chapter, the effect of CK2 on metal toxicity to mammalian cells was investigated by two 
lines of experiments using the CK2 inhibitor and siRNA-mediated knock-down of CK2 
expression. The real-time quantitative polymerase chain reaction (qPCR) was employed to 
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evaluate the degree of expression knockdown to the individual CK2 subunits by their siRNA. 
Finally, the effect of metal ions on CK2 expression was also studied.     
 
6.2 Results  
6.2.1 Determination of IC25 and IC50 of metal ions in Neuro2a and SH-SY5Y cells 
In order to investigate the effects of protein kinase CK2 on metal toxicity, an appropriate 
dosage of a given metal was determined initially. Following the methods as described in 
Chapter 2.4.6, the dose response curves for the metals of interest were obtained and the IC25 
and IC50
 of each metal ion were worked out. Figures 6.1 – 6.5 show the dose response curves 
for ZnSO₄, CrO3, NaAsO2 and Al(mal)3, as well as solvent controls for human neuroblastomas 
cells (SH-SY5Y) and mouse neuroblastomas cells (Neuro2a). IC50 values for the metals 
obtained were used for subsequent experiments unless otherwise stated.  
  
 
Figure 6.1. Dose response curves of zinc sulphate for SH-SY5Y and Neuro2a cells.  
The cells were treated with a range of ZnSO₄ concentrations as shown and the cell viability 
was determined with MTT assay. The IC50 for SH-SY5Y cells was determined to be 175 µM 
while the IC50 for Neuro2a cells was 240 µM. Experiments consisted of 8 replicates. Data 
points represent the average of triplicate experiments and error bars represent SEM.     
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Figure 6.2. Dose response curves of chromium trioxide for SH-SY5Y and Neuro2a cells. 
The cells were treated with a range of CrO3 concentrations as shown and the cell viability was 
determined with MTT assay. The IC50 for SH-SY5Y cells was determined to be 18 µM while 
the IC50 for Neuro2a cells was 13 µM. Experiments consisted of 8 replicates. Data points 
represent the average of triplicate experiments and error bars represent SEM.     
 
 
Figure 6.3. Dose response curves of sodium arsenite for SH-SY5Y and Neuro2a cells.  
The cells were treated with a range of NaAsO2 concentrations as shown and the cell viability 
was determined with MTT assay. The IC50 for SH-SY5Y cells was determined to be 32 µM 
while the IC50 for Neuro2a cells was 15 µM. Experiments consisted of 8 replicates. Data points 
represent the average of triplicate experiments and error bars represent SEM.     
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Figure 6.4. Dose response curves of aluminium maltol for SH-SY5Y and Neuro2a cells at 
6 h. The cells were treated with a range of Al(mal)3 concentrations as shown and the cell 
viability was determined with MTT assay. The IC50 for SH-SY5Y cells was determined to be 
2500 µM while the IC50 for Neuro2a cells was 1900 µM. Experiments consisted of 8 replicates. 
Data points represent the average of triplicate experiments and error bars represent SEM. 
 
 
Figure 6.5. Dose response curves of aluminium maltol for SH-SY5Y cells at 24 h and 48 
h. The cells were treated with a range of Al(mal)3 concentrations as shown and the cell viability 
was determined with MTT assay. The IC50 for 24 h was determined to be 1000 µM while the 
IC50 for 48 h was 175 µM. Experiments consisted of 8 replicates. Data points represent the 
average of triplicate experiments and error bars represent SEM. 
 
 
6.2.2 Viability studies of Neuro2a and SH-SY5Y cells under metal ion stress in 
the presence of CK2 inhibitor  
While the effect of CK2 inhibitor TBB in the presence of metals was similar in both cell lines 
(Figure 6.6), some distinct differences are apparent. At both the IC50 and IC25 concentrations 
the reduced toxicity observed when CK2 is inhibited is much more pronounced in Neuro2a 
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cells. The exception to the considerably greater effect of CK2 inhibition in Neuro2a cells is the 
IC50 of zinc in SH-SY5Y cells, which shows an effect that is almost equivalent to the effect in 
Neuro2a cells. Another major difference is that inhibition of CK2 appears to have no effect on 
the viability of SH-SY5Y cells in the presence of Cr6+. Despite these differences, inhibition of 
CK2 activity in the presence of metals allows for greater viability in both cells types indicating 
that the role discovered in yeast regarding the facilitation of metal toxicity is evolutionarily 
conserved in higher eukaryotes. 
 
 
Figure 6.6 Cell viability under CK2 inhibition by TBB in the presence of individual metal ions.  
Cells were monitored until 80% confluent. They were then treated with 20 µM TBB or an equal 
volume of solvent and returned to the incubator for 3 h. After the incubation cells were treated 
with the IC25 and IC50 of the individual metal ions or an equal volume of H2O. Normalised 
viability represents the ratio of the viability of metal treated cells over the viability of H2O 
treated cells. Experiments were conducted in triplicate and contained eight replicates. Data 
points represent the average and error bars are the SEM. NS= not significant, ** p < 0.01, *** 
p < 0.001. 
 
6.2.3 Viability studies of Neuro2a and SH-SY5Y cells under metal ion stress in 
the presence of CK2 specific siRNA.   
Inhibition of CK2 as shown in Figure 6.6, provided insights into the role of CK2 activity in 
metal ion toxicity. However, to simulate the deletion mutants for individual CK2 subunits in 
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yeast and dissect the possible independent roles of CK2 subunits in mammalian cells, I 
performed knockdown experiments of individual CK2 subunits using specific siRNA for 
CK2α, CK2α’ and CK2β. The conservation of the negative effect of CK2α’ (cka2p in yeast), 
in the presence of certain metal ions can be inferred from the resultant phenotypes (Figure 6.7). 
In other words, inhibition of CK2α’ results in a beneficial effect on cell viability. As seen in 
the yeast model, absence of CK2α’ results in greater viability in the presence of both Zn2+ and 
Al3+. Moreover, knockdown of CK2α’ also increases the viability of Neuro2a cells in the 
presence of Cr6+ and As3+, while such tolerance to these metals is absent in human SH-SY5Y 
cells.    
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Figure 6.7. The effects of expression knockdown of CK2 subunits in the presence of metal ions. 
Cells at 80% confluence were transfected with individual siRNA specific for CK2α, CK2α’ and CK2β respectively, followed by a 32 h incubation, 
5 h treatment of metal ions and then an MTT assay to quantify cell viability. The mock treatment with no siRNA served as the control. Data 
represents the average of three independent experiments conducted in triplicate. Error bars are SEM. One-way ANOVA was used to compare the 
means of groups with a post hoc Tukey’s test. *** p < 0.001, ** p < 0.01, * p < 0.05, not significant where not shown. 
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6.2.4 Validation of siRNA Knockdown via qPCR 
To quantify efficiency of siRNA knockdown of individual CK2 subunit expression, the total 
RNA samples were prepared from cells treated with and without the siRNA of individual CK2 
subunits, according to the protocol in Chapter 2.4.10, qPCR analysis was then conducted 
according to Chapter 2.4.7-2.4.9.  
 
 
Figure 6.8. Relative expression of CK2 subunits after siRNA knockdown.  
Total RNA samples of individual knockdown treatments were harvested at 32 h post 
knockdown, and reverse transcribed (as described in Chapter 2.4.8) and qPCR using CK2 
subunit specific TAQMAN® assays (as described in Chapter 2.4.9) was undertaken. The 
relative expression was determined using the 2-∆∆CT method with GAPDH as the endogenous 
control (Schmittgen & Livak, 2008). Under CK2α knockdown the relative expression of CK2α 
was 20.2%, CK2α’ was 94% and CK2β was 90%; under CK2α’ knockdown CK2α was 116%, 
CK2α’ was 27% and CK2β was 76%; under CKβ knockdown CKα was 59%, CK2α’ was 79% 
and CK2β was 20%. The data above represents the average of three experiments, error bars 
represent SEM.   
 
6.2.5 Relative expression of CK2 subunits under metal ion treatment. 
As the data shown previously demonstrates, the expression level of CK2 subunits, such as the 
deletion of individual CK2 subunits in yeast or the siRNA knockdown in neuronal cells, leads 
to different phenotypes under metal ion exposure. A reverse question is asked here, that is, does 
metal ion presence affect the expression of CK2 subunits? One of the renowned aspects of 
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CK2, which contribute to its enigmatic nature is its apparent lack of regulation by other factors. 
Therefore, the attempt to uncover an environmental factor (metal ion presence) that could 
impact upon its transcription would be valuable. Using qPCR, I determined that the presence 
of Zn2+ and Al3+ do significantly affect the expression of certain subunits of CK2. Under Zn2+ 
exposure both catalytic subunits are upregulated as well as the β subunit, similarly, under Al3+ 
exposure the α, α’ and β subunits are upregulated.       
 
 
Figure 6.9. Relative expression of CK2 subunits in the presence of metal ions.  
SH-SY5Y cells were grown to 80% confluence and treated with IC50 of ZnSO4, CrO3, NaAsO2, 
and Al(mal)3. RNA was harvested at 3 h for ZnSO4, CrO3 and NaAsO2 and 24 h for Al(mal)3. 
RNA samples were prepared and reverse transcribed as described earlier, and qPCR was 
performed using TAQMAN® assays. Differential expression under treated and untreated was 
normalised to GAPDH expression using the 2-∆∆CT method (Schmittgen & Livak, 2008) A one-
sample T test was used to compare the relative expression of each subunit under metal exposure 
to the relative expression of the subunit in the untreated samples. * p < 0.05, ** p < 0.01.  Data 
represents the average of three independent experiments conducted in triplicate. Error bars 
represent SEM.  
133 
 
6.3 Discussion  
6.3.1 CK2 activity is inversely correlated with cell viability under metal ion 
exposure  
Figure 6.6 demonstrates, in the case of mouse neuroblastoma cells, CK2 activity is inversely 
related to cell viability in the presence of Zn2+, Cr6+, As3+ and Al3+, while in human 
neuroblastoma cells this is true for Zn2+, As3+ and Al3+. As the inhibitor used in this study was 
the ATP analogue TBB, it does not distinguish between monomeric (CK2α, CK2α’) or 
tetrameric CK2 (ααββ, α’α’ββ, αα’ββ). Therefore, the results in Figure 6.6 should be considered 
along with the siRNA knockdown data. This will be discussed later. 
 
Further, the findings described in this chapter need to be related to the results from S. cerevisiae 
reported in the previous chapters. Just to recap, in yeast I found that in the case of Zn2+, Cka2p 
(equivalent of mammalian CK2α’) interferes with the cell’s ability to detoxify the metal; in the 
case of Cr6+, CK2 tetramers lead to a higher level of intracellular metal ion; in the case of As3+, 
monomeric regulatory subunits are responsible for tolerance to the metal ion; and in the case 
of Al3+, Cka2p is responsible for the uptake of the metal ion. The question is: “Are these 
apparent functional differences conserved in mammals?”.    
 
6.3.2 Evolutionarily conserved regulatory effect of CK2 on metal toxicity 
Through the use of specific CK2 subunit knockdown by siRNA (Figure 6.7), I have shown 
that, in both mouse and human neuroblastomas, knockdown of CK2α’ expression results in 
greater tolerance to both Zn2+ and Al3+. The effectiveness of the knockdown of the targeted 
CK2 subunits was confirmed by use of qPCR. Here I must acknowledge that it would be 
valuable to conduct experiments to confirm the reduction at the protein level, e.g. by 
immunoblotting. The data from the mouse neuroblastomas also demonstrated that CK2 
subunits, particularly catalytic subunits, are involved in the toxicity of Cr6+ and As3+, while 
this effect was not observed in human neuroblastomas.   
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6.3.3 The effect of metals on CK2 expression  
The results for the expression of CK2 subunits under IC50 Zn
2+ treatment (Figure 6.9) indicate 
that all three subunits are upregulated by the presence of Zn2+. This is contrary to the finding 
in Figure 6.6 where inhibition of CK2 by TBB leads to increased cell viability under IC50 Zn
2+, 
in other words, higher CK2 activity does not benefit the cell’s survival under zinc ion stress. A 
possible explanation could be that one dataset (Figure 6.9) is at the mRNA level and the other 
is at the protein level (Figure 6.6). Clearly further light needs to be shed on this difference in 
future investigations. Moreover, the upregulation of all three subunits in response to Zn2+ may 
indicate that the subunits are co-regulated. Interestingly, the relative expression of CK2α’ was 
increased by the least amount under zinc treatment (Figure 6.9). The siRNA data (Figure 6.7) 
indicate the reduction in viability under IC50 Zn
2+ treatment is attributable to CK2α’ which 
correlates well with the yeast data which indicate that removal of CKA2 allows CK2 to perform 
a vital function in the presence of Zn2+ (Johnson et al., 2017). Therefore, the expression of the 
CK2α’ subunit is not beneficial to the cell’s response to the acute exposure to toxic amounts of 
Zn2+. This further demonstrates the concept that individual CK2 subunits have distinct 
biological function (Johnson et al., 2016a, 2016b; Johnson et al., 2017).  
 
The CK2 knockdown data for Al3+ toxicity (Figure 6.7) is in agreement with the yeast data 
(Figure 3.1) (Johnson et al., 2017) showing that CK2α’ is the subunit responsible for aluminium 
toxicity as its deletion or knockdown leads to increased cell viability. However, as with zinc, 
the exposure of Al3+ results in the up-regulation of all three subunits of CK2. This may again 
support the idea of co-regulation of CK2 by metal ions, or that the discrepancy between the 
inhibitor study (Figure 6.6) and the metal ion’s effect on CK2 expression (Figure 6.9) is due to 
the two datasets being at different levels (one at protein level and the other at mRNA level). 
While the expression of CK2 subunits under Cr6+ were not statistically significant, it is 
interesting that all three subunits showed downregulation. This is in agreement with the 
findings of two previous studies (Jin et al., 2008; Ye & Shi, 2001).  
 
The identification of CK2’s role in the regulation of metal toxicity in neuronal cells can be used 
to aid in the understanding of certain health problems given that metal ions are contributing 
factors in neurodegenerative disorders such as Alzheimer’s disease (Bolognin et al., 2011; 
Bush, 2000; Tomljenovic, 2011) and cancers (Franklin & Costello, 2009; NRC, 2001; WHO, 
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1990). The findings of this chapter provide a basis upon which this topic can be further 
explored.  
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7 Final discussion  
7.1 New role for an old enzyme – protein kinase CK2  
The novel discoveries described in Chapters 3-6 demonstrate that CK2 regulates metal ion 
toxicity. This adds a new dimension to the well-known roles of CK2 such as regulating cell 
proliferation and anti-apoptosis (Litchfield, 2003). By employing the individual deletion 
mutants of CK2 subunits (CKA1, CKA2, CKB1 and CKB2) in S. cerevisiae and the non-
biased high throughput functional genomics with genome-wide deletion mutant screening, 
the distinctive details of CK2’s involvement in regulating metal toxicity were revealed. And 
the findings from the yeast model organism were extended to mammalian cells. 
 
7.1.1 Distinctive roles of individual CK2 subunits in metal toxicity 
It is becoming clear that beyond the functions of tetrameric CK2 there exists numerous 
distinct functions for monomeric CK2 subunits (Bibby & Litchfield, 2005; Domanska et al., 
2005; M. Faust & Montenarh, 2000; Janeczko et al., 2011; Kubiński et al., 2007). The 
findings contained in this thesis provide further evidence for these individually functioning 
subunits having distinct roles in metal ion toxicity. The evidence presented in Chapter 3 
shows that Cka2p (CK2α’ is its mammalian equivalent) is involved in Al3+ uptake, while 
Cka1p (CK2α) is a major regulator for Zn2+ sequestration. The role of Cka2p in Al3+ was 
established through the growth phenotypes of the wildtype and CK2 deletion mutants. At 
Al3+ doses of 0.4 and 0.8 mM, the wildtype, cka1∆, ckb1∆ and ckb2∆ all experienced 
markedly reduced growth (reduced by approximately 66%), however cka2∆ growth was only 
reduced by 10%. The protective effect of CKA2 deletion on growth under Al3+ treatment was 
clearly seen across the whole range of Al3+ concentrations used (Figure 3.1). For example, at 
the 2.5 mM dose, cka2∆ grew 75% of its untreated control while the wildtype did not grow at 
all. That this phenotype was only observed in the cka2∆ strain indicates a discrete function of 
this subunit in facilitating the toxicity of Al3+.  
 
The role of Cka1p in the sequestration of Zn2+ was elucidated by observing the growth 
phenotypes of the CK2 deletion mutants, double deletion mutants and by use of a CK2 
inhibitor. The dose response curves (Figure 3.2.2) show the reduction of toxicity conferred by 
deletion of CKA2 to Zn2+ is much narrower than that observed in response to Al3+, possibly 
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reflecting the fact that the cell has a well evolved response to Zn2+ and that the homeostatic 
mechanisms in place can buffer toxicity only to a point or threshold. Interestingly and in 
contrast to the Al3+ response, the resistance of CKA2 deletion to zinc is reduced when the 
regulatory β subunits are also absent (Figures 3.10-3.11). These observations imply that the 
reduction of Zn2+ toxicity in a CKA2 deletion is not due to the loss of a direct function of 
Cka2p, but rather to the removal of interference, by cka2p, in Zn2+ detoxification. That is 
when cka2p is removed, the other subunits are better able to mount a resistance to the metal 
ion overload. Conversely, when the cell lacks Cka2p and the tetramer such resistant response 
is attenuated, which is confirmed by the inhibition studies presented in Figure 3.17, showing 
that in a CKA2 deletion, inhibition of the remaining CK2 entities abolishes the resistance, 
while this inhibition has little effect on the response to Al3+. This evidence leads to the 
conclusion that the resistance to Zn2+ conferred by CKA2 deletion is not related to Zn2+ 
uptake, as is the case for Al3+ (Figure 3.16), but rather, it is due to some intracellular 
homeostatic mechanism possibly related to vacuolar sequestration of Zn2+ (Figure 3.18 – 
3.19). 
 
Chapters 3 and 4 provide evidence that monomeric regulatory subunits are relevant to As3+ 
toxicity. In the single deletion mutants, CKB2 deletion provided the greatest resistance to 
As3+ at 1.6 mM and was the only mutant to exhibit growth at the 3.2 mM concentration. As 
tetramer formation requires both regulatory subunits, the growth exhibited by CKB2 deletion 
at the 3.2 mM concentration cannot be attributed to a lack of tetramer activity, because 
deletion of CKB1, which also lacks the tetramer, did not exhibit the same growth phenotype. 
Examination of the double deletion phenotypes under As3+ stress (Figure 3.12 and 3.13) 
revealed that deletion of both CKB1 and CKB2 result in the greatest decrease in viability. 
This decrease in viability cannot be related to tetramer function as the single regulatory 
deletion mutant (ckb2Δ) (tetramer lacking) showed increased resistance to As3+. The data 
indicates that the regulatory subunits have functions outside the tetramer, which means the 
regulatory subunits of CK2 likely interact with the other proteins or enzymes. Such evidence 
is thus far deficient in literature; therefore, the findings of this thesis are significant to our 
knowledge and understanding of CK2’s biological functions.  
 
Chapters 3 and 5 indicate that intracellular Cr6+ content and the associated oxidative stress are 
related to the presence or absence of specific CK2 subunits. Deletion of CKB1and CKB2 
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provides tolerance to Cr6+. This finding indicates a possible adverse role for CK2 tetramers 
under hexavalent chromium stress.  
 
7.1.2 The molecular mechanisms of CK2 in regulating metal toxicity 
The mechanisms by which a toxicant causes stress, in many cases, require that the toxicant 
enters the cell. For example, the action of Cr6+ is related to its intracellular reduction which 
produces numerous free radicals (Armienta-Hernández and Rodríguez-Castillo 1995). It 
therefore stands to reason that a major mechanism by which a gene deletion may result in 
tolerance to a toxicant is likely by limiting the uptake of the toxicant. This is indeed what is 
observed in the case of Al3+. The observed phenotypes of CK2 mutants under Al3+ stress, as 
just described earlier, were suggestive of two possibilities: (1) cka2p facilitates uptake or, (2) 
cka2p hinders detoxification. The investigation of the intracellular metal ion content of CK2 
mutants after Al3+ exposure demonstrates that the absence of Cka2p results in a markedly 
reduced level of intracellular Al3+ compared to the wildtype and even the other CK2 mutants 
(Figure 3.16). This reduction was greatest at the earliest time point measured (4 h). Hence, 
these findings suggest that cka2p facilitates uptake, in other words, lacking Cka2p prevents the 
initial uptake of the metal ion. The data, for the first time, indicates that monomeric cka2p is 
directly involved in the intracellular level of the toxicant Al3+. As aluminium toxicity to crops 
and plants increases greatly with the soil acidity (Becaria, Campbell, & Bondy, 2002; Becaria 
et al., 2006), the findings here should be of significance to agriculture. For example, by 
genetically manipulation a plant with low levels of CKA2 to be better adapted to acidic soil. 
 
The contrasting mechanism by which a gene deletion may provide tolerance to a toxicant is 
epitomised by the data generated under acute Zn2+ stress. As stated above in Chapter 7.1.1 the 
findings concerning Zn2+ resistance indicate that the increased viability of a cka2Δ in the 
presence of Zn2+ can be attributed to the pool of CK2 entities that remain in the absence of 
Cka2p such as Cka1p, Ckb1p, Ckb2p and tetramers formed from these three subunits. The ICP-
MS data (Figure 3.16), demonstrates that reduced uptake like the case of Al3+ is not the reason 
for the resultant tolerance because the Zn2+ level of cka2Δ is similar to that of the wildtype. 
Removal of Cka2p allows the cell to more effectively reduce the amount of labile Zn2+ by 
compartmental sequestration. In yeast, vacuolar Zn2+ storage is facilitated by the transport 
proteins Zrc1p and Cot1p. By screening double deletions of CK2 subunits together with ZRC1 
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or COT1we saw that both cka1Δzrc1Δ and cka1Δcot1Δ exhibited identical phenotypes to 
zrc1Δ and cot1Δ in control conditions and under Zn2+ stress. This indicates that Cka1p and 
Zrc1p and/or Cot1p are involved in the same pathway, that is, the compartmental sequestration 
of Zn2+.  
 
Under As3+ stress we find clear evidence of a need for monomeric regulatory subunits when 
the cell is exposed to the metalloid. The tolerance conferred by deletion of ckb1Δ or ckb2Δ 
results from the remaining monomeric regulatory subunit (e.g. Ckb2p in ckb1Δ). This is 
confirmed by the abolition of tolerance in the double deletion mutants of CKB1 and CKB2 (e.g. 
ckb1Δckb2Δ). When one considers the ICP-MS data (Figure 4.2), the growth phenotypes of 
ckb1Δ and ckb2Δ appear to be the result of reduced cellular content of As3+. The double 
deletion phenotypes of these regulatory subunits with the known uptake transporter of As3+ 
FPS1 show similar phenotypes to the fps1Δ single deletion mutant indicating that they likely 
work in concert to regulate the uptake of As3+. As the genome-wide deletion mutants screen 
data reveals the involvement of the MAP kinase pathway in response to As3+ exposure, it is 
likely that Ckb1p or Ckb2p interacts with MAPK, MAPKK or MAPKKK. This again reiterates 
the previous points that CK2 subunits have discrete functions apart from their functions as 
tetramers, and that the regulatory subunits can interact with the other proteins such as the ones 
in the MAP kinase pathway. 
 
In contrast to the involvement of CK2 in the cell’s response to Al3+, Zn2+ and As3+, the findings 
described in Chapters 3 and 5 demonstrate that CK2 is indeed involved in Cr6+ toxicity to the 
cell, however, the exact molecular mechanism is unclear. The mechanism by which CK2 is 
involved in Cr6+ toxicity, as is the case for Al3+ appears to be related to uptake. The ICP-MS 
data revealed that intracellular Cr6+ content of the CK2 mutants, after Cr6+ exposure was 
significantly reduced in CKA1∆, CKB1∆ and CKB2∆ while it was increased in CKA2, 
indicating that CK2 is involved in Cr6+ uptake. This finding leads to the conclusion that Cka1p, 
Ckb1p and Ckb2p in fact regulate Cr6+ uptake.  
 
The role of CK2 here is interesting. It contrasts with the role of this enzyme in Zn2+ and Al3+ 
toxicity. In the case of Cr6+ toxicity we find that lacking cka2p leads to an increase in 
intracellular Cr6+, while lacking the other CK2 subunits leads to a decrease in intracellular Cr6+. 
Considering all the findings in regard to the effect of CK2 subunits on metal ion toxicity, we 
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can clearly appreciate the functional diversity of individual CK2 subunits against different 
metal ions. One has to realise that without taking advantage of the deletion mutants of CK2 
subunits in S. cerevisiae, such discoveries could not be made, highlighting the usefulness of 
this model organism. 
 
7.1.3 Conservation of CK2’s new role from yeast to mammalian cells 
After having firmly established the role of CK2 in metal toxicity in the yeast system I have 
extended the discovery to mammalian cells as described in Chapter 6. siRNA knockdown 
experiments of CK2 subunits revealed that knockdown of CK2α’ resulted in a significant 
increase in viability of two mammalian neuronal cell lines in the presence of Al3+ (Figure 6.7). 
This finding provides the first insight into the role of CK2 in the regulation of Al3+ toxicity in 
humans. The ubiquitous nature of Al3+ (Delhaize & Ryan, 1995) and its reported links with 
neurodegenerative disease (Tomljenovic, 2011) highlight the importance of understanding the 
way the metal ion interacts with the cell. Al3+ has no known cellular function, whilst its cellular 
toxicity is a problem to human health. As no membrane-bound Al3+ transporter has been 
reported to date, the exact mode of regulation for Al3+ uptake by CK2α’ remains unclear. 
Because Al3+ is associated with neurodegenerative disorders, the involvement of CK2α’ in Al3+ 
uptake, as demonstrated in this study, provides an insight into the potential role of CK2α’ in 
the development of neurodegenerative diseases such as Alzheimer’s disease. 
 
Inhibition of CK2 by its specific inhibitor TBB resulted in increased viability under Zn2+ stress 
(Figure 6.6).  Further knockdown of CK2 subunits using specific siRNA (Figure 6.7) revealed 
that the activity or presence of CK2α’ was a major cause of this observed Zn2+ toxicity, as 
knockdown of CK2α’ resulted in a significant reduction in toxicity of Zn2+ (Figure 6.7). These 
findings are in agreement with the previous findings in the yeast system.  
 
CK2’s role in As3+ toxicity is mainly related to its two regulatory subunits in the yeast model 
organism. Because there is only one gene for the β subunit in mammalian cells and 
knockdown of this β gene expression would affect not only the expression of this very gene 
but also the level of tetramers, it is therefore not possible to understand the effect of 
knockdown of the β subunit. Reduction in overall CK2 activity by its inhibitor TBB did 
however result in the greater viability of both mammalian cell types tested at the IC50 and the 
141 
 
IC25 doses for As
3+ (Figure 6.6). In the case of Neuro2a cells, knockdown of all three 
subunits (CK2α, CK2α’ and CK2β) resulted in greater viability at the IC50 dose. This data 
indicates that CK2 activity is detrimental in the presence of As3+, however unlike the data 
from the yeast studies I am not able to confirm the role of individual CK2 regulatory subunits 
in mammalian cells.   
 
In the case of Cr6+, the data from the Neuro2a cells demonstrate that CK2 activity is 
correlated with reduced viability in the presence of Cr6+, this is further confirmed by the 
siRNA knockdown.  
 
In summation, the findings in Chapter 6 confirms the major finding in the yeast model 
organism, that is, CK2 regulates metal toxicity in mammalian cells.  
 
7.2 The significance of the findings and future work 
Until now there has been very little explicit exploration of the role of CK2 in metal ion toxicity. 
As detailed in Chapter 1.1.2 “Metals and biology” the metal ions that are the focus of this study 
are implicated in neurodegeneration and cancer. Understanding the cellular mechanisms that 
govern their toxicity is therefore prerequisite for understanding their resultant disease states. 
My findings described in this thesis will open a novel vista of study concerning the protein 
kinase CK2. That this enzyme has a role in the toxicity of metals is both startling and banal, 
startling for the fact that this enzyme has been the focus of so much study for so long and yet 
this aspect of its personality has remained hidden; banal because of its sheer number of 
functions and the pleiotropic nature of this enzyme, therefore unsurprising. Due to the roles of 
CK2 in oncogenesis and the links of CK2 with neurodegeneration, this new discovery of CK2’s 
role in metal toxicity is significant, as metals like Cr6+ and As3+ are major environmental 
pollutants implicated in cancers and neurodegenerative disorders.  
 
The overall experimental findings here shed light on a new facet of CK2 functionality. 
However, it needs to be acknowledged that the experiments associated with the use of TBB as 
an inhibitor and siRNA against individual CK2 subunit genes have limitations due to their 
potential off target effects. While observing a change in the phenotype (e.g. toxicity or uptake 
of metals) under TBB inhibition or siRNA knockdown is meaningful, acknowledging their 
limitations and performing additional assays should add veracity to the dataset described in 
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Chapters 3 and 6. Whilst there is no absolutely specific inhibitor against a given enzyme, the 
data acquired by the use of TBB against CK2 is useful when considered together with the 
siRNA knockdown and phenotypic screening of deletion mutants. In terms of the employment 
of siRNA in targeting the individual CK2 subunit genes, it would make the knockdown data 
more robust if CK2 activity or CK2 protein levels were quantified by enzymatic assays or 
immunoblotting, in addition to the qPCR measurements at the transcriptional level performed 
in this study. A point should be made that the validity of the data is strengthened because the 
siRNA molecules used here were purchased from the manufacturer, Dharmacon USA. The 
product purchased contains four specific sequences for each target gene, and their designing is 
based on stringent parameters which are reported to reduce off target effects by 90%.  In 
Chapter 6, the knockdown efficiency for each transcript of CK2 was between 73% and 80% 
according to qPCR, which is within the expected range reported by Dharmacon.  Furthermore, 
future knockdown studies should include a nonsense siRNA as a negative control. And if 
possible, a rescue assay to re-introduce the knockdown target gene should also be performed.  
 
Research questions that can be postulated as a result of this thesis, include: “How does CK2α’ 
regulate Al3+ uptake and toxicity?”, “What is the precise mechanism by which CK2 regulates 
Zn2+ homeostasis?”, “With which proteins do monomeric CK2 subunits interact?”.  
 
In conclusion, the findings of this study add to our understanding of protein kinase CK2 and 
its biological role in regulating metal toxicity. By using the CK2 deletion mutants of S. 
cerevisiae in the context metal ion exposure, discrete functions of individual CK2 subunits 
were clearly revealed. The intricacies of CK2 subunits in regulating Zn2+ and Al3+ were 
delineated in detail using ICP-MS and the specific CK2 inhibitor. The genome-wide deletion 
mutant screening revealed the detailed molecular mechanisms for metal toxicity such as As3+.  
The datasets described in the thesis should be of significance to both medicine and 
agriculture, and have been used to update the yeast genomic functionality in Saccharomyces 
Genome Database (https://www.yeastgenome.org/) after their publications (Johnson et al., 
2016a, 2016b; Johnson et al., 2017). As both CK2 and metal ions are key players in 
neurodegeneration and oncogenesis, the details of CK2 and metal ion toxicity uncovered 
herein have direct bearing on neurodegenerative and cancer research. 
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9 Appendices  
9.1 Appendix A 
9.1.1 Double deletions generated for this study 
Genes 
deleted  
Genotype  
A1;AFT1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; atf1∆0::KanMX 
A1;AFT2 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; atf2∆0::KanMX 
A1;ARR1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; arr1∆0::KanMX 
A1;ARR2 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; arr2∆0::KanMX 
A1;ARR3 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; arr3∆0::KanMX 
A1;ASK10 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; ask10∆0::KanMX 
A1;ATX2 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; atx2∆0::KanMX 
A1;BUL1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; bul1∆0::KanMX 
A1;CCH1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; cch1∆0::KanMX 
A1;CKA1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; cka1∆0::KanMX 
A1;CKA2 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; cka2∆0::KanMX 
A1;CKB1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; ckb1∆0::KanMX 
A1;CKB2 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; ckb2∆0::KanMX 
A1;COT1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; cot1∆0::KanMX 
A1;CUP2 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; cup2∆0::KanMX 
A1;DNF1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; dnf1∆0::KanMX 
A1;FET3 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; fet3∆0::KanMX 
A1;FET4 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; fet4∆0::KanMX 
A1;FET5 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; fet5∆0::KanMX 
A1;FIT2 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; fit2∆0::KanMX 
A1;FIT3 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; fit3∆0::KanMX 
A1;FPS1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; fps1∆0::KanMX 
A1;GUP1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; gup1∆0::KanMX 
A1;HOG1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; hog1∆0::KanMX 
A1;LEM3 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; lem3∆0::KanMX 
A1;MID1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; mid1∆0::KanMX 
A1;MMT1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; mmt1∆0::KanMX 
A1;MMT2 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; mmt2∆0::KanMX 
A1;MRS3 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; mrs3∆0::KanMX 
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A1;MRS4 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; mrs4∆0::KanMX 
A1;MSC2 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; msc2∆0::KanMX 
A1;MTF1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; mtf1∆0::KanMX 
A1;PBS2 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; pbs2∆0::KanMX 
A1;PHO4 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; pho4∆0::KanMX 
A1;PHO81 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; pho81∆0::KanMX 
A1;PHO84 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; pho84∆0::KanMX 
A1;PMC1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; pmc1∆0::KanMX 
A1;PMR1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; pmr1∆0::KanMX 
A1;SLT2 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; slt2∆0::KanMX 
A1;SNF3 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; snf3∆0::KanMX 
A1;SSK1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; ssk1∆0::KanMX 
A1;SSK2 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; ssk2∆0::KanMX 
A1;SSK22 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; ssk22∆0::KanMX 
A1;SSU1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; ssu1∆0::KanMX 
A1;SUL1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; sul1∆0::KanMX 
A1;VCX1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; vcx1∆0::KanMX 
A1;YAP1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; yap1∆0::KanMX 
A1;YAP3 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; yap3∆0::KanMX 
A1;YCF1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; ycf1∆0::KanMX 
A1;YKE4 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; yke4∆0::KanMX 
A1;YPK1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; ypk1∆0::KanMX 
A1;YVC1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; yvc1∆0::KanMX 
A1;ZAP1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; zap1∆0::KanMX 
A1;ZPS1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; zps1∆0::KanMX 
A1;ZRC1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; zrc1∆0::KanMX 
A1;ZRG17 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; zrg17∆0::KanMX 
A1;ZRG8 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; zrg8∆0::KanMX 
A1;ZRT1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; zrt1∆0::KanMX 
A1;ZRT2 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; zrt2∆0::KanMX 
A1;ZRT3 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka1Δ0::URA; zrt3∆0::KanMX 
A2;AFT1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; atf1∆0::KanMX 
A2;AFT2 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; atf2∆0::KanMX 
A2;ARR1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; arr1∆0::KanMX 
A2;ARR2 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; arr2∆0::KanMX 
A2;ARR3 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; arr3∆0::KanMX 
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A2;ASK10 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; ask10∆0::KanMX 
A2;ATX2 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; atx2∆0::KanMX 
A2;BUL1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; bul1∆0::KanMX 
A2;CCH1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; cch1∆0::KanMX 
A2;CKA1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; cka1∆0::KanMX 
A2;CKA2 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; cka2∆0::KanMX 
A2;CKB1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; ckb1∆0::KanMX 
A2;CKB2 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; ckb2∆0::KanMX 
A2;COT1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; cot1∆0::KanMX 
A2;CUP2 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; cup2∆0::KanMX 
A2;DNF1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; dnf1∆0::KanMX 
A2;FET3 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; fet3∆0::KanMX 
A2;FET4 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; fet4∆0::KanMX 
A2;FET5 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; fet5∆0::KanMX 
A2;FIT2 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; fit2∆0::KanMX 
A2;FIT3 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; fit3∆0::KanMX 
A2;FPS1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; fps1∆0::KanMX 
A2;GUP1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; gup1∆0::KanMX 
A2;HOG1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; hog1∆0::KanMX 
A2;LEM3 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; lem3∆0::KanMX 
A2;MID1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; mid1∆0::KanMX 
A2;MMT1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; mmt1∆0::KanMX 
A2;MMT2 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; mmt2∆0::KanMX 
A2;MRS3 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; mrs3∆0::KanMX 
A2;MRS4 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; mrs4∆0::KanMX 
A2;MSC2 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; msc2∆0::KanMX 
A2;MTF1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; mtf1∆0::KanMX 
A2;PBS2 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; pbs2∆0::KanMX 
A2;PHO4 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; pho4∆0::KanMX 
A2;PHO81 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; pho81∆0::KanMX 
A2;PHO84 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; pho84∆0::KanMX 
A2;PMC1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; pmc1∆0::KanMX 
A2;PMR1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; pmr1∆0::KanMX 
A2;SLT2 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; slt2∆0::KanMX 
A2;SNF3 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; snf3∆0::KanMX 
A2;SSK1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; ssk1∆0::KanMX 
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A2;SSK2 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; ssk2∆0::KanMX 
A2;SSK22 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; ssk22∆0::KanMX 
A2;SSU1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; ssu1∆0::KanMX 
A2;SUL1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; sul1∆0::KanMX 
A2;VCX1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; vcx1∆0::KanMX 
A2;YAP1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; yap1∆0::KanMX 
A2;YAP3 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; yap3∆0::KanMX 
A2;YCF1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; ycf1∆0::KanMX 
A2;YKE4 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; yke4∆0::KanMX 
A2;YPK1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; ypk1∆0::KanMX 
A2;YVC1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; yvc1∆0::KanMX 
A2;ZAP1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; zap1∆0::KanMX 
A2;ZPS1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; zps1∆0::KanMX 
A2;ZRC1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; zrc1∆0::KanMX 
A2;ZRG17 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; zrg17∆0::KanMX 
A2;ZRG8 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; zrg8∆0::KanMX 
A2;ZRT1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; zrt1∆0::KanMX 
A2;ZRT2 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; zrt2∆0::KanMX 
A2;ZRT3 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; cka2Δ0::URA; zrt3∆0::KanMX 
B1;AFT1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; atf1∆0::KanMX 
B1;AFT2 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; atf2∆0::KanMX 
B1;ARR1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; arr1∆0::KanMX 
B1;ARR2 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; arr2∆0::KanMX 
B1;ARR3 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; arr3∆0::KanMX 
B1;ASK10 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; ask10∆0::KanMX 
B1;ATX2 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; atx2∆0::KanMX 
B1;BUL1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; bul1∆0::KanMX 
B1;CCH1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; cch1∆0::KanMX 
B1;CKA1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; cka1∆0::KanMX 
B1;CKA2 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; cka2∆0::KanMX 
B1;CKB1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; ckb1∆0::KanMX 
B1;CKB2 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; ckb2∆0::KanMX 
B1;COT1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; cot1∆0::KanMX 
B1;CUP2 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; cup2∆0::KanMX 
B1;DNF1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; dnf1∆0::KanMX 
B1;FET3 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; fet3∆0::KanMX 
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B1;FET4 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; fet4∆0::KanMX 
B1;FET5 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; fet5∆0::KanMX 
B1;FIT2 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; fit2∆0::KanMX 
B1;FIT3 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; fit3∆0::KanMX 
B1;FPS1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; fps1∆0::KanMX 
B1;GUP1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; gup1∆0::KanMX 
B1;HOG1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; hog1∆0::KanMX 
B1;LEM3 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; lem3∆0::KanMX 
B1;MID1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; mid1∆0::KanMX 
B1;MMT1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; mmt1∆0::KanMX 
B1;MMT2 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; mmt2∆0::KanMX 
B1;MRS3 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; mrs3∆0::KanMX 
B1;MRS4 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; mrs4∆0::KanMX 
B1;MSC2 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; msc2∆0::KanMX 
B1;MTF1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; mtf1∆0::KanMX 
B1;PBS2 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; pbs2∆0::KanMX 
B1;PHO4 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; pho4∆0::KanMX 
B1;PHO81 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; pho81∆0::KanMX 
B1;PHO84 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; pho84∆0::KanMX 
B1;PMC1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; pmc1∆0::KanMX 
B1;PMR1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; pmr1∆0::KanMX 
B1;SLT2 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; slt2∆0::KanMX 
B1;SNF3 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; snf3∆0::KanMX 
B1;SSK1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; ssk1∆0::KanMX 
B1;SSK2 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; ssk2∆0::KanMX 
B1;SSK22 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; ssk22∆0::KanMX 
B1;SSU1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; ssu1∆0::KanMX 
B1;SUL1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; sul1∆0::KanMX 
B1;VCX1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; vcx1∆0::KanMX 
B1;YAP1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; yap1∆0::KanMX 
B1;YAP3 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; yap3∆0::KanMX 
B1;YCF1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; ycf1∆0::KanMX 
B1;YKE4 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; yke4∆0::KanMX 
B1;YPK1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; ypk1∆0::KanMX 
B1;YVC1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; yvc1∆0::KanMX 
B1;ZAP1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; zap1∆0::KanMX 
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B1;ZPS1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; zps1∆0::KanMX 
B1;ZRC1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; zrc1∆0::KanMX 
B1;ZRG17 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; zrg17∆0::KanMX 
B1;ZRG8 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; zrg8∆0::KanMX 
B1;ZRT1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; zrt1∆0::KanMX 
B1;ZRT2 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; zrt2∆0::KanMX 
B1;ZRT3 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb1Δ0::URA; zrt3∆0::KanMX 
B2;AFT1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; atf1∆0::KanMX 
B2;AFT2 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; atf2∆0::KanMX 
B2;ARR1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; arr1∆0::KanMX 
B2;ARR2 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; arr2∆0::KanMX 
B2;ARR3 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; arr3∆0::KanMX 
B2;ASK10 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; ask10∆0::KanMX 
B2;ATX2 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; atx2∆0::KanMX 
B2;BUL1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; bul1∆0::KanMX 
B2;CCH1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; cch1∆0::KanMX 
B2;CKA1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; cka1∆0::KanMX 
B2;CKA2 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; cka2∆0::KanMX 
B2;CKB1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; ckb1∆0::KanMX 
B2;CKB2 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; ckb2∆0::KanMX 
B2;COT1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; cot1∆0::KanMX 
B2;CUP2 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; cup2∆0::KanMX 
B2;DNF1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; dnf1∆0::KanMX 
B2;FET3 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; fet3∆0::KanMX 
B2;FET4 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; fet4∆0::KanMX 
B2;FET5 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; fet5∆0::KanMX 
B2;FIT2 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; fit2∆0::KanMX 
B2;FIT3 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; fit3∆0::KanMX 
B2;FPS1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; fps1∆0::KanMX 
B2;GUP1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; gup1∆0::KanMX 
B2;HOG1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; hog1∆0::KanMX 
B2;LEM3 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; lem3∆0::KanMX 
B2;MID1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; mid1∆0::KanMX 
B2;MMT1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; mmt1∆0::KanMX 
B2;MMT2 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; mmt2∆0::KanMX 
B2;MRS3 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; mrs3∆0::KanMX 
166 
 
B2;MRS4 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; mrs4∆0::KanMX 
B2;MSC2 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; msc2∆0::KanMX 
B2;MTF1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; mtf1∆0::KanMX 
B2;PBS2 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; pbs2∆0::KanMX 
B2;PHO4 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; pho4∆0::KanMX 
B2;PHO81 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; pho81∆0::KanMX 
B2;PHO84 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; pho84∆0::KanMX 
B2;PMC1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; pmc1∆0::KanMX 
B2;PMR1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; pmr1∆0::KanMX 
B2;SLT2 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; slt2∆0::KanMX 
B2;SNF3 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; snf3∆0::KanMX 
B2;SSK1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; ssk1∆0::KanMX 
B2;SSK2 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; ssk2∆0::KanMX 
B2;SSK22 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; ssk22∆0::KanMX 
B2;SSU1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; ssu1∆0::KanMX 
B2;SUL1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; sul1∆0::KanMX 
B2;VCX1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; vcx1∆0::KanMX 
B2;YAP1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; yap1∆0::KanMX 
B2;YAP3 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; yap3∆0::KanMX 
B2;YCF1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; ycf1∆0::KanMX 
B2;YKE4 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; yke4∆0::KanMX 
B2;YPK1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; ypk1∆0::KanMX 
B2;YVC1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; yvc1∆0::KanMX 
B2;ZAP1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; zap1∆0::KanMX 
B2;ZPS1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; zps1∆0::KanMX 
B2;ZRC1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; zrc1∆0::KanMX 
B2;ZRG17 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; zrg17∆0::KanMX 
B2;ZRG8 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; zrg8∆0::KanMX 
B2;ZRT1 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; zrt1∆0::KanMX 
B2;ZRT2 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; zrt2∆0::KanMX 
B2;ZRT3 ura3Δ; leu2Δ0; his3Δ1; can1Δ::LEU2-MFA1p-HIS3; ckb2Δ0::URA; zrt3∆0::KanMX 
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9.2 Appendix B  
9.2.1 Annotated list of deletion mutants sensitive to As3+ 
Systematic 
name  
Standard 
name  
Description  
YLR113W HOG1 Mitogen-activated protein kinase involved in osmoregulation; controls global 
reallocation of RNAPII in osmotic shock; activates CDC28 by stimulating 
antisense RNA transcription; mediates recruitment/activation of RNAPII at 
Hot1p-dependent promoters; with Mrc1p defines novel S-phase checkpoint 
that prevent conflicts between DNA replication and transcription; nuclear 
form represses pseudohyphal growth; autophosphorylates; protein 
abundance increases under DNA replication stress 
YJL128C PBS2 MAP kinase kinase of the HOG signaling pathway; activated under severe 
osmotic stress; mitophagy-specific regulator; plays a role in regulating Ty1 
transposition 
YLR006C SSK1 Cytoplasmic phosphorelay intermediate osmosensor and regulator; part of a 
two-component signal transducer that mediates osmosensing via a 
phosphorelay mechanism; required for mitophagy; dephosphorylated form is 
degraded by the ubiquitin-proteasome system; potential Cdc28p substrate 
YMR275C BUL1 Ubiquitin-binding component of the Rsp5p E3-ubiquitin ligase complex 
YDR181C SAS4 Subunit of the SAS complex; acetylates free histones and nucleosomes and 
regulates transcriptional silencing 
YML007W YAP1 Basic leucine zipper (bZIP) transcription factor; required for oxidative stress 
tolerance; activated by H2O2 through the multistep formation of disulfide 
bonds and transit from the cytoplasm to the nucleus; mediates resistance to 
cadmium; relative distribution to the nucleus increases upon DNA replication 
stress 
YGR057C LST7 Protein possibly involved in a post-Golgi secretory pathway; required for the 
transport of nitrogen-regulated amino acid permease Gap1p from the Golgi to 
the cell surface 
YJL179W PFD1 Subunit of heterohexameric prefoldin; involved in the biogenesis of actin and 
of alpha- and gamma-tubulin 
YGL100W SEH1 Subunit of the Nup84 nuclear pore and SEACAT subcomplexes; SEA is a 
coatomer-related complex that associates dynamically with the vacuole; 
human SEH1 homolog 
YJL120W 
 
Partially overlaps the verified gene YJL121C/RPE1; deletion confers sensitivity 
to GSAO 
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YKL176C LST4 Protein possibly involved in a post-Golgi secretory pathway; required for the 
transport of nitrogen-regulated amino acid permease Gap1p from the Golgi to 
the cell surface 
YPR201W ARR3 Plasma membrane metalloid/H+ antiporter; member of 
bile/arsenite/riboflavin transporter (BART) superfamily; transports arsenite 
and antimonite; required for resistance to arsenic compounds; transcription is 
activated by Arr1p in the presence of arsenite 
YBR126C TPS1 Synthase subunit of trehalose-6-P synthase/phosphatase complex: expression 
is induced by the stress response and repressed by the Ras-cAMP pathway 
YOL081W IRA2 GTPase-activating protein; negatively regulates RAS by converting it from the 
GTP- to the GDP-bound inactive form 
YPR199C ARR1 Transcriptional activator of the basic leucine zipper (bZIP) family; required for 
transcription of genes involved in resistance to arsenic compounds 
YNL229C URE2 Nitrogen catabolite repression transcriptional regulator; has glutathione 
peroxidase activity and can mutate to acquire GST activity; altered form 
creates [URE3] prion 
YBR069C TAT1 Amino acid transporter for valine, leucine, isoleucine, and tyrosine; low-
affinity tryptophan and histidine transporter 
YHL009C YAP3 Basic leucine zipper (bZIP) transcription factor 
YNR031C SSK2 MAP kinase kinase kinase of HOG1 mitogen-activated signaling pathway; 
interacts with Ssk1p, leading to autophosphorylation and activation of Ssk2p 
which phosphorylates Pbs2p; also mediates actin cytoskeleton recovery from 
osmotic stress; a HOG-independent function of Ssk2p mediates the calcium-
sensitive phenotype of the ptp2 msg5 double disruptant; SSK2 has a paralog, 
SSK22, that arose from the whole genome duplication 
YDL020C RPN4 Transcription factor that stimulates expression of proteasome genes; RPN4 is 
transcriptionally regulated by various stress responses 
YGR078C PAC10 Part of the heteromeric co-chaperone GimC/prefoldin complex; complex 
promotes efficient protein folding 
YDL066W IDP1 Mitochondrial NADP-specific isocitrate dehydrogenase; catalyzes the 
oxidation of isocitrate to alpha-ketoglutarate 
YOR350C MNE1 Protein involved in splicing Group I aI5-beta intron from COX1 mRNA; 
mitochondrial matrix protein 
YDR149C 
 
Dubious open reading frame; overlaps the verified gene NUM1/YDR150W; 
null mutation blocks anaerobic growth 
YOR265W RBL2 Protein involved in microtubule morphogenesis 
YGL012W ERG4 C-24(28) sterol reductase; catalyzes the final step in ergosterol biosynthesis  
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YPR123C 
 
Dubious open reading frame; partially/completely overlaps the verified ORF 
CTR 
YLR087C CSF1 Protein required for fermentation at low temperature; plays a role in the 
maturation of secretory proteins 
YLR268W SEC22 R-SNARE protein; assembles into SNARE complex with Bet1p, Bos1p and 
Sed5p; cycles between the ER and Golgi complex; involved in anterograde and 
retrograde transport between the ER and Golgi 
YJL062W LAS21 Integral plasma membrane protein; involved in the synthesis of the 
glycosylphosphatidylinositol (GPI) core structure; mutations affect cell wall 
integrity 
YER007W PAC2 Microtubule effector required for tubulin heterodimer formation 
YDL021W GPM2 Homolog of Gpm1p phosphoglycerate mutase; converts 3-phosphoglycerate 
to 2-phosphoglycerate in glycolysis 
YOR258W HNT3 DNA 5' AMP hydrolase involved in DNA repair; member of the histidine triad 
(HIT) superfamily of nucleotide-binding proteins 
YDL069C CBS1 Mitochondrial translational activator of the COB mRNA 
YPL241C CIN2 GTPase-activating protein (GAP) for Cin4p; tubulin folding factor C involved in 
beta-tubulin (Tub2p) folding 
YLR200W YKE2 Subunit of the heterohexameric Gim/prefoldin protein complex; involved in 
the folding of alpha-tubulin, beta-tubulin, and actin 
YML124C TUB3 Alpha-tubulin; associates with beta-tubulin (Tub2p) to form tubulin dimer, 
which polymerizes to form microtubules 
YDR463W STP1 Transcription factor; undergoes proteolytic processing by SPS (Ssy1p-Ptr3p-
Ssy5p)-sensor component Ssy5p in response to extracellular amino acids; 
activates transcription of amino acid permease genes  
YHR030C SLT2 Serine/threonine MAP kinase; involved in regulating maintenance of cell wall 
integrity, cell cycle progression, and nuclear mRNA retention in heat shock; 
required for mitophagy and pexophagy; affects recruitment of mitochondria 
to phagophore assembly site (PAS); plays a role in adaptive response of cells 
to cold; regulated by the PKC1-mediated signaling pathway; SLT2 has a 
paralog, KDX1, that arose from the whole genome duplication 
YDR448W ADA2 Transcription coactivator; component of the ADA and SAGA transcriptional 
adaptor/HAT (histone acetyltransferase) complexes 
YGR056W RSC1 Component of the RSC chromatin remodeling complex; required for 
expression of mid-late sporulation-specific genes 
YLR372W ELO3  involved in fatty acid and sphingolipid biosynthesis 
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YOR383C FIT3 Mannoprotein that is incorporated into the cell wall; incorporated via a 
glycosylphosphatidylinositol (GPI) anchor; involved in the retention of 
siderophore-iron in the cell wall  
YDL037C BSC1 Protein of unconfirmed function; similar to cell surface flocculin Flo11p 
YDR176W NGG1 Subunit of chromatin modifying histone acetyltransferase complexes; member 
of the ADA complex, the SAGA complex, and the SLIK complex; transcriptional 
regulator involved in glucose repression of Gal4p-regulated genes 
YBL024W NCL1 increases proportion of tRNALeu(CAA) with m5C at wobble position in 
response to hydrogen peroxide, causing selective translation of mRNA from 
genes enriched in TTG codon; loss of NCL1 confers hypersensitivity to 
oxidative stress; similar to Nop2p and human proliferation associated 
nucleolar protein p120 
YFL041W FET5 Multicopper oxidase; integral membrane protein with similarity to Fet3p; may 
have a role in iron transport 
YJR073C OPI3 Methylene-fatty-acyl-phospholipid synthase; catalyzes the last two steps in 
phosphatidylcholine biosynthesis 
YDR028C REG1 Inactivates Snf1p 
YMR294W JNM1 Component of the yeast dynactin complex; required for proper nuclear 
migration and spindle partitioning during mitotic anaphase B 
YFL001W DEG1 tRNA:pseudouridine synthase 
YAL024C LTE1 Protein similar to GDP/GTP exchange factors 
YML041C VPS71 Nucleosome-binding component of the SWR1 complex; required for vacuolar 
protein sorting 
YAL012W CYS3 Cystathionine gamma-lyase; catalyzes one of the two reactions involved in the 
transsulfuration pathway that yields cysteine from homocysteine  
YBR164C ARL1 Soluble GTPase with a role in regulation of membrane traffic; regulates 
potassium influx; role in membrane organization at trans-Golgi network 
YDL057W 
 
Putative protein of unknown function; YDL057W is not an essential gene 
YDR525W API2 Dubious open reading frame; unlikely to encode a functional protein, based on 
available experimental and comparative sequence data; not conserved in 
closely related Saccharomyces species; 26% of ORF overlaps the dubious ORF 
YDR524C-A; insertion mutation in a cdc34-2 mutant background causes 
altered bud morphology 
YDR074W TPS2 Phosphatase subunit of the trehalose-6-P synthase/phosphatase complex 
YDL051W LHP1 RNA binding protein required for maturation of tRNA and U6 snRNA 
YPL269W KAR9 Karyogamy protein; required for correct positioning of the mitotic spindle and 
for orienting cytoplasmic microtubules 
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YBL031W SHE1 Mitotic spindle protein, inhibits dynein function 
YOR382W FIT2 Mannoprotein that is incorporated into the cell wall; incorporated via a 
glycosylphosphatidylinositol (GPI) anchor; involved in the retention of 
siderophore-iron in the cell wall  
YAL011W SWC3 component of the SWR1 complex 
YDR485C VPS72 Htz1p-binding component of the SWR1 complex; required for vacuolar protein 
sorting 
YDL076C RXT3 Component of the Rpd3L histone deacetylase complex 
YLL040C VPS13 Protein involved in prospore membrane morphogenesis; vacuolar protein 
sorting 
YOR360C PDE2 High-affinity cyclic AMP phosphodiesterase; component of the cAMP-
dependent protein kinase signaling system 
YML117W NAB6 Putative RNA-binding protein; associates with mRNAs encoding cell wall 
proteins in high-throughput studies; deletion mutants display increased 
sensitivity to some cell wall disrupting agents; expression negatively regulated 
by cAMP 
YDL052C SLC1 1-acyl-sn-glycerol-3-phosphate acyltransferase; catalyzes the acylation of 
lysophosphatidic acid to form phosphatidic acid, a key intermediate in lipid 
metabolism; enzymatic activity detected in lipid particles and microsomes 
YOR338W 
 
Putative protein of unknown function; YOR338W transcription is regulated by 
Azf1p and its transcript is a specific target of the G protein effector Scp160p; 
identified as being required for sporulation in a high-throughput mutant 
screen; YOR338W has a paralog, FUN19, that arose from the whole genome 
duplication 
YDL050C 
 
Dubious open reading frame; unlikely to encode a functional protein, based on 
available experimental and comparative sequence data 
YHR154W RTT107 Protein implicated in Mms22-dependent DNA repair during S phase; 
YPR070W MED1 Subunit of the RNA polymerase II mediator complex; associates with core 
polymerase subunits to form the RNA polymerase II holoenzyme; essential for 
transcriptional regulation 
YBR298C MAL31 Maltose permease; high-affinity maltose transporter (alpha-glucoside 
transporter); encoded in the MAL3 complex locus; member of the 12 
transmembrane domain superfamily of sugar transporters;  
YOR291W YPK9 Vacuolar protein with a possible role in sequestering heavy metals; homolog 
of human ATP13A2 (PARK9), mutations in which are associated with Parkinson 
disease and Kufor-Rakeb syndrome 
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9.3 Appendix C  
9.3.1 Annotated list of deletion mutants tolerant to As3+ 
Systematic 
name  
Standard 
name  
Description  
YBR189W RPS9B Protein component of the small (40S) ribosomal subunit 
YMR143W RPS16A Protein component of the small (40S) ribosomal subunit 
YLL044W 
 
Dubious open reading frame 
YCR031C RPS14A Protein component of the small (40S) ribosomal subunit 
YDR450W RPS18A Protein component of the small (40S) ribosomal subunit 
YFR032C-A RPL29 Ribosomal 60S subunit protein L29 
YIL014C-A 
 
Putative protein of unknown function 
YLR444C 
 
Dubious open reading frame 
YJR014W TMA22 Protein of unknown function; associates with ribosomes and has a putative 
RNA binding domain 
YLL043W FPS1 Aquaglyceroporin, plasma membrane channel; involved in efflux of glycerol 
and xylitol, and in uptake of acetic acid and the trivalent metalloids arsenite 
and antimonite 
YLR111W 
 
Dubious open reading frame 
YML063W RPS1B Ribosomal protein 10 (rp10) of the small (40S) subunit 
YJL136C RPS21B Protein component of the small (40S) ribosomal subunit 
YMR269W TMA23 Nucleolar protein implicated in ribosome biogenesis 
YLR264W RPS28B Protein component of the small (40S) ribosomal subunit 
YLR185W RPL37A Ribosomal 60S subunit protein L37A 
YGL088W 
 
Dubious open reading frame 
YLR448W RPL6B Ribosomal 60S subunit protein L6B; binds 5.8S rRNA 
YLR388W RPS29A Protein component of the small (40S) ribosomal subunit 
YPR043W RPL43A Ribosomal 60S subunit protein L43A 
YNL069C RPL16B Ribosomal 60S subunit protein L16B 
YDR417C 
 
Dubious open reading frame 
YDL061C RPS29B Protein component of the small (40S) ribosomal subunit 
YDR447C RPS17B Ribosomal protein 51 (rp51) of the small (40s) subunit 
YLR402W 
 
Dubious open reading frame 
YMR142C RPL13B Ribosomal 60S subunit protein L13B 
YDR500C RPL37B Ribosomal 60S subunit protein L37B 
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YCR063W BUD31 Component of the SF3b subcomplex of the U2 snRNP; increases efficiency of 
first and second step pre-mRNA splicing 
YLR367W RPS22B Protein component of the small (40S) ribosomal subunit 
YLR184W 
 
Dubious open reading frame 
YML009C-A 
 
Dubious open reading frame 
YGR097W ASK10 Regulator of the Fps1p glycerol channel; under nonstress conditions, binds to 
Fps1p to positively regulate glycerol transport; under osmotic stress, multiple 
phosphorylation by Hog1p causes Ask10p to dissociate from Fps1p 
YPL249C-A RPL36B Ribosomal 60S subunit protein L36B 
YIL008W URM1 Ubiquitin-like protein involved in thiolation of cytoplasmic tRNAs; receives 
sulfur from the E1-like enzyme Uba4p and transfers it to tRNA; also functions 
as a protein tag with roles in nutrient sensing and oxidative stress response 
YGL019W CKB1 Beta regulatory subunit of casein kinase 2 (CK2); a Ser/Thr protein kinase with 
roles in cell growth and proliferation 
YOR039W CKB2 Beta' regulatory subunit of casein kinase 2 (CK2); a Ser/Thr protein kinase 
with roles in cell growth and proliferation 
YDL194W SNF3 Plasma membrane low glucose sensor, regulates glucose transport; contains 
12 predicted transmembrane segments and a long C-terminal tail required for 
induction of hexose transporters 
YFR034C PHO4 Basic helix-loop-helix (bHLH) transcription factor of the myc-family; activates 
transcription cooperatively with Pho2p in response to phosphate limitation 
YGR233C PHO81 Cyclin-dependent kinase (CDK) inhibitor; regulates Pho80p-Pho85p and Pcl7p-
Pho85p cyclin-CDK complexes in response to phosphate levels 
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9.4 Appendix D  
9.4.1 Annotated list of deletion mutants sensitive to Cr6+ 
Systematic  
Name 
Standard name  Description  
YLL043W FPS1 Aquaglyceroporin, plasma membrane channel 
YPL274W SAM3 High-affinity S-adenosylmethionine permease 
YHR178W STB5 Transcription factor; involved in regulating multidrug resistance and 
oxidative stress response 
YMR192W GYL1 Putative GTPase activating protein (GAP) with a role in exocytosis 
YNL196C SLZ1 Sporulation-specific protein with a leucine zipper motif 
YMR275C BUL1 Ubiquitin-binding component of the Rsp5p E3-ubiquitin ligase complex 
YMR180C CTL1 RNA 5'-triphosphatase, localizes to both the nucleus and cytoplasm 
YNL098C RAS2 GTP-binding protein; regulates nitrogen starvation response, sporulation, 
and filamentous growth 
YPR070W MED1 Subunit of the RNA polymerase II mediator complex 
YMR097C MTG1 Putative GTPase peripheral to the mitochondrial inner membrane 
YPR059C YPR059C Dubious open reading frame 
YOR036W PEP12 Target membrane receptor (t-SNARE); for vesicular intermediates 
traveling between the Golgi apparatus and the vacuole 
YNR052C POP2 RNase of the DEDD superfamily; subunit of the Ccr4-Not complex that 
mediates 3' to 5' mRNA deadenylation 
YMR312W ELP6 Subunit of hexameric RecA-like ATPase Elp456 Elongator subcomplex; 
which is required for modification of wobble nucleosides in tRNA 
YBR278W DPB3 Third-largest subunit of DNA polymerase II (DNA polymerase epsilon) 
YFL007W BLM10 Proteasome activator; binds the core proteasome (CP) and stimulates 
proteasome-mediated protein degradation by inducing gate opening 
YPR150W YPR150W Dubious open reading frame 
YHR154W RTT107 Protein implicated in Mms22-dependent DNA repair during S phase; 
involved in recruiting the SMC5/6 complex to double-strand breaks 
YKR074W AIM29 Putative protein of unknown function 
YLR312C-B YLR312C-B Merged open reading frame 
YHR021C RPS27B Protein component of the small (40S) ribosomal subunit 
YGL168W HUR1 Protein of unknown function 
YDL068W YDL068W Dubious open reading frame 
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YER032W FIR1 Protein involved in 3' mRNA processing; interacts with Ref2p; APCC(Cdh1) 
substrate; potential Cdc28p substrate 
YDR442W YDR442W Dubious open reading frame 
YDR477W SNF1 AMP-activated serine/threonine protein kinase; found in a complex 
containing Snf4p and members of the Sip1p/Sip2p/Gal83p family 
YFL015C YFL015C Dubious open reading frame 
YFL020C PAU5 Member of the seripauperin multigene family 
YMR216C SKY1 SR protein kinase (SRPK); involved in regulating proteins involved in mRNA 
metabolism and cation homeostasis 
YOR308C SNU66 Component of the U4/U6.U5 snRNP complex; involved in pre-mRNA 
splicing via spliceosome 
YML024W RPS17A Ribosomal protein 51 (rp51) of the small (40s) subunit 
YNL119W NCS2 Protein required for uridine thiolation of Lys(UUU) and Glu(UUC) tRNAs 
YMR263W SAP30 Component of Rpd3L histone deacetylase complex; involved in silencing 
at telomeres, rDNA, and silent mating-type loci; involved in telomere 
maintenance 
YER065C ICL1 Isocitrate lyase; catalyzes the formation of succinate and glyoxylate from 
isocitrate, a key reaction of the glyoxylate cycle 
YBR271W EFM2 S-adenosylmethionine-dependent methyltransferase; seven-beta-strand 
lysine methyltransferase which dimethylates translation elongation factor 
EF2 (Eft1p and Eft2p) at lysine 613 and methylates EF3 (Yef3p) at lysine 
187 
YLR268W SEC22 R-SNARE protein; assembles into SNARE complex with Bet1p, Bos1p and 
Sed5p; cycles between the ER and Golgi complex 
YML002W YML002W Putative protein of unknown function 
YPR049C ATG11 Adapter protein for pexophagy and the Cvt targeting pathway 
YOR356W CIR2 Putative ortholog of human ETF-dH; found in a large supramolecular 
complex with other mitochondrial dehydrogenases 
YPR119W CLB2 B-type cyclin involved in cell cycle progression 
YMR179W SPT21 Protein with a role in transcriptional silencing 
YNL229C URE2 Nitrogen catabolite repression transcriptional regulator 
YLR384C IKI3 Subunit of Elongator complex; Elongator is required for modification of 
wobble nucleosides in tRNA 
YMR058W FET3 Ferro-O2-oxidoreductase; multicopper oxidase that oxidizes ferrous 
(Fe2+) to ferric iron (Fe3+) for subsequent cellular uptake by 
transmembrane permease Ftr1p 
YOR355W GDS1 Protein of unknown function 
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YMR156C TPP1 DNA 3'-phosphatase; functions in repair of endogenous damage of 
double-stranded DNA, activity is specific for removal of 3' phosphates at 
strand breaks 
YGR104C SRB5 Subunit of the RNA polymerase II mediator complex 
YLR374C YLR374C Dubious open reading frame 
YNL070W TOM7 Component of the TOM (translocase of outer membrane) complex 
YDL050C YDL050C Dubious open reading frame 
YIL044C AGE2 ADP-ribosylation factor (ARF) GTPase activating protein (GAP) effector 
YGL173C XRN1 Evolutionarily-conserved 5'-3' exonuclease; component of cytoplasmic 
processing (P) bodies involved in mRNA decay 
YPR189W SKI3 Ski complex component and TPR protein; mediates 3'-5' RNA degradation 
by the cytoplasmic exosome 
YDL093W PMT5 Protein O-mannosyltransferase; transfers mannose residues from dolichyl 
phosphate-D-mannose to protein serine/threonine residues 
YPR174C YPR174C Protein of unknown function 
YPL258C THI21 Hydroxymethylpyrimidine (HMP) and HMP-phosphate kinase 
YCR044C PER1 Protein of the endoplasmic reticulum 
YHR194W MDM31 Mitochondrial protein that may have a role in phospholipid metabolism 
YOR382W FIT2 Mannoprotein that is incorporated into the cell wall;  involved in the 
retention of siderophore-iron in the cell wall  
YMR228W MTF1 Mitochondrial RNA polymerase specificity factor; has structural similarity 
to S-adenosylmethionine-dependent methyltransferases and functional 
similarity to bacterial sigma-factors 
YGL163C RAD54 DNA-dependent ATPase that stimulates strand exchange; modifies the 
topology of double-stranded DNA; involved in the recombinational repair 
of double-strand breaks in DNA during vegetative growth and meiosis 
YMR241W YHM2 Citrate and oxoglutarate carrier protein 
YMR282C AEP2 Mitochondrial protein 
YCR063W BUD31 Component of the SF3b subcomplex of the U2 snRNP; increases efficiency 
of first and second step pre-mRNA splicing 
YML071C COG8 Component of the conserved oligomeric Golgi complex; a cytosolic 
tethering complex (Cog1p through Cog8p) that functions in protein 
trafficking to mediate fusion of transport vesicles to Golgi compartments 
YMR116C ASC1 G-protein beta subunit and guanine dissociation inhibitor for Gpa2p; 
ortholog of RACK1 that inhibits translation; 
YMR299C DYN3 Dynein light intermediate chain (LIC); localizes with dynein 
YCR081W SRB8 Subunit of the RNA polymerase II mediator complex 
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YOR164C GET4 Protein involved in inserting tail-anchored proteins into ER membranes 
YPL269W KAR9 Karyogamy protein; required for correct positioning of the mitotic spindle 
and for orienting cytoplasmic microtubules 
YER056C-A RPL34A Ribosomal 60S subunit protein L34A 
YMR307W GAS1 Beta-1,3-glucanosyltransferase; required for cell wall assembly and also 
has a role in transcriptional silencing 
YML032C RAD52 Protein that stimulates strand exchange; stimulates strand exchange by 
facilitating Rad51p binding to single-stranded DNA; anneals 
complementary single-stranded DNA; involved in the repair of double-
strand breaks in DNA during vegetative growth and meiosis and UV 
induced sister chromatid recombination 
YER087C-A YER087C-A Dubious open reading frame 
YEL027W VMA3 Proteolipid subunit c of the V0 domain of vacuolar H(+)-ATPase; required 
for vacuolar acidification and important for copper and iron metal ion 
homeostasis 
YMR219W ESC1 Protein localized to the nuclear periphery; involved in telomeric silencing 
YMR286W MRPL33 Mitochondrial ribosomal protein of the large subunit 
YOR270C VPH1 Subunit a of vacuolar-ATPase V0 domain 
YFL043C YFL043C Merged open reading frame 
YGL167C PMR1 High affinity Ca2+/Mn2+ P-type ATPase 
YMR152W YIM1 Protein of unknown function 
YKR098C UBP11 Ubiquitin-specific protease; cleaves ubiquitin from ubiquitinated proteins 
YFL031W HAC1 Basic leucine zipper (bZIP) transcription factor (ATF/CREB1 homolog); 
regulates the unfolded protein response 
YFL046W FMP32 Putative assembly factor for cytochrome c oxidase 
YCL061C MRC1 S-phase checkpoint protein required for DNA replication 
YDR363W-A SEM1 Component of lid subcomplex of 26S proteasome regulatory subunit 
YCR077C PAT1 Deadenylation-dependent mRNA-decapping factor 
YFL032W YFL032W Dubious open reading frame 
YMR150C IMP1 Catalytic subunit of mitochondrial inner membrane peptidase complex 
YDL046W NPC2 Sterol transport protein and functional homolog of human NPC2/He1 
YDR540C IRC4 Putative protein of unknown function 
YFL040W YFL040W Putative transporter 
YNL219C ALG9 Mannosyltransferase, involved in N-linked glycosylation 
YER020W GPA2 Nucleotide binding alpha subunit of the heterotrimeric G protein 
YFR007W YFH7 Putative kinase with similarity to the PRK/URK/PANK kinase subfamily 
YDL070W BDF2 Protein involved in transcription initiation 
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YDL033C SLM3 tRNA-specific 2-thiouridylase; responsible for 2-thiolation of the wobble 
base of mitochondrial tRNAs 
YER019W ISC1 Inositol phosphosphingolipid phospholipase C; mitochondrial membrane 
localized 
YER024W YAT2 Carnitine acetyltransferase 
YKR082W NUP133 Subunit of Nup84p subcomplex of nuclear pore complex (NPC); 
contributes to nucleocytoplasmic transport, NPC biogenesis; also plays 
roles in several processes that may require localization of genes or 
chromosomes at nuclear periphery, including double-strand break repair, 
transcription and chromatin silencing 
YPL161C BEM4 Protein involved in establishment of cell polarity and bud emergence 
YKL113C RAD27 5' to 3' exonuclease, 5' flap endonuclease; required for Okazaki fragment 
processing and maturation, for long-patch base-excision repair and large 
loop repair (LLR), ribonucleotide excision repair 
YMR242C RPL20A Ribosomal 60S subunit protein L20A 
YER033C ZRG8 Protein of unknown function 
YMR154C RIM13 Calpain-like cysteine protease 
YMR193W MRPL24 Mitochondrial ribosomal protein of the large subunit 
YMR151W YIM2 Dubious open reading frame 
YDL059C RAD59 Protein involved DNA double-strand break repair 
YMR205C PFK2 Beta subunit of heterooctameric phosphofructokinase 
YER039C HVG1 Protein of unknown function 
YOR346W REV1 Deoxycytidyl transferase; involved in repair of abasic sites and adducted 
guanines in damaged DNA by translesion synthesis (TLS) 
YDL089W NUR1 Protein involved in regulation of mitotic exit 
YLR425W TUS1 Guanine nucleotide exchange factor (GEF) that modulate Rho1p activity; 
involved in the cell integrity signaling pathway 
YKL048C ELM1 Serine/threonine protein kinase that regulates cellular morphogenesis 
YAL026C DRS2 Trans-golgi network aminophospholipid translocase (flippase) 
YER034W YER034W Protein of unknown function 
YFR010W UBP6 Ubiquitin-specific protease 
YOR347C PYK2 Pyruvate kinase; appears to be modulated by phosphorylation 
YER016W BIM1 Microtubule plus end-tracking protein; together with Kar9p makes up the 
cortical microtubule capture site and delays the exit from mitosis when 
the spindle is oriented abnormally 
YDR069C DOA4 Ubiquitin hydrolase; deubiquitinates intralumenal vesicle (ILVs) cargo 
proteins; required for recycling ubiquitin from proteasome-bound 
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ubiquitinated intermediates, acts at the late endosome/prevacuolar 
compartment to recover ubiquitin from ubiquitinated membrane proteins 
destined for the vacuole 
YFR008W FAR7 Protein involved in recovery from pheromone-induced cell cycle arrest 
YOR307C SLY41 Protein involved in ER-to-Golgi transport 
YER074W RPS24A Protein component of the small (40S) ribosomal subunit 
YER081W SER3 3-phosphoglycerate dehydrogenase; catalyzes the first step in serine and 
glycine biosynthesis 
YDR048C YDR048C Dubious open reading frame 
YFL030W AGX1 Alanine:glyoxylate aminotransferase (AGT); catalyzes the synthesis of 
glycine from glyoxylate, which is one of three pathways for glycine 
biosynthesis in yeast 
YDL076C RXT3 Component of the Rpd3L histone deacetylase complex; involved in 
histone deacetylation; protein abundance increases in response to DNA 
replication stress 
YCR065W HCM1 Forkhead transcription factor; drives S-phase activation of genes involved 
in chromosome segregation, spindle dynamics, budding; also activates 
genes involved in respiration, use of alternative energy sources (like 
proline), NAD synthesis, oxidative stress resistance 
YER030W CHZ1 Histone chaperone for Htz1p/H2A-H2B dimer; required for the 
stabilization of the Chz1p-Htz1-H2B complex 
YNL199C GCR2 Transcriptional activator of genes involved in glycolysis; interacts and 
functions with the DNA-binding protein Gcr1p 
YFL006W YFL006W Merged open reading frame 
YMR190C SGS1 RecQ family nucleolar DNA helicase; role in genome integrity 
maintenance, chromosome synapsis, meiotic joint molecule/crossover 
formation 
YOR304C-A BIL1 Protein that binds Bud6p and has a role in actin cable assembly 
YLR286C CTS1 Endochitinase; required for cell separation after mitosis 
YMR121C RPL15B Ribosomal 60S subunit protein L15B 
YFL001W DEG1 tRNA:pseudouridine synthase; introduces pseudouridines at position 38 
or 39 in tRNA 
YKL002W DID4 Class E Vps protein of the ESCRT-III complex 
YER019C-A SBH2 Ssh1p-Sss1p-Sbh2p complex component 
YIL043C CBR1 Cytochrome b reductase 
YER072W VTC1 Subunit of the vacuolar transporter chaperone (VTC) complex 
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YFL041W FET5 Multicopper oxidase; integral membrane protein with similarity to Fet3p; 
may have a role in iron transport 
YGR188C BUB1 Protein kinase involved in the cell cycle checkpoint into anaphase 
YLR398C SKI2 Ski complex component and putative RNA helicase 
YNL068C FKH2 Forkhead family transcription factor; plays a major role in the expression 
of G2/M phase genes 
YER095W RAD51 Strand exchange protein; forms a helical filament with DNA that searches 
for homology; involved in the recombinational repair of double-strand 
breaks in DNA during vegetative growth and meiosis; homolog of Dmc1p 
and bacterial RecA protein 
YBR277C YBR277C Dubious open reading frame 
YER084W YER084W Protein of unknown function 
YCR066W RAD18 E3 ubiquitin ligase; forms heterodimer with Rad6p to monoubiquitinate 
PCNA-K164; heterodimer binds single-stranded DNA and has single-
stranded DNA dependent ATPase activity 
YKR084C HBS1 GTPase with similarity to translation release factors 
YKR001C VPS1 Dynamin-like GTPase required for vacuolar sorting 
YHR141C RPL42B Ribosomal 60S subunit protein L42B 
YHL005C YHL005C Dubious open reading frame 
YNL250W RAD50 Subunit of MRX complex with Mre11p and Xrs2p; complex is involved in 
processing double-strand DNA breaks in vegetative cells, initiation of 
meiotic DSBs, telomere maintenance, and nonhomologous end joining; 
forms nuclear foci upon DNA replication stress 
YDL065C PEX19 Chaperone and import receptor for newly-synthesized class I PMPs 
YER075C PTP3 Phosphotyrosine-specific protein phosphatase; involved in the 
inactivation of mitogen-activated protein kinase (MAPK) during osmolarity 
sensing 
YPR123C YPR123C Dubious open reading frame 
YER045C ACA1 ATF/CREB family basic leucine zipper (bZIP) transcription factor 
YIL097W FYV10 Subunit of GID complex; involved in proteasome-dependent catabolite 
inactivation of gluconeogenic enzymes FBPase, PEPCK, and c-MDH 
YJR102C VPS25 Component of the ESCRT-II complex 
YOR383C FIT3 Mannoprotein that is incorporated into the cell wall; incorporated via a 
glycosylphosphatidylinositol (GPI) anchor; involved in the retention of 
siderophore-iron in the cell wall  
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YLR148W PEP3 Component of CORVET membrane tethering complex; vacuolar peripheral 
membrane protein that promotes vesicular docking/fusion reactions in 
conjunction with SNARE proteins, required for vacuolar biogenesis 
YCR087W YCR087W Dubious open reading frame 
YDL021W GPM2 Homolog of Gpm1p phosphoglycerate mutase 
YPL101W ELP4 Subunit of hexameric RecA-like ATPase Elp456 Elongator subcomplex; 
which is required for modification of wobble nucleosides in tRNA 
YDR027C VPS54 Component of the GARP (Golgi-associated retrograde protein) complex; 
GARP is required for the recycling of proteins from endosomes to the late 
Golgi, and for mitosis after DNA damage induced checkpoint arrest 
YCR034W ELO2 Fatty acid elongase, involved in sphingolipid biosynthesis; acts on fatty 
acids of up to 24 carbons in length; mutations have regulatory effects on 
1,3-beta-glucan synthase, vacuolar ATPase, and the secretory pathway 
YCR087C-A YCR087C-A Putative protein of unknown function 
YPR120C CLB5 B-type cyclin involved in DNA replication during S phase 
YHR031C RRM3 DNA helicase involved in rDNA replication and Ty1 transposition 
YOR322C LDB19 Alpha-arrestin involved in ubiquitin-dependent endocytosis 
YER041W YEN1 Holliday junction resolvase; promotes template switching during break-
induced replication (BIR), causing non-reciprocal translocations (NRTs) 
YAL021C CCR4 Component of the CCR4-NOT transcriptional complex; CCR4-NOT is 
involved in regulation of gene expression 
YAL002W VPS8 Membrane-binding component of the CORVET complex 
YPR061C JID1 Probable Hsp40p co-chaperone 
YCR086W CSM1 Nucleolar protein that mediates homolog segregation during meiosis I 
YAL024C LTE1 Protein similar to GDP/GTP exchange factors 
YHR012W VPS29 Subunit of the membrane-associated retromer complex; endosomal 
protein; essential for endosome-to-Golgi retrograde transport 
YLR417W VPS36 Component of the ESCRT-II complex 
YOR123C LEO1 Component of the Paf1 complex; which associates with RNA polymerase II 
and is involved in histone methylation 
YER056C FCY2 Purine-cytosine permease; mediates purine (adenine, guanine, and 
hypoxanthine) and cytosine accumulation 
YGR240C PFK1 Alpha subunit of heterooctameric phosphofructokinase 
YMR123W PKR1 V-ATPase assembly factor; functions with other V-ATPase assembly 
factors in the ER to efficiently assemble the V-ATPase membrane sector 
(V0) 
YPL195W APL5 Delta adaptin-like subunit of the clathrin associated protein complex 
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YJL092W SRS2 DNA helicase and DNA-dependent ATPase; involved in DNA repair and 
checkpoint recovery, needed for proper timing of commitment to meiotic 
recombination and transition from Meiosis I to II 
YJL029C VPS53 Component of the GARP (Golgi-associated retrograde protein) complex; 
GARP is required for the recycling of proteins from endosomes to the late 
Golgi, and for mitosis after DNA damage induced checkpoint arrest 
YNL141W AAH1 Adenine deaminase (adenine aminohydrolase); converts adenine to 
hypoxanthine 
YLR025W SNF7 One of four subunits of the ESCRT-III complex; involved in the sorting of 
transmembrane proteins into the multivesicular body (MVB) pathway; 
recruited from the cytoplasm to endosomal membranes 
YDL077C VAM6 Guanine nucleotide exchange factor for the GTPase Gtr1p; subunit of the 
HOPS endocytic tethering complex 
YER044C-A MEI4 Meiosis-specific protein involved in forming DSBs; involved in double-
strand break (DSBs) formation during meiotic recombination 
YDR080W VPS41 Subunit of the HOPS endocytic tethering complex 
YGL071W AFT1 Transcription factor involved in iron utilization and homeostasis 
YPR164W MMS1 Subunit of E3 ubiquitin ligase complex involved in replication repair; 
stabilizes protein components of the replication fork such as the fork-
pausing complex and leading strand polymerase, preventing fork collapse 
and promoting efficient recovery during replication stress 
YCL008C STP22 Component of the ESCRT-I complex; ESCRT-I is involved in ubiquitin-
dependent sorting of proteins into the endosome 
YLR396C VPS33 ATP-binding protein that is a subunit of the HOPS and CORVET complexes 
YER151C UBP3 Ubiquitin-specific protease involved in transport and osmotic response 
YGR229C SMI1 Protein involved in the regulation of cell wall synthesis 
YPL065W VPS28 Component of the ESCRT-I complex; complex is involved in ubiquitin-
dependent sorting of proteins into the endosome 
YPL045W VPS16 Subunit of the HOPS and the CORVET complexes; part of the Class C Vps 
complex essential for membrane docking and fusion at Golgi-to-
endosome and endosome-to-vacuole protein transport stages 
YKR035W-A DID2 Class E protein of the vacuolar protein-sorting (Vps) pathway; binds Vps4p 
and directs it to dissociate ESCRT-III complexes; forms a functional and 
physical complex with Ist1p; human ortholog may be altered in breast 
tumors 
YDL080C THI3 Regulatory protein that binds Pdc2p and Thi2p transcription factors 
YPR173C VPS4 AAA-ATPase involved in multivesicular body (MVB) protein sorting 
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YPL002C SNF8 Component of the ESCRT-II complex; ESCRT-II is involved in ubiquitin-
dependent sorting of proteins into the endosome 
YJL117W PHO86 Endoplasmic reticulum (ER) resident protein; required for ER exit of the 
high-affinity phosphate transporter Pho84p, specifically required for 
packaging of Pho84p into COPII vesicles; protein abundance increases in 
response to DNA replication stress 
YML117W NAB6 Putative RNA-binding protein; associates with mRNAs encoding cell wall 
proteins in high-throughput studies 
YLR181C VTA1 Multivesicular body (MVB) protein; involved in endosomal protein sorting; 
regulates Vps4p activity by promoting its oligomerization 
YHR030C SLT2 Serine/threonine MAP kinase; involved in regulating maintenance of cell 
wall integrity, cell cycle progression, and nuclear mRNA retention in heat 
shock; 
YJL095W BCK1 MAPKKK acting in the protein kinase C signaling pathway; the kinase C 
signaling pathway controls cell integrity 
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9.5 Appendix E 
9.5.1 Annotated list of deletion mutants tolerant to Cr6+ 
Systematic 
Name 
Standard name  Description  
YLL006W MMM1 ER integral membrane protein, ERMES complex subunit 
YLR091W GEP5 Protein of unknown function 
YBR191W RPL21A Ribosomal 60S subunit protein L21A 
YIL052C RPL34B Ribosomal 60S subunit protein L34B 
YBR031W RPL4A Ribosomal 60S subunit protein L4A 
YML027W YOX1 Homeobox transcriptional repressor 
YLR361C DCR2 Phosphoesterase; involved in downregulation of the unfolded protein 
response (UPR) 
YJR061W YJR061W Putative protein of unknown function; non-essential gene; 
transcription repressed by Rm101p; YJR061W has a paralog, MNN4, 
that arose from the whole genome duplication 
YKR006C MRPL13 Mitochondrial ribosomal protein of the large subunit 
YJL096W MRPL49 Mitochondrial ribosomal protein of the large subunit 
YJR044C VPS55 Late endosomal protein involved in late endosome to vacuole 
transport 
YPL092W SSU1 Plasma membrane sulfite pump involved in sulfite metabolism; 
required for efficient sulfite efflux; major facilitator superfamily 
protein 
YJR088C EMC2 Member of conserved ER transmembrane complex 
YJR056C YJR056C Protein of unknown function 
YML041C VPS71 Nucleosome-binding component of the SWR1 complex; SWR1 
exchanges histone variant H2AZ (Htz1p) for chromatin-bound histone 
H2A; required for vacuolar protein sorting 
YPL189W GUP2 Probable membrane protein; possible role in proton symport of 
glycerol 
YML038C YMD8 Putative nucleotide sugar transporter; has similarity to Vrg4p 
YJR031C GEA1 Guanine nucleotide exchange factor for ADP ribosylation factors 
(ARFs); involved in vesicular transport between the Golgi and ER, 
Golgi organization, and actin cytoskeleton organization; GEA1 has a 
paralog, GEA2, that arose from the whole genome duplication 
YPL184C MRN1 RNA-binding protein that may be involved in translational regulation 
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YMR269W TMA23 Nucleolar protein implicated in ribosome biogenesis; deletion extends 
chronological lifespan 
YBR170C NPL4 Substrate-recruiting cofactor of the Cdc48p-Npl4p-Ufd1p segregase; 
assists Cdc48p in the dislocation of misfolded, polyubiquitinated ERAD 
substrates that are subsequently delivered to the proteasome for 
degradation 
YBR092C PHO3 Constitutively expressed acid phosphatase similar to Pho5p; brought 
to the cell surface by transport vesicles; hydrolyzes thiamin 
phosphates in the periplasmic space, increasing cellular thiamin 
uptake; expression is repressed by thiamine 
YBR098W MMS4 Subunit of structure-specific Mms4p-Mus81p endonuclease 
YPL096W PNG1 Conserved peptide N-glycanase; required for deglycosylation of 
misfolded glycoproteins during proteasome-dependent degradation 
YPL032C SVL3 Protein of unknown function; mutant phenotype suggests a potential 
role in vacuolar function 
YKL216W URA1 Dihydroorotate dehydrogenase; catalyzes the fourth enzymatic step 
in the de novo biosynthesis of pyrimidines, converting dihydroorotic 
acid into orotic acid 
YBR157C ICS2 Protein of unknown function; null mutation does not confer any 
obvious defects in growth, spore germination, viability, or 
carbohydrate utilization 
YER119C-A YER119C-A Dubious open reading frame 
YDL215C GDH2 NAD(+)-dependent glutamate dehydrogenase 
YJR051W OSM1 Fumarate reductase, catalyzes the reduction of fumarate to succinate 
YBR162W-A YSY6 Protein of unknown function; expression suppresses a secretory 
pathway mutation in E. coli; has similarity to the mammalian RAMP4 
protein involved in secretion 
YBR221C PDB1 E1 beta subunit of the pyruvate dehydrogenase (PDH) complex 
YIL090W ICE2 Integral ER membrane protein with type-III transmembrane domains; 
required for maintenance of ER zinc homeostasis 
YKR032W YKR032W Dubious open reading frame 
YJR049C UTR1 ATP-NADH kinase; phosphorylates both NAD and NADH; active as a 
hexamer; enhances the activity of ferric reductase (Fre1p); UTR1 has a 
paralog, YEF1, that arose from the whole genome duplication 
YPL080C YPL080C Dubious open reading frame 
YKR044W UIP5 Protein of unknown function that interacts with Ulp1p 
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YJR062C NTA1 Amidase; removes the amide group from N-terminal asparagine and 
glutamine residues to generate proteins with N-terminal aspartate 
and glutamate residues that are targets of ubiquitin-mediated 
degradation 
YBR151W APD1 Protein of unknown function 
YOR139C YOR139C Dubious open reading frame 
YPR166C MRP2 Mitochondrial ribosomal protein of the small subunit 
YGL057C GEP7 Protein of unknown function 
YML063W RPS1B Ribosomal protein 10 (rp10) of the small (40S) subunit 
YBR146W MRPS9 Mitochondrial ribosomal protein of the small subunit 
YBR139W YBR139W Putative serine type carboxypeptidase 
YCL050C APA1 AP4A phosphorylase; bifunctional diadenosine 5',5'''-P1,P4-
tetraphosphate phosphorylase and ADP sulfurylase involved in 
catabolism of bis(5'-nucleosidyl) tetraphosphates 
YOR309C YOR309C Dubious open reading frame 
YGL087C MMS2 Ubiquitin-conjugating enzyme variant; involved in error-free 
postreplication repair 
YBR189W RPS9B Protein component of the small (40S) ribosomal subunit 
YBR185C MBA1 Membrane-associated mitochondrial ribosome receptor 
YBR159W IFA38 Microsomal beta-keto-reductase; contains oleate response element 
(ORE) sequence in the promoter region 
YBR120C CBP6 Mitochondrial protein required for translation of the COB mRNA 
YJR018W YJR018W Dubious open reading frame 
YJL006C CTK2 Beta subunit of C-terminal domain kinase I (CTDK-I); which 
phosphorylates both RNA pol II subunit Rpo21p to affect transcription 
and pre-mRNA 3' end processing, and ribosomal protein Rps2p to 
increase translational fidelity 
YCL026C YCL026C Deleted ORF; does not encode a protein 
YBR275C RIF1 Protein that binds to the Rap1p C-terminus 
YKR043C SHB17 Sedoheptulose bisphosphatase involved in riboneogenesis 
YDR268W MSW1 Mitochondrial tryptophanyl-tRNA synthetase 
YBR226C YBR226C Dubious open reading frame 
YBR233W PBP2 RNA binding protein; has similarity to mammalian heterogeneous 
nuclear RNP K protein, involved in the regulation of telomere position 
effect and telomere length; relative distribution to the nucleus 
increases upon DNA replication stress 
YBR288C APM3 Mu3-like subunit of the clathrin associated protein complex (AP-3) 
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YDR241W BUD26 Dubious open reading frame 
YBR294W SUL1 High affinity sulfate permease of the SulP anion transporter family; 
sulfate uptake is mediated by specific sulfate transporters Sul1p and 
Sul2p, which control the concentration of endogenous activated 
sulfate intermediates 
YGL019W CKB1 Beta regulatory subunit of casein kinase 2 (CK2); a Ser/Thr protein 
kinase with roles in cell growth and proliferation 
YIL035C CKA1 Alpha catalytic subunit of casein kinase 2 (CK2); a Ser/Thr protein 
kinase with roles in cell growth and proliferation 
YOR039W CKB2 Beta' regulatory subunit of casein kinase 2 (CK2); a Ser/Thr protein 
kinase with roles in cell growth and proliferation; CK2 
 
